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Abstract 
Synovitis is a key mediator of osteoarthritis (OA) and in the perpetuation of 
cartilage degradation, and approximately 60% of lameness in the horse has 
previously been attributed to OA. Synovial inflammation is characterised by a 
mononuclear cell infiltration into the synovial membrane, with concurrent 
increases in catabolic cytokines predominantly produced by synovial 
macrophages. These cytokines cause changes in fibroblast-like synoviocyte 
gene expression, including the up-regulation of damaging cartilage matrix 
degrading proteinases and further cytokines. It was therefore hypothesised 
that the synovial membrane may represent a disease-modifying target. When 
referring to synovial macrophages and fibroblast-like synovioctyes 
collectively, the term synoviocytes is used.  
The general aims of this thesis were to design and test an anti-cytokine 
therapy; short interfering RNA (siRNA), and to analyse its potential with 
respect to decreasing target catabolic cytokines produced by synoviocytes. 
Delivery of this therapy to synoviocytes via biodegradable polymer 
microspheres was also examined. The effects of the therapy and therapy-
delivery system on synoviocyte and cartilage health, were assessed using in 
vitro co-culture systems, which were designed and used to elucidate 
interactions between the two predominant cell populations present during 
synovitis; synovial macrophages and fibroblast-like synoviocytes.  
Successful equine anti-IL-1β siRNA was designed and tested on equine 
synovoicytes. These cells were also shown to successfully phagocytose 2-
6µm biodegradable polymer microspheres in a highly efficient manner. A 
novel multi-species in vitro model was created to quantify cell-specific 
responses to inflammatory stimulation, of both macrophages and fibroblast-
like synoviocytes in co-culture. This model revealed that macrophages can 
stimulate fibroblast-like synoviocyte mitosis, and modulate its ADAMTS5 
mRNA expression in an inflammatory environment. Using an inflammatory 
stimulated co-culture model involving a mixed culture of macrophages, 
fibroblast-like synoviocytes and cartilage explants, it was observed that the 
mixed synoviocyte culture can also act to moderate the inflammatory 
response. Synoviocytes were shown to exert a protective mechanism over 
cartilage glycosaminoglycan release, whilst driving the inflammatory 
 
 XV 
response through the production of pro-inflammatory cytokines. This thesis 
has successfully provided the initial design and testing of an equine anti-IL-
1β therapy and delivery vehicle in vitro, providing a platform for further 
experimentation to assess the efficiency of delivery and therapeutic potential 
when used together.  
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Chapter 1. Introduction 
 
Exploring the role of Synovitis in Equine Osteoarthritis and its Potential 
as a Therapeutic Target for Anti-cytokine RNA Interference Delivered by 
PLGA-Microspheres 
 
 
1.1  The Equine Joint  
 
1.1.1 The Synovial Joint 
A common joint capsule surrounds the articulating surfaces of bones, 
creating a multi-tissue intra-articular environment known as the synovial joint. 
Synovial membrane lines the inside of the joint capsule and produces 
synovial fluid by acting as a macromolecular sieve to filter certain nutrients 
and small proteins from the plasma into the intra-articular space. Cells within 
the synovial membrane, known as fibroblast-like synoviocytes (FLS), 
produce molecules of a larger molecular weight found within synovial fluid, 
such as glycosaminoglycans (GAGs) and proteoglycans. Synovial fluid fills 
the intra-articular space, lubricating the articular cartilage-covered surfaces 
of the long bones to aid frictionless movement between the bone surfaces, 
providing nutrients to the avascular cartilage and acting as a transport 
medium for cellular signalling molecules. Extra- and intra-capsular 
ligamentous and muscular attachments provide joint stability and produce 
flexion, extension and rotation of the joint (Frisbie 2012). 
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Diarthrodial joints are the most common type of synovial joint found within 
the equine skeleton. They are designed to facilitate equine athletic exertions 
and must withstand high degrees of flexion and extension, and large 
compressional forces. A traumatic incident, loss of joint stability or joint tissue 
integrity, or irregularity in joint conformation, can lead to the production of 
factors which incite the inflammatory process, or can result in abnormal 
loading patterns which in turn also produces pro-inflammatory factors. These  
incite the intra-articular inflammatory cascade and potentially result in 
osteoarthritis (Heinegård and Saxne 2011). The space within the joint 
capsule is exposed to two tissues, the synovial membrane and articular 
cartilage. 
 
1.1.2 Synovial Membrane 
The synovial membrane is formed from an outer fibrous subintimal layer, 
which contains the synovial vasculature and nerve innervation, and an inner 
intima layer in which two main cell populations reside; FLS and synovial 
macrophages. The intima layer lining consists of overlapping cells around 
three FLS thick, with no basement membrane or tight cell junctions 
(Ghadially 1983) and is surrounded by a collagen-free fibrillar matrix 
(Edwards 1994). The majority of the subintimal layer is made up of collagen 
fibres interspersed with fibroblasts (Moskalewski, Osiecka-Iwan et al. 2014), 
areolar and fatty tissue (Frisbie 2012). FLS precursor cells reside within the 
intimal lining and FLS expand locally (Alwan, Carter et al. 1991). FLS 
proliferation can be stimulated by factors including macrophage inhibitory 
factor (MIF) (Edwards 1994, Lacey, Sampey et al. 2003) and interleukin-1 
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(IL-1) (Lacey, Sampey et al. 2003, Rosengren, Boyle et al. 2007), both of 
which are produced by synovial macrophages. This may explain why 
synovial hyperplasia is observed during inflammatory conditions. Synovial 
macrophages are thought to arise from two origins; from precursors residing 
within the intimal lining and from a systemic bone-marrow derived lineage 
(Edwards 1994). The maturation of macrophages descended from intimal 
lining precursors were found to be dependent on locally produced 
macrophage colony stimulating factor (M-CSF) (Edwards 1994). Whereas 
bone marrow derived macrophages may represent those seen during the 
mononuclear cellular infiltration of the synovial membrane that characterises 
synovitis.  
 
Synovial fluid is chiefly produced by the intima layer. Proteins and nutrients 
extravasate from subintimal vasculature before being filtered by the intima 
layer into synovial fluid. Molecules of <10kDa can move through the intima 
layer, which is why the synovial fluid is often thought of as an ultrafiltrate of 
the plasma (Frisbie 2012). Larger molecules found within the synovial fluid, 
such as the glycosaminoglycan hyaluronan (Yielding, Tomkins et al. 1957) 
and the proteoglycan lubricin (Jay, Britt et al. 2000), are synthesised by FLS 
and released directly into the intra-articular space, although chondrocytes 
also synthesise hyaluronan (Mason, Kimura et al. 1982). These are critical to 
reduce friction during movement and provide adequate articular cartilage 
surface lubrication (Jay, Britt et al. 2000, Scanzello and Goldring 2012). The 
concentration of hyaluronan and lubricin changes, and the molecular weight 
of hyaluronan reduces, during pathological processes, which contributes to 
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the initiation of cartilage degradation (Scanzello and Goldring 2012). FLS 
and macrophages are also capable of producing cytokines, aggrecanases 
and matrix metalloproteinases (MMPs) which contribute to inflammation and 
cartilage degradation (Frisbie 2012). 
 
1.1.3  Cartilage 
Cartilage is a specialised tissue designed to protect articulating bone 
surfaces from compressive and shear forces (Poole, Kobayashi et al. 2002), 
and facilitate pain-free, frictionless movement of the skeleton (Houard, 
Goldring et al. 2013). Chondrocytes, the only cell-type found within articular 
cartilage, are embedded within extracellular matrix (ECM) synthesised by the 
chondrocytes (Goldring and Marcu 2009). Different compositions of ECM are 
found within particular locations relative to the chondrocyte. Directly 
enveloping the chondrocyte is the pericellular matrix which mainly consists of 
hyaluronan and proteoglycan, with some collagen VI. Chondrocytes 
synthesise hyaluronan which, once released, can bind to the chondrocyte 
cell membrane through the cell surface receptor CD44, or to the ECM 
(Cohen, Klein et al. 2003). A fibrillar pericellular capsule encases the 
pericellular matrix, which is surrounded by the territorial matrix. Within this 
area, collagen fibrils extend outwards between 5-10µm from the pericellular 
capsule and provide some resistance to mechanical stress. These 
components; the chondrocyte, pericelluar matrix and capsule, and territorial 
matrix, form a unit called the chondron. In-between chondrons lies the inter-
territorial matrix, which chiefly contains collagen type II, aggrecan aggregates 
involving hyaluronan, cartilage oligomeric protein (COMP) and other link 
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proteins to facilitate cross-linking of the collagen network. This network 
provides resistance to compressive and shear forces (Goldring and Marcu 
2009, Frisbie 2012). See figure 1.1 which has been adapted (McIlwraith 
2005, Heinegård and Saxne 2011). 
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Figure 1.1 The Different areas of ECM surrounding the chondrocyte. Different compositions of ECM are found within particular 
locations relative to the chondrocyte; the pericellular matrix directly surrounds the chondrocyte and is composed of hylauronan, 
proteoglycan and collagen VI. The territorial matrix surrounds this and contains collagen fibrils radiating from the pericellular matrix 
outwards. These areas including the chondrocyte form a unit called the chondron. Between chondrons lies the inter-territorial matrix which 
chiefly contains collagen type II, aggrecan aggregates involving hyaluronan, COMP and other link proteins. Diagram adapted from 
McIlwraith et al. (2005) and Heinegård and Saxne (2011). 
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Differences between regions of the cartilage at varying distances from the 
articular surface also occur. The orientation of collagen fibres, and 
chondrocyte morphology changes in each region. The area adjacent to the 
articular surface, the superficial zone, contains tightly packed smaller-
diameter (~31nm) collagen fibres that run parallel to the articular surface 
(Frisbie 2012). The ECM has a high decorin (Goldring and Marcu 2009) and 
collagen (Frisbie 2012), and low glycosaminoglycan and aggrecan (Goldring 
and Marcu 2009) content. Chondrocytes lie close together, flattened and 
elongated with their longitudinal axes lying parallel to the articular surface. 
This arrangement of densely packed cells and collagen fibres adjacent to the 
articular surface provides high tensile strength to resist shear forces, and 
impedes the movement of high molecular weight molecules, such as 
hyaluronan, from leaving the ECM whilst allowing smaller molecules such as 
nutrients and cytokines to move freely (Frisbie 2012). The 
intermediate/transitional zone collagen network, contains larger-diameter 
collagen fibres (~40-100nm) arranged in a random formation (Frisbie 2012). 
Chondrocytes are large, round and also randomly spaced apart, and 
chondrons are formed around each individual chondrocyte. The deep zone 
contains the largest-diameter collagen fibrils which are anchored in the 
calcified cartilage and subchondral bone lying beneath this surface (Martel-
Pelletier, Boileau et al. 2008, Goldring and Marcu 2009). Fibres are 
orientated perpendicular to the articular surface. Large chondrocytes align 
themselves into vertical columns also running perpendicular to the articular 
surface and the chondrons surrounding them combine. The tidemark 
separates the deep zone and the calcified cartilage layer which contains 
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mineralised cells and matrix overlying the subchondral bone (Frisbie 2012). 
Chondrocytes within the calcified cartilage layer have been shown to express 
markers of hypertrophy, and with increasing age, evidence of blood vessels 
and nerves originating from the underlying subchondral bone layer become 
apparent (Houard, Goldring et al. 2013) (Figure 1.2).  
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Figure 1.2 Chondrocyte and collagen organization and distribution within different zones of articular cartilage. The superficial zone lies 
in contact with the synovial fluid and confers tensile properties associated with articulating joint forces. This zone contains few proteoglycans, a 
thin layer of dense collagen fibrils and flat, elongated chondrocytes orientated parallel to the cartilage surface. The transitional (middle) zone 
contains fewer chondrocytes which are larger and spherical with a random distribution. Aggrecan is abundant and with thick decussating collagen 
fibrils, forms layers of tissue that correspond to up to 60% of overall cartilage height. In the deep zone aggrecan content is high (providing 
resistance to compressive force) and chondrocytes are spherical, arranged in columns and low in density. Collagen fibrils are radially distributed 
and are structurally largest in this zone. Calcified cartilage anchors the cartilage to the bone via collagen fibrils that penetrate from the deep zone 
to the calcified cartilage. Chondrocytes are hypertrophic and are physically separated from the deep region by the ‘tidemark’ (Martell-Pelletier, 
Boileau et al. 2008). 
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1.1.4  Cartilage Extracellular Matrix 
The majority of mature cartilage is comprised of ECM, and chondrocytes 
represent between 1-12% of the volume depending on the species. It has 
been shown that there is an inverse relationship between cell density and 
thickness of articular cartilage (Stockwell 1971). Approximately 70% of 
cartilage wet weight is water, however, when analysing the dry weight 
components, 50% is collagen, 35% proteoglycan, 10% glycoprotein (growth 
factors, COMP and proteinases), 3% minerals, 1% lipids and 1% 
miscellaneous substances (Frisbie 2012). Under normal healthy conditions, a 
fine balance between anabolic and catabolic mechanisms maintains a steady 
composition of ECM components. Chondrocytes slowly synthesise ECM 
constituents, maintained by a group of matrix metalloproteinases (MMPs) 
and aggrecanases (Goldring and Marcu 2009).  
 
1.1.4.1  Collagen  
The collagen network within the ECM provides resistance to compressive 
and shear strains, and also acts as a scaffold around which all other matrix 
components are situated. Collagen is synthesised by chondrocytes, however 
turnover is extremely slow which contributes to the poor regenerative 
capacity of cartilage (Goldring and Marcu 2009). Collagen type II is by far the 
most abundant form found in articular cartilage, constituting between 90-95% 
of total collagen content (Vachon, Keeley et al. 1990). Collagen type II is a 
homotrimer, made up of three identical alpha chains that form collagen fibrils. 
Within the fibrils each strand is characteristically offset by 25%, otherwise 
known as a quarter stagger (Frisbie 2012). Type IX and XI are also present 
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in the inter-territorial matrix of articular cartilage, type IX is found on the 
surface of the type II collagen fibril, whereas type XI is found both within and 
on the type II fibril surface (Poole, Kobayashi et al. 2002). Type VI collagen is 
also found within the territorial region of the chondron (Goldring and Marcu 
2009). 
 
1.1.4.2  Proteoglycans 
Proteoglycans contain a core protein with covalently attached GAGs, which 
are made up of linear carbohydrate chains involving repeating disaccharide 
units with negatively-charged sulphate and carboxylate groups (Stanton, 
Melrose et al. 2011, Hynes and Naba 2012). The GAG side chains are 
characteristic for each proteoglycan (Hardingham and Fosang 1992), 
whereas the protein cores are diverse and unrelated to one another in their 
structure (Stanton, Melrose et al. 2011). Side chains may comprise 
chondroitin sulphate, dermatan sulphate, keratan sulphate, heparan sulphate 
or heparan, and each proteoglycan may have a different combination of 
these chain types covalently-bound to its core protein (Stanton, Melrose et 
al. 2011).  
 
Aggrecan is the most abundant and largest aggregating proteoglycan found 
in cartilage ECM. It has a core protein with three globular domains (G1-3), an 
interglobular domain (IGD) between G1 and G2, and a large region of 
covalently-associated GAGs made up of chondroitin sulphate chains and a 
smaller region of keratan sulphate chains (Hardingham and Fosang 1992). 
Chondroitin sulphate is comprised of two alternating monosaccharides N-
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acetyl-D-galactosamine and D-glucuronic acid, whilst keratan sulphate is 
made up of repeating disaccharides galactose and N-acetyl-D-
galactosamine. The molecule is non-covalently bound to hyaluronan at the 
G1 domain and stabilised with a link protein (a small glycoprotein) (Goldring 
and Marcu 2009). The GAGs high negative charge strongly attracts an 
abundance of water molecules which produces the cartilage swelling 
pressure providing stiffness and resistance to mechanical compression, 
whilst also allowing the distribution of load through the tissue (Brew, Clegg et 
al. 2010, Stanton, Melrose et al. 2011). Cartilage properties therefore depend 
on the amount of aggrecan and hyaluronan content within the ECM, and their 
interaction with the collagen network. 
 
Other small proteoglycans, known as leucine-rich proteoglycans (LRPs) exist 
within the ECM; biglycan, decorin and fibromodulin. They contain low 
molecular weight (~40kDa) leucine-rich core proteins, which are structurally 
related to one another (Hardingham and Fosang 1992), and have only one or 
two GAG chains attached. For example, biglycan has one or two 
chondroitin/dermatan sulphate GAG chains bound to a core protein of 38kDa 
(Palmer and Bertone 1994). These proteoglycans contribute to the formation 
and stabilisation of the ECM (Frisbie 2012). Decorin has been associated 
with the regulation of fibrillogenesis (including the determination of fibre 
diameter) and collagen organisation (Palmer and Bertone 1994), and 
fibromodulin has also been implicated in the organisation of the ECM 
(Hardingham and Fosang 1992).  
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1.1.5  Osteoarthritis 
Osteoarthritis (OA) is a major cause of disability in the UK and results in the 
breakdown of the articular cartilage within synovial joints. During OA, 
chondrocytes fail to maintain the equilibrium between anabolic and catabolic 
processes which normally preserve the composition of ECM. Anabolic 
processes are inhibited whilst catabolic processes accelerate, causing the  
integrity of the ECM to fail which leads to the degradation of cartilage 
(Goldring and Marcu 2009). This is caused by an increase in chondrocyte 
and synoviocyte synthesised pro-inflammatory cytokines and proteases, 
such as MMPs and aggrecanases. Two key cytokines, IL-1β and TNF-α, 
stimulate a multitude of pro-catabolic activities including the up-regulation of 
other pro-inflammatory cytokines, aggrecanases and MMPs, whilst inhibiting 
chondrocyte synthesis of aggrecan and type II collagen. Aggrecanases and 
MMPs cleave ECM constituents such as collagen, aggrecan and other small 
matrix proteins, which leads to the ultimate failure of the cartilage matrix. The 
synovial contribution to this inflammatory cascade is not completely 
understood and further investigation into its role in the pathogenesis of 
osteoarthritis is needed. The pathogenesis of osteoarthritis is described in 
more detail further on.  
 
1.1.6  Proteolysis 
The proteolysis of aggrecan is facilitated by two major proteinase families; 
the MMPs and a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTS) family (these are also referred to as aggrecanases). Both 
families of proteinases cleave aggrecan at specific sites on the aggrecan 
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core protein (Durigova, Nagase et al. 2011). Aggrecan degradation facilitated 
by these families contributes to ECM turnover during normal cartilage 
homeostasis. However, during pathological conditions levels of these 
enzymes can increase, additionally MMPs can also degrade collagen, and 
these factors cause a catabolic state resulting in cartilage breakdown. During 
the early stages of osteoarthritis, the loss of aggrecan can be reversed, 
however the degradation and loss of collagen type II from the ECM, that 
subsequently occurs, is permanent (Loeser, Goldring et al. 2012, Felson and 
Hodgson 2014). This is discussed in more detail in section 1.4.5 
Aggrecanases and Matrix Metalloproteinases. 
!
!
!
!
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1.2   Synovitis 
 
1.2.1  Equine Synovitis Plays a Major Role in the Pathophysiology 
of Osteoarthritis 
In 67.6% of racehorses in training, lameness causes the greatest number of 
lost training days (Rossdale, Hopes et al. 1985), and it is by far the most 
important factor in the wastage of young racehorses (Jeffcott, Rossdale et al. 
1982). Surveys estimate that up to 60% of lameness in the horse is related to 
OA (McIlwraith 2011). Equine OA is considered a group of disorders with the 
same outcome: progressive degradation of the tissues within synovial joints 
(McIlwraith, Frisbie et al. 2012). The metacarpophalangeal joint is the most 
common site for spontaneous OA in the racehorse, followed by the carpal 
joints (McIlwraith, Frisbie et al. 2012). 
 
Synovitis clinically manifests as a palpable joint thickening, due to the 
inflamed synovial membrane, or as synovial fluid effusion (Sellam and 
Berenbaum 2010). Synovitis can be detected by ultrasound, MRI (with and 
without contrast enhancement) and through arthroscopic examination. These 
modalities have diagnosed synovitis in patients where synovitis was clinically 
unapparent. Synovitis was found in up to 50% of OA patients as confirmed 
by arthroscopy (Attur, Samuels et al. 2010). Non-contrast imaging modalities 
grade the joint as a whole-organ including assessment of total synovial fluid 
volume, or extent of synovial cavity distension. Contrast enhanced MRI and 
US can now distinguish synovial thickening from effusion; a recent study 
diagnosed synovitis in 95% and 70% of joints with and without an effusion, 
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suggesting that synovial thickening and effusion are discrete (Scanzello and 
Goldring 2012).  
 
In horses, synovitis has long been associated with OA in high motion joints, 
but inflammation due to capsulitis or synovitis is also believed to be almost 
always present in equine OA (McIlwraith and Vachon 1988).  However, 
further investigation is required to determine the exact incidence of 
concomitant synovitis and OA. 
 
OA is characterised by cartilage degeneration, subchondral bone sclerosis, 
osteophyte formation, varying degrees of synovial inflammation and 
periarticular tissue fibrosis (Kidd, Fuller et al. 2001). The exact role that 
synovitis plays is unknown, but it is becoming widely acknowledged as an 
important mediator of the disease process (Ley, Ekman et al. 2009). Post-
traumatic OA occurs after a single traumatic event (Rickey, Cruz et al. 2012) 
to the joint causing joint degeneration, dysfunction and pain (Buckwalter and 
Brown 2004). Whereas traumatic osteochondrosis (also known as palmar 
osteochondral disease) is caused by a focal overloading within the joint, 
leading to subchondral bone damage, which mainly occurs in racehorses 
(Rickey, Cruz et al. 2012). OA, once termed a non-inflammatory disease, is 
now considered a complex condition potentially involving all joint 
components and should now be considered a whole joint disease (Goldring 
and Marcu 2009, Goldring and Otero 2011, Goldring, Otero et al.), although 
the majority of OA research remains focused on cartilage injury (Lee, Kisiday 
et al. 2013). However, the synovial membrane, subchondral bone, and 
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associated adipose tissue are under scrutiny in regards to their contribution 
to the pathophysiology of OA. Synovitis plays a highly influential role in 
driving the progression of OA and in the perpetuation of cartilage 
degradation. Equine synovitis alone, without concurrent joint instability or 
injury, has been found capable of potentiating cartilage degradation (Lee, 
Kisiday et al. 2013). This organ, the synovium, is therefore an ideal 
therapeutic target for disease modifying OA drugs (DMOADs), and could 
reveal the presence of acute OA through the analysis of biomarkers or 
imaging modalities. 
 
1.2.2  An Introduction to Equine Synovitis Research 
Since the 1980s, it has been evident that synovitis plays a role in the 
pathogenesis of equine OA (McIlwraith and Vachon 1988). Equine OA can 
be caused by a primary traumatic event or occur naturally, and humans and 
equids both commonly experience spontaneous OA (McIlwraith, Frisbie et al. 
2012). Intra-articular (IA) deleterious agents such as lipopolysaccharide 
(LPS) and interleukin-1 (IL-1) were, and still continue to be, used to model 
naturally occurring OA without the influence of joint trauma or instability. 
Early models produced IA changes similar to those seen in naturally 
occurring OA, inferring that synovitis is capable of inducing cartilage 
degradation (McIlwraith and Van Sickle 1981). Equine IL-1β was first 
characterised in 1990 (May, Hooke et al. 1990), and was quickly identified 
within synovial fluid (SF) (Morris, McDonald et al. 1990) and serum of horses 
with OA, alongside a molecule capable of inhibiting this cytokine (Alwan, 
Carter et al. 1991, May, Hooke et al. 1992). IL-1β secreted from equine 
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peripheral blood mononuclear cells (EPBMC) was then shown to stimulate 
prostaglandin E2 (PGE2) production from synovial cells and chondrocytes in 
vitro (May, Hooke et al. 1992). These characteristics highlighted the value of 
IL-1β in reproducing naturally occurring OA in the horse. Throughout the 
1990s, synovitis models were further refined to elicit a mild to moderate 
synovitis with associated clinical signs, such as lameness and increased 
surface skin temperature, but without deleterious systemic effects (Palmer 
and Bertone 1994). Synovial fluid white blood cell count (WBCC), total 
protein (TP) and pro-inflammatory mediators were concurrently elevated. 
Various doses of LPS (Hawkins, MacKay et al. 1993) and recombinant 
equine IL-1β (ReIL-1β) (Simmons, Bertone et al. 1999) were tested as 
synovitis-inducing agents, concluding that doses >0.5ng LPS per joint 
caused systemic endotoxaemia (Palmer and Bertone 1994). Intra-articular 
LPS (0.2µg/kg bwt) caused enhanced immunoreactivity for IL-1β, TNF-α and 
TNF-α receptors within synovium and non-calcified cartilage, further 
reinforcing that the inflammed synovium is an important source of pro-
inflammatory mediators in joint disease (Todhunter, Kincaid et al. 1996). IL-
1β and TNF-α are considered chief pro-inflammatory drivers of the OA 
disease process. Extensive research into the equine IL-1β cytokine has 
revealed an alternatively spliced transcript minus exon 5, which includes the 
IL-1β converting enzyme (ICE) cleavage site within SF (Kato, Youn et al. 
1996); and an IL-1 receptor antagonist (IL-1RA) which was isolated from 
LPS-stimulated EPBMCs and identified through molecular cloning and 
functional expression tests (Kato, Ohashi et al. 1997). This receptor 
antagonist is now one of the most extensively researched proteins with 
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respect to DMOADs in equids (Frisbie and McIlwraith 2000). The ReIL-1β 
synovitis model revealed a positive association between IL-1β and SF 
interleukin-6 (IL-6) levels (Simmons, Bertone et al. 1999) and IL-6 was then 
discovered to be a sensitive and specific marker for joint disease in vivo 
when lameness is intermittent or difficult to identify (Bertone, Palmer et al. 
2001). Both bioactive and normal SF TNF-α levels do not correlate with the 
degree of articular cartilage damage in a joint, or the SF WBCC. In one 
study, bioactive TNF-α was significantly induced in joints suffering from 
degenerative joint disease post-racing, but this did not significantly differ from 
normal joints. However, these joints contained osteochondral chip fractures; 
an acute inflammatory response may have been induced by the impact of 
racing but a concurrent chronic inflammatory response was also present 
(Billinghurst, Fretz et al. 1995). In a second study, SF TNF-α levels were 
detected in horses with no signs of active inflammation present which may 
explain the lack of correlation (Jouglin, Robert et al. 2000). The majority of 
SF TNF-α was therefore postulated to have been produced by resident 
articular cells, rather than SF cells, due to the non-linear WBCC, further 
emphasising the role of synovitis on IA cytokine levels (Billinghurst, Fretz et 
al. 1995). In a study looking at naturally occurring active disease, there were 
no correlations found between TNF-α and grade of articular cartilage 
damage (Ley, Ekman et al. 2007).  
Equine articular IL-1β gene expression is constitutive and primarily produced 
by the synovial membrane (Trumble, Trotter et al. 2001). Aside from being a 
principal driver of inflammation and cartilage degradation, IL-1β is also a 
crucial regulator of the balance between anabolism and catabolism required 
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for normal joint homeostasis. This finding was reinforced by murine studies 
investigating the complete deletion of the IL-1β gene and the gene encoding 
ICE, which transforms IL-1β into an active enzyme, which demonstrated that 
a lack of these genes accelerated development of OA cartilage lesions after 
undergoing surgery to destabilise the joint of interest (Clements, Price et al. 
2003). These lesions were associated with increased levels of MMP, 
aggrecanase and collagenase-generated cleavage neoepitopes in areas 
adjacent to the lesion, whilst remote areas showed no evidence of their 
presence. It may be hypothesised that whilst IL-1β is known to stimulate the 
production of proteases, it may also moderate the degree of their up-
regulation.  
 
1.2.2.1  In Vitro Research 
The Effects of IL-1β on Cartilage 
When cartilage explants were exposed to IL-1β in vitro, cartilage sulphated 
GAG (sGAG) content decreased (Pettipher, Higgs et al. 1986, Gregg, Fortier 
et al. 2006, Gregg, Fortier et al. 2006) whilst sGAG content within the culture 
media increased (Busschers, Holt et al. 2010). Histological analysis of 
cartilage explants stimulated with IL-1β revealed decreased levels of sGAG 
within the extracellular matrix (Pettipher, Higgs et al. 1986, Ley, Svala et al. 
2011). More detailed study of gene expression indicated that chondrocyte 
aggrecan and collagen type II mRNA levels were inhibited by IL-1β (Gregg, 
Fortier et al. 2006, Gregg, Fortier et al. 2006, Ley, Svala et al. 2011). 
Furthermore, IL-1β up-regulated chondrocyte MMP gene expression 
(Busschers, Holt et al. 2010, Ley, Svala et al. 2011), including MMP3 and 
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MMP13 (Flannery, Little et al. 1999, Gregg, Fortier et al. 2006, Gregg, Fortier 
et al. 2006), and aggrecanase gene expression (Flannery, Little et al. 1999); 
ADAMTS4 (by 27 fold) and ADAMTS5 (by 13 fold) (Busschers, Holt et al. 
2010). These studies conclude that certain concentrations of IL-1β can 
promote the degradation of the cartilage ECM, both through the up-
regulation of ECM-cleaving enzymes, and the down-regulation of anabolic 
gene expression.  
 
Chondrocytes and Synoviocytes Can Influence Each Other 
However, when cartilage explants were co-cultured with synoviocytes, the 
influence of IL-1β on cartilage degradation was significantly altered. Cartilage 
explant sGAG content, chondrocyte aggrecan gene expression and cartilage 
metachromasia were significantly less reduced under these conditions 
(Gregg, Fortier et al. 2006). However, the degree of sGAG within explant 
culture media was unchanged. These findings may reflect a positive anabolic 
stimulus from synoviocytes on chondrocyte aggrecan synthesis, rather than 
an anti-catabolic effect.  
 
IL-1β has also been shown to stimulate synoviocyte MMP3 and -13 gene 
expression, however this was less up-regulated by IL-1β in the presence of 
cartilage (Gregg, Fortier et al. 2006), which may suggest an anti-catabolic 
feedback mechanism produced by the cartilage. A similar synoviocyte 
response was noted in the presence of injured cartilage; FLS ADAMTS4 and 
-5 gene expression was lower compared to FLS cultured independently and 
with uninjured cartilage, however expression of MMP-1 was increased and 
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tissue inhibitor of metalloproteinases (TIMP)-1 was decreased (Lee, Kisiday 
et al. 2013). However, chondrocyte aggrecan synthesis was lower when 
injured cartilage was cultured with FLS compared to injured cartilage cultured 
alone (Lee, Kisiday et al. 2013). Furthermore, when injured bovine cartilage 
was co-cultured with synovial explants, there was an increase in catabolic 
chondrocyte gene expression, resulting in a reduction of cartilage aggrecan 
content (Lee, Fitzgerald et al. 2009). The FLS culture used in Lee et al 
(2013) did not express detectable IL-1β or TNF-α, which are the chief 
cytokines produced during synovitis and are therefore unrepresentative of 
the responses occurring within an inflamed joint. Whereas the synovial 
explants used in Lee et al. (2009) contain synovial macrophages and may 
more closely reflect intra-articular responses to injury. These studies do, 
however, emphasise the simultaneous catabolic and anabolic responses, 
and the complex interactions between the different cell populations, 
occurring during inflammation. Ultimately, it is crucial to fully elucidate inter-
cellular communications when evaluating potential disease modifying targets.  
 
1.2.2.2  In Vivo Research 
Studies on the in vivo cell responses to intra-articular recombinant-equine IL-
1β and LPS have shown that they resemble those produced by in vitro 
models. Chondroctye ADAMTS4, ADAMTS5, IL-1β and MMP1 gene 
expression were all up-regulated compared to normal joints. However it is 
worth noting that MMP13 and TNF-α were not significantly affected (Ross, 
Kisiday et al. 2012). These changes in gene expression generally reflect 
those observed in vitro, apart from the disparity in chondrocyte expression of 
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MMP13. Synoviocyte gene expression of IL-1β, MMP1 and ADAMTS4 were 
significantly up-regulated, whilst MMP13, ADAMTS5 and TNF-α gene 
expression did not differ between treated and control joints (Ross, Kisiday et 
al. 2012).  
 
1.2.2.3  Naturally Occurring Joint Disease 
In naturally occurring OA, no increase in synoviocyte IL-1β gene expression 
was observed, whereas TNF-α was significantly up-regulated in moderate 
OA compared to non-diseased joints. OA chondrocyte IL-1β and TNF-α gene 
expression were significantly up-regulated compared to normal 
chondrocytes. MMP-13 gene expression was significantly up-regulated by 
both OA synoviocytes and chondrocytes. ADAMTS4 gene expression was 
not significantly up-regulated by synoviocytes whereas an increase was seen 
in chondrocyte gene expression between normal and OA conditions. 
ADAMTS5 synoviocyte gene expression was significantly up-regulated in 
moderate OA compared to non-diseased joints, whereas chondrocyte gene 
expression was unchanged (Kamm, Nixon et al. 2010).  
 
There is a degree of disparity when comparing the in vivo synoviocyte and 
chondrocyte mRNA levels of cytokines, aggrecanases and MMPs induced by 
intra-articular administration of IL-1β, to those observed during naturally 
occurring OA. When analysing mRNA levels on exposure to intra-articular IL-
1β, they reflect the initial cell response to injury. However, mRNA levels 
observed in cells isolated from osteoarthritic joints, are displaying the 
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response to injury inflicted over a longer period of time. This may explain the 
differences in response observed.  
 
 Innate Immunity Activates the Intra-Articular Inflammatory Response 
Joint structures can be injured either through repetitive cycles of over-loading 
causing a build up of micro-trauma known as stress-induced fatigue damage, 
or through a single traumatic event. Damage results in the release of 
endogenous molecules known as damage-associated molecular patterns 
(DAMPS), either from cartilage ECM disruption or through cell injury (Li, Shi 
et al. 2011). DAMPs trigger pattern recognition receptors (PRRs), which 
activate the inflammatory response (Berenbaum 2013). Two predominant 
types of PRRs are the toll-like receptors (TLRs) and receptor for advanced 
glycation end-products (RAGE) (Sellam and Berenbaum 2010, Goldring and 
Otero 2011). TLRs initiate the major signalling pathways involved in the 
inflammatory response during the early stages of OA (Berenbaum 2013). 
They activate the nuclear factor-kappa B (NF-κB) pathway which leads to the 
production of pro-inflammatory cytokines, chemokines and aggrecanases 
(Liu-Bryan 2013). TLRs are present on synovioctyes and chondrocytes 
during OA, and chondrocyte TLRs and RAGE have been found to be up-
regulated during OA (Li, Shi et al. 2011, Berenbaum 2013). RAGE activated 
pathways are triggered when advanced glycation end products (AGEs) bind 
to receptors on chondrocytes, up-regulating pro-inflammatory cytokines and 
MMPs (Berenbaum 2013). A second innate immune system; the complement 
system, also plays an influential part in the inflammatory response during 
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OA. Complement complex deposits have been found in synovial tissue and 
correlate with the extent of synovitis present (Haseeb and Haqqi 2013).  
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1.3  The Role of the Synovium in the Pathophysiology of 
Osteoarthritis 
 
Inflammation is a key driver in the development and progression of OA, even 
in the early stages of the disease (Kapoor, Martel-Pelletier et al. 2011). The 
extent to which synovitis affects the pathogenesis of OA is not completely 
understood, but it is known to be strongly associated (Scanzello and 
Goldring 2012). OA tissue and synovial fluid, when compared with ‘normal 
synovial fluid’ was found to be highly enriched with plasma proteins, 
complement components and cytokines (Sokolove and Lepus 2013). 
Comparison of OA synovium and chondrocyte microarray data, to OA 
synovial fluid proteomic analysis has recently confirmed that the synovial 
membrane contributes to this rich soup of inflammatory-associated proteins 
present in OA synovial fluid. Proteins that play a role in the acute phase 
response and complement pathways were found, in part, to be produced by 
the synovium (Ritter, Subbaiah et al. 2013).  
 
Equine synovitis is characterised by an infiltration of mononuclear cells into 
the synovial membrane and synovial fluid (McIlwraith, Frisbie et al. 2010), 
with a concurrent associated enzymatic response (Todhunter, Kincaid et al. 
1996). This is accompanied by hyperplasia of the intima layer, oedema, 
vascularisation, and fibrosis of the subintima (Sutton, Clutterbuck et al. 2009, 
Frisbie 2012). Within this cellular infiltration are T-cells, B-cells and an 
abundance of macrophages. An up regulation of synoviocyte gene 
expression, and increased synovial fluid concentration, of pro-inflammatory 
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cytokines IL-1β and TNF-α, have a major impact on the pathophysiology of 
equine OA (Kamm, Nixon et al. 2010). These pro-inflammatory cytokines dis-
regulate the expression of other cytokines, matrix metalloproteinases and 
aggrecanases; upsetting the chondrocyte metabolic equilibrium and resulting 
in an excessive catabolic state. This leads us to recognise pro-inflammatory 
cytokines produced by the synovium, alongside those produced by 
chondrocytes, as important drivers of cartilage degradation. However, the 
temporal relationship between subchondral bone damage, inflammation of 
the synovial tissue, and cartilage erosion, is still largely unknown (Kapoor, 
Martel-Pelletier et al. 2011), even though cartilage, bone (Kapoor, Martel-
Pelletier et al. 2011), synovium (Ritter, Subbaiah et al. 2013) and adipose 
tissue (Houard, Goldring et al. 2013) have all been found to contribute to the 
inflammatory process. Acute synovitis may be one of the first changes to 
occur in OA; synovial tissue has been shown to over-express inflammatory 
mediators such as pro-inflammatory cytokines (Benito et al. 2005); especially 
IL-1β and TNF-α (Todhunter et al. 1996). In comparison to normal equine 
joints, OA equine synovium exhibits significantly up-regulated gene 
expression of TNF-α, ADAMTS5 and MMP13 at all stages of OA, and IL-1β 
was moderately up-regulated. Whereas chondrocytes in OA cartilage 
significantly up-regulated the gene expression of IL-1β, TNF-α, ADAMTS4 
and MMP13 (Kamm, Nixon et al. 2010).  
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1.3.1  Fibroblast-Like Synoviocytes and Their Contribution to 
Synovitis 
FLS are cells of mesenchymal stromal lineage found within the synovial 
membrane (Bartok and Firestein 2010). As explained previously, FLS 
precursors reside within the synovial membrane, and FLS expand locally 
(Alwan, Carter et al. 1991). Whilst FLS and subintimal fibroblasts share some 
similarities such as the expression of collagen, vimentin and CD90, FLS also 
express specific markers including uridine diphosphoglucose-dehydrogenase 
(UDPGD), vascular cell adhesion molecule-1 (CD106) (VCAM-1) and 
calcium-dependent adhesion molecule-11 (Cadherin-11) (Bartok and 
Firestein 2010). These factors play roles in both normal joint maintenance 
and in joint disease. Cadherin-11 is crucial for the adhesion and organisation 
of synoviocytes within the synovial membrane, and cadherin deficient mice 
have been found to develop a disordered synovial membrane with a 
defective inflammatory response rendering the mice resistant to inflammatory 
arthritis (Lee, Kiener et al. 2007). UDPGD is a hyaluronan synthesis-related 
enzyme which is very specific to the FLS (Edwards 1994, Rosengren, Boyle 
et al. 2007) whereas VCAM-1 is thought to bind mononuclear cells in the 
synovial membrane (Bartok and Firestein 2010).  
 
FLS Help Drive the Mononuclear Cellular Infiltration Seen in Synovitis 
The chemotaxis of mononuclear cells into the synovial membrane, a process 
which aids in characterising synovitis, is driven by a number of chemokines 
(Haringman, Smeets et al. 2006) and growth factors such as transforming 
growth factor-β (TGF-β) (Allen, Manthey et al. 1990) and platelet derived 
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growth factors (PDGF) (Deuel, Senior et al. 1982). Pro-inflammatory 
cytokines such as IL-1β have also been shown to stimulate the production of 
chemokines in OA chondrocytes (Haseeb and Haqqi 2013). Amongst the key 
chemotaxis inducing chemokines, is the macrophage chemoattractant 
protein-1 (MCP-1 or CCL-2). FLS have been found to be an important source 
of MCP-1, which also contributes to monocyte activation (Villiger, Terkeltaub 
et al. 1992). The activated synovial membrane is a potent producer of 
mediators such as IL-1β, TNF-α, TGF-β and PDGF which in turn stimulate 
further MCP-1 secretion resulting in a positive feedback cycle cultivating the 
inflammatory response (Villiger, Terkeltaub et al. 1992). Two further 
chemokines, involved in chemotaxis and the exacerbation of the 
inflammatory response, found to be expressed by OA FLS are the growth 
regulatory oncogene-β (GROβ) and the granulocyte chemotactic protein 
(GCP-2) (Scaife, Brown et al. 2004). Abundant expression of the chemokine 
receptor CCR-5 has been observed on cells within inflamed synovium 
(Haringman, Smeets et al. 2006). OA FLS have also been found to express 
CCR-5 and activation of this receptor with its ligands CCL-19 and CCL-21 
has been shown to result in cell migration and increased secretion of 
vascular endothelial growth factor (VEGF) which promotes angiogenesis 
(Haseeb and Haqqi 2013).  
 
FLS Help Drive the Inflammatory Reaction  
FLS are key mediators of tissue destruction, through the production of 
MMPs, inflammatory cytokines, chemokines, proteases and indirectly 
through the regulation of monocytes. During early OA, the soluble CD14 
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receptor within synovial fluid, has been found to enhance the FLS response 
to TLR-2 and -4 ligands (Nair, Kanda et al. 2012). Binding of ligands to these 
receptors promotes pro-inflammatory cytokine gene expression. Cytokines 
IL-1β and TNF-α, chiefly produced by synovial macrophages (Bondeson, 
Wainwright et al. 2006) but also by FLS, can increase the secretion of 
themselves (Fernandes, Martel-Pelletier et al. 2002) and can promote FLS 
production of IL-6, IL-8, leukocyte inhibitory factor (LIF), proteases and PGE2 
(Pelletier, Martel-Pelletier et al. 2001). A substantial difference was detected 
when examining differentially expressed genes between FLS from 
rheumatoid arthritis (RA) and OA, however, a common observation was their 
increase in IL-6 and MCP-1 protein (Scaife, Brown et al. 2004). IL-6 is 
significantly elevated in OA synovium and contributes to the development of 
OA by potentiating the effects of IL-1β when stimulating MMP production and 
inhibiting proteoglycan production, however it can also promote tissue 
inhibitor of metalloproteinase (TIMP) (Fernandes, Martel-Pelletier et al. 
2002). FLS also have the ability to activate T cells and support B cell survival 
(Filer, Parsonage et al. 2006, Donlin, Jayatilleke et al. 2014). Furthermore 
FLS have been found to express MMP10, which is associated with the 
invasion potential of these cells (Davidson, Waters et al. 2006). 
 
FLS Can Exert Both Protective and Catabolic Effects  
Equine FLS co-cultured with mechanically injured equine cartilage explants, 
down-regulated their gene expression of ADAMTS4 and -5, and TIMP-1, and 
up-regulated their MMP1 expression, compared to those exposed to non-
injured cartilage. The mechanically injured cartilage, in co-culture with 
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synoviocytes, experienced increased chondrocyte gene expression of 
collagen type II and ADAMTS5. However on histologic examination, 
decreased focal cell loss and decreased chondrocyte cluster formation were 
observed (Lee, Kisiday et al. 2013). These findings suggest cross-talk 
between synoviocyte and chondrocyte populations influence their gene 
expression. In a similar experiment, bovine mechanically injured cartilage 
was co-cultured with bovine synovial explants which contained other cell 
types alongside FLS. No increase in chondrocyte ADAMTS5 gene 
expression was observed, but an increase in ADAMTS5 protein was present 
in relation to both injury and co-culture (Lee, Fitzgerald et al. 2009). Other 
synovial cells, such as synovial macrophages, may have prevented the FLS-
induced increase in chondrocyte ADAMTS5 gene expression observed in the 
first study, or this could be a species-related difference. As well as promoting 
the inflammatory response, FLS have also been observed to moderate the 
synovial macrophage reaction. FLS strongly suppress TNF-mediated 
induction of an interferon (IFN)-β autocrine loop and downstream expression 
of IFN-stimulated genes that are classical of macrophage activation (Donlin, 
Jayatilleke et al. 2014) 
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1.3.2  Synovial Macrophages and their Contribution to Synovitis  
 
Synovial Macrophages become Activated in Synovitis and Exert a 
Significant Influence on Cartilage Degradation 
As previously described, upon initiation of an inflammatory event the 
synovium experiences a massive cellular infiltration; mononuclear cells 
extravasate from blood vessels into the intima layer and synovial fluid (Caron 
2011). Equine histopathology grading systems consider small areas of 
mononuclear cells to reflect a grade 1 synovitis, whereas a marked presence 
of mononuclear cells in greater than 50% of the section is classified a grade 
4 synovitis (McIlwraith, Frisbie et al. 2010). Similar synovitis grading systems 
are available for the dog, sheep and goat, however they also incorporate the 
scoring of lymphoid follicles within the synovial membrane (Cook, Kuroki et 
al. 2010, Little, Smith et al. 2010). Macrophages are abundant within this 
cellular infiltration (Haseeb and Haqqi 2013) and chemokines responsible for 
their chemotaxis have been implicated in the development of OA (Blom, van 
Lent et al. 2004). Whether factors from injured cartilage activate the 
macrophages, or other stimuli initiate macrophage activation, which 
subsequently causes them to influence cartilage degradation, is  unknown. 
The predominant roles of activated macrophages include pro-inflammatory 
cytokine production and phagocytosis of pathogenic material. Macrophages 
manifest in three distinct activated phenotypes; the classically activated, the 
alternatively activated and the type II-activated macrophage. The classically 
activated macrophage is triggered by IFN-γ and TLR signalling; once TLR-
ligands are bound endogenous TNF-α production by the macrophage 
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commences. This induces an up-regulation in the gene expression of pro-
inflammatory cytokines IL-1, TNF-α, IL-6 and IL-12, and VEGF (Haywood, 
McWilliams et al. 2003). VEGF is the principal driver of angiogenesis, also 
seen in the intimal layer at the onset of synovitis, and a recent study has 
shown that anti-VEGF antibodies can reduce the onset of OA (Nagai, Sato et 
al. 2014). The alternatively activated macrophages are activated by IL-4, 
however they fail to produce nitric oxide which diminishes their ability to kill 
phagocytosed microbes. The type II-activated macrophages are similarly 
stimulated to the classically activated macrophages but secrete a large 
amount of IL-10, suggesting this population have anti-inflammatory 
properties (Mosser 2003).  
 
Activated synovial macrophages produce significant amounts of the pro-
inflammatory cytokines IL-1β and TNF-α, which play a crucial role in the 
pathogenesis of OA. Bondeson et al. (2006) extracted synovial macrophages 
from digested human synovial membrane using CD14+ beads. The resulting 
synovial cultures produced significantly less IL-1β and TNF-α than those 
containing synovial macrophages. Cultures also experienced significantly 
reduced gene expression of IL-6, IL-8, MMP1 and -3, which are chiefly 
produced by synovial fibroblasts (Bondeson, Wainwright et al. 2006).  
 
On further investigation using IL-1β and TNF-α inhibitors in synovial cultures, 
it was noted that the inhibition of both cytokines were necessary to reduce IL-
6, IL-8, MCP-1, MMP1, -3, -9, and -13 to the same extent as that of synovial 
macrophage depleted cultures (Bondeson, Wainwright et al. 2006). Using the 
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synovial culture model descried above, it was also found that synovial 
macrophage TNF-α was the main driver of FLS ADAMTS4 gene expression, 
and that neither IL-1β nor TNF-α had any influence over FLS ADAMTS5 
gene expression (Bondeson, Wainwright et al. 2006). This finding was 
contradicted by Kamm et al. 2010 (Kamm, Nixon et al. 2010) which may 
highlight differences between human and equine synovium. This will be 
discussed in more detail further on.  
 
Activated Macrophages Stimulate Osteophyte Formation and MMP-
Induced Cartilage Degradation 
A murine model of collagenase-induced arthritis (CIA) depleted of synovial 
macrophages by intra-articular administration of clodronate-liposomes, 
produced a 66-84% reduction in osteophyte formation (Blom, van Lent et al. 
2004). A concurrent decrease in the production of growth factors TGF-β, and 
bone morphogenetic proteins-2 and -4 in the intima layer were also observed 
(Blom, van Lent et al. 2004). In a subsequent study using a similar 
macrophage depleted murine model subjected to intra-articular administered 
TGF-β, it was observed that macrophages were crucial intermediate factors 
in osteophyte formation induced by TGF-β (van Lent, Blom et al. 2004). 
Macrophages obviously play a pivotal role in the degree of bone pathology 
observed during OA.  
 
Activated synovial macrophages have also been associated with MMP-
mediated cartilage damage, and appear to up-regulate MMP production 
within the synovial membrane (Blom, van Lent et al. 2007). Proteinases such 
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as MMPs and aggrecanases (ADAMTS family) cleave aggrecan, one of the 
chief constituents of cartilage ECM, within its interglobular domain but 
between different amino acid sequences. Neoepitope antibodies designed 
for specific N or C terminal amino acid sequences, can identify the origin of 
these aggrecan fragments, and subsequently determine whether they were 
produced through MMP or aggrecanase proteolysis (Stanton, Golub et al. 
2011). These antibodies will only bind to protein degradation products and 
not intact protein (Fosang, Last et al. 2010), allowing measurable changes in 
ECM degradation. Mice depleted of macrophages and subjected to the CIA 
model, were found to have generated fewer MMP-induced neoepitope 
fragments than those of control mice (Blom, van Lent et al. 2007). 
Furthermore a significant reduction in macrophage-depleted synovial 
membrane MMP3 and MMP9 gene expression was observed, which did not 
occur in cartilage, implying that synovial macrophages mediate MMP 
production in the synovial membrane.  
 
Highlights 
1. Activated synovial macrophages play a major role in osteophyte 
formation and cartilage degradation, through the production of growth 
factors (VEGF and TGF-β), and proteases (MMP3 and -9).  
2. Synovial macrophages are significant producers of IL-1β and TNF-α 
which drive the inflammatory pathway. 
3. During inflammation synovial macrophages influence FLS through 
signalling mediators and IL-1β and TNF-α. 
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1.4  The Role of Pro-inflammatory Cytokines in Osteoarthritis 
 
1.4.1  Interleukin-1  
 
The complex pathway of interleukin-1 instigated cellular activation, 
involves many factors including membrane bound and soluble 
receptors, receptor accessory proteins, soluble forms of both 
interleukin isoforms and receptor antagonist proteins (Figure 1.3). This 
multifactorial cascade makes it ideal for therapeutic intervention.  
 
IL-1β is a pro-inflammatory cytokine, produced within the joint by FLS, 
synovial macrophages, chondrocytes and osteoblasts. It is a key driver of 
cartilage degeneration within OA, however it also plays a complex role in 
joint homeostasis (Kapoor, Martel-Pelletier et al. 2011). IL-1β knock out mice 
experienced accelerated cartilage lesion formation after joint destabilisation 
compared to control mice (Clements, Price et al. 2003). However IL-1β also 
has catabolic influences, decreasing chondrocyte gene expression of type II 
collagen, aggrecan, and proteoglycans (Gregg, Fortier et al. 2006), and 
increasing chondrocyte gene expression of MMP1, -3 and -13, all key 
mediators of cartilage destruction (Kapoor, Martel-Pelletier et al. 2011). 
Blocking IL-1 action with recombinant IL-1 receptor antagonist (IL-1RA) was 
found to significantly reduce MMP-derived aggrecan neoepitopes (van 
Meurs, van Lent et al. 1998), directly linking IL-1 to MMP-mediated cartilage 
degradation. There is a fine balance between inhibiting the catabolic effects 
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of  IL-1β and disrupting joint homeostasis, which needs to be considered 
when targeting IL-1β .   
 
IL-1 is produced in two isoforms α and β; around 26% of their amino-acid 
sequences are homologous, and each is transcribed from a separate gene, 
however IL-1β mRNA predominates (Dinarello 1988). Both isoforms are first 
synthesised as precursor proteins (31kDa), before being activated 
(proteolytically cleaved to 17.5kDa forms) by intracellular ICE (Caspase I) 
enabling them to bind to receptors (Clements, Price et al. 2003). Both bind to 
the same specific cell membrane bound receptors (Dower, Kronheim et al. 
1986); IL-1 receptor type I (IL-1RI) and type II (IL-1RII). IL-1RI is an 80kDa 
member of the immunoglobulin superfamily, and contains a 20kDa 
cytoplasmic element crucial for the transduction of IL-1β intracellular 
signalling (Saklatvala, Davis et al. 1996, Murray, Parry-Jones et al. 2015). IL-
1RII is commonly termed a decoy receptor (around 67kDa), as it contains a 
short cytoplasmic element which is unable to transduce a signal (Kapoor, 
Martel-Pelletier et al. 2011). An increase in IL-1Rs have been observed in 
both OA synoviocytes and chondrocytes (Kapoor, Martel-Pelletier et al. 
2011), and within areas surrounding cartilage lesions. Equine IL-1 was first 
characterised at The University of Liverpool in 1990 by Stephen May (May, 
Hooke et al. 1990).  
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Figure 1.3 IL-1 Signaling Pathways. In response to a stimulus such as LPS, transcription of the gene encoding IL-1β is 
initiated. IL-1β ismade as an inactive precursor protein and caspase-1 cleaves this pro-IL-1β to make the active IL-1β. A 
variety of factors can promote or inhibit the release of active IL-1β. Once released, IL-1β binds to IL-1RI alongside IL-1 
receptor accessory protein (IL-1RAcp) and signal transduction is triggered, including co-localisation of myeloid differentiation 
primary response protein 88 (MyD88), IL-1 receptor associated kinase (IRAK-1) and IRAK-2, recruitment of TNF receptor 
associated factor 6 (TRAF-6) and activation of nuclear factor kappa B (NFκB) from complex with IκB. Conversely IL-1RII 
does not induce signal transduction (Murray, Parry-Jones et al. 2015) 
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1.4.1.1 Soluble Interleukin-1 Receptors Act as Interleukin-1 
Scavengers 
Proteases lyse and release both membrane bound IL-1Rs to produce soluble 
forms; sIL-1RI and sIL-1RII. These act as scavengers of both interleukin 
isoforms and IL-1RA; sIL-1RI preferentially binds to IL-1RA, whereas sIL-
1RII preferentially binds to IL-1β (Svenson, Hansen et al. 1993, Dinarello 
1996, Jotanovic, Mihelic et al. 2012).  
 
1.4.1.2  Soluble Interleukin-1 Receptor Accessory Protein 
Scavenges Interleukin-1β 
IL-1 receptor accessory protein also exists in both membrane bound (IL-
1RAcp) and soluble (sIL-1RAcp) forms. Once IL-1β has bound to IL-1RI, the 
IL-1RAcp is required to initiate intracellular signalling (Svenson, Hansen et 
al. 1993), sIL-1RAcp is unable to carry out this function. sIL-1RAcp 
scavenges IL-1β using 2 methods (1) sIL-1RAcp competes with membrane 
bound IL-1RAcp to bind IL-1β to IL-1RI. sIL-1RAcp will inhibit the cytokine’s 
function. (2) sIL-1RAcp and sIL-1RII preferentially bind to IL-1β, acting as a 
soluble sIL-1RII scavenger. Once IL-1β is bound to the sIL-1RII with the 
accompanying receptor accessory protein no signal transduction will occur 
and the cytokine’s function will be inhibited. When sIL-1RAcp and sIL-1RII 
interact, it increases the IL-1 binding affinity of the receptor by 100-fold, 
whilst maintaining a low binding affinity to IL-1RA (Smith, Hanna et al. 2003).  
 
 !
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1.4.1.3  Interleukin 1 Receptor Antagonist Protein  
This protein binds to the 80kDa membrane bound IL-1RI on fibroblasts and T 
cells with high affinity, and with lower affinity to IL-1RII on neutrophils and B 
cells. Once bound it does not initiate any IL-1 mediated protein kinase signal 
transduction (Dripps, Brandhuber et al. 1991). A 10-1000 fold increase of IL-
1RA to IL-1 must occur to block all of the available IL-1 receptors that are up-
regulated during OA (Wehling, Moser et al.). Recombinant IL-1RA has 
previously been reported to reduce the severity of disease in animal models, 
suggesting that this recombinant protein may hold therapeutic qualities. A 
group in Tokyo successfully produced a non-glycosylated recombinant 
version of equine IL-1RA protein. E.Coli were transformed with a 
recombinant equine IL-1RA containing plasmid and expanded. Recombinant 
equine IL-1RA protein was then extracted from these cells, and used to 
successfully inhibit cytotoxic activity of IL-1. They hypothesised that, as in 
human medicine, this recombinant protein could be used in a therapeutic 
manner (Kato, Ohashi et al. 1997). After a thorough literature search, no 
further investigation into this therapeutic pathway could be found. There are 
two IL-1RA protein preparations currently licensed for humans, Anakinra 
(Kineret), which is a recombinant human IL-1RA, and Orthokine, which is an 
autologous IL-1RA injection. They elicit certain clinical and biological 
responses and have been shown to produce statistically significant 
improvements in pain scores in knee OA as assessed by the KOOS (knee 
injury and osteoarthritis outcome score) (Jotanovic, Mihelic et al. 2012). 
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1.4.1.4  Interleukin-1β Signal Transduction 
The intracellular portion of IL-1R1 is very similar to that of the TLR, and is 
termed the Toll-and-IL-1 receptor (TIR) region (Kapoor, Martel-Pelletier et al. 
2011). TLRs are important PRRs; recognising pathogen associated 
molecular patterns (PAMPS) such as LPS (Bobacz, Sunk et al. 2007, Kwon, 
Vandenplas et al. 2010), and DAMPs such as cartilage degradation 
fragments (Nair, Kanda et al. 2012). These receptors activate many 
pathways including two major pathways, the NF-κB pathway (Kwon, 
Vandenplas et al. 2010), and IL-1R Associated kinase (IRAK) (Janssens and 
Beyaert 2003). These pathways play a major role in the regulation of 
inflammatory cytokine and MMP gene expression. IRAK partly controls the 
mitogen-activated protein kinases (MAPK); ERK, JNK and p38. Protein 
kinases are enzymes, which add phosphate groups (phosphorylation) to 
other proteins, causing them to functionally change; this can be reversed by 
specific protein phosphatases, which remove phosphate groups. These 
pathways regulate signal transduction and eventually transcriptional factors 
of specific genes.   
 
1.4.2  Tumour Necrosis Factor-α 
TNF-α is the second major pro-inflammatory cytokine responsible for the 
pathophysiology of OA, but it is also involved in maintaining joint 
homeostasis. This cytokine is produced in two isoforms; TNF-α is primarily 
produced by monocytes and macrophages but all joint cells are capable of 
producing this cytokine, whereas TNF-β is produced by activated T 
lymphocytes (Saklatvala, Davis et al. 1996). Both isoforms bind to two 
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specific cell membrane receptors TNFRI (p55) and TNFRII (p75) (Saklatvala, 
Davis et al. 1996, Russo and Polosa 2005); TNFRI is responsible for driving 
the inflammatory response (Nophar, Kemper et al. 1990) (Figure 1.4). TNFRI 
is up-regulated in OA chondrocytes (Westacott, Atkins et al. 1994) and 
synovial fibroblasts (Alaaeddine, DiBattista et al. 1997), and is the more 
dominant receptor for mediating TNF activity in articular tissues. TNF 
activates a number of protein kinases, similar to IL-1 (Saklatvala, Davis et al. 
1996). Since the 1980s it has been known that TNF-α suppresses 
proteoglycan synthesis and degrades proteoglycan through proteolysis 
(Saklatvala 1986).  
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Figure 1.4 TNF-α Signalling Pathways. Binding of TNF-α to TNFRI results in the configuration of TRADD (TNFR-associated death 
domain) and FADD (Fas-associated death domain). TRADD complex recruits the adapter protein TRAF-2 (TNFR-associated factor 2), 
whereas FADD stimulates the caspase cascade. Known downstream signalling molecules that interact with TRAF-2 and NIK (NF-κB-
inducing kinase), RIP (receptor-interacting protein) and ASKI (apoptosis signal-regulating kinase I) and these are capable of chanelling 
signals towards cell death and inflammation. Binding of TNF-α to TNFR2 recruits the adapter protein TRAF-2, which directly activates 
the inflammatory cascade via the generation of NF-κB or p38 MAPK (mitogen-activated protein kinase) and activates caspase-mediated 
cell death through recruitment of FADD and RIP (Russo and Polosa 2005). 
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1.4.3 Interleukin-1β and Tumour Necrosis Factor-α  
Both IL-1β and TNF-α potentiate similar responses. Chondrocyte gene 
expression of MMPs, nitric oxide (NO) and PGE2 are stimulated whilst 
synthesis of link protein and type II collagen is inhibited by both IL-1β and 
TNF-α (Lefebvre, Peeters-Joris et al. 1990, Frisbie 2012). These cytokines 
also increase chondrocyte gene expression of IL-6 (Guerne, Carson et al. 
1990), IL-8 (Lotz, Terkeltaub et al. 1992), and synoviocyte MCP-1 (Villiger, 
Terkeltaub et al. 1992). They also induce reactive oxygen species (ROS) 
which contribute to cartilage degeneration, and down-regulate expression of 
antioxidants (Kapoor, Martel-Pelletier et al. 2011).  
 
1.4.4  Interleukin-6  
The IL-6 subfamily of cytokines share the signal transducing receptor-β 
subunit gp130 (Rose-John, Scheller et al. 2006); IL-6 and IL-6 alpha receptor 
(IL-6Rα) bind together to form a signalling complex (Boulanger, Chow et al. 
2003). Soluble IL-6Rα (sIL-6Rα) can bind to IL-6 to induce IL-6 effects on 
cells that don’t express the receptor. However, soluble gp130 also exists and 
can bind to IL-6/sIL-6Rα and inhibit their actions (Narazaki, Yasukawa et al. 
1993).  
 
IL-6 is produced by equine synoviocytes and chondrocytes in both normal 
and diseased joints (Ishimi, Miyaura et al. 1990, Ley, Ekman et al. 2009), 
and this has been reproduced in equine models such as LPS-induced 
arthritis (Hawkins, MacKay et al. 1993), and synovectomy-induced synovitis. 
IL-6 has been associated with bone resorption (Ishimi, Miyaura et al. 1990), !
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equine subchondral bone cysts (Rechenberg, Leutenegger et al. 2001) and 
equine chip fractures (Ley, Ekman et al. 2007). This is interesting as 
synovitis is always a concurrent finding in joints suffering from chip fractures 
(Ley, Ekman et al. 2007). Whether cytokines produced from an inflamed 
synovial membrane predispose the bone to a chip fracture, or the chip 
fracture itself produces cytokines causing synovitis, is so far unknown. 
Significant correlation between synovial fluid IL-6 and TP concentrations 
were associated with chip fractures, yet no correlation to WBCC occurred. IL-
6 is therefore most likely produced by resident joint cells rather than 
infiltrating synovial fluid cells (Ley, Ekman et al. 2007). Both IL-1β and TNF-α 
can directly stimulate IL-6 production (David, Farley et al. 2007). Whether IL-
6 exerts a predominantly anabolic or catabolic effect upon cartilage in OA is 
so far unknown. IL-6 reduces cartilage loss in murine models (de Hooge, van 
de Loo et al. 2005) and IL-1 induced PGE2 production in chondrocytes and 
synoviocytes (Hauptmann, Van Damme et al. 1991). IL-6 can also up-
regulate chondrocyte SOX-9 (SRY-box-9 gene) (Ley, Svala et al. 2011) and 
TIMP production (Lotz and Guerne 1991). However, IL-6 can also up-
regulate MMP-1, MMP-13 and C-reactive protein (CRP) levels. CRP has 
been linked to OA in humans; high baseline levels of IL-6 and CRP were 
associated with an increased risk of cartilage damage visualised through 
magnetic resonance imaging (Kapoor, Martel-Pelletier et al. 2011). Some 
studies suggest the effects of IL-6 are determined by the presence of the 
soluble IL-6Rα (sIL-6Rα) as IL-6 has been found to inhibit proteoglycan 
synthesis (Guerne, Desgeorges et al. 1999) and induce aggrecanase-
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mediated proteoglycan catabolism (Flannery, Little et al. 2000) in the 
presence of sIL-6Rα. 
 
 
1.4.5  Aggrecanases and Matrix Metalloproteinases 
 
1.4.5.1  Matrix Metalloproteinases  
MMPs are capable of degrading cartilage ECM proteins which is essential for 
normal ECM turnover. However in pathological conditions, catabolic 
processes outweigh anabolic chondrocyte metabolism resulting in the 
degradation of cartilage (Vincenti and Brinckerhoff 2002, Fosang, Last et al. 
2010). Key members of this large family of proteinases, in regards to 
cartilage degradation during OA, are the interstitial collagenases MMP1 and -
13 (Goldring, Otero et al. 2011), the gelatinases MMP2 and MMP9 (Clegg 
and Carter 1999) and the stromelysin MMP3 (Peffers, Thornton et al. 2015). 
MMPs are produced as latent proteins; most are secreted in a pro-form and 
are activated in the extracellular environment  (Clegg and Carter 1999). A 
small percent undergo intracellular furin-like activation before being secreted. 
Interstitial collagenases (MMP1 and MMP13) are able to unwind the type II 
collagen triple helix, making it vulnerable to MMP9 proteolysis. MMP3 is the 
most highly expressed MMP in cartilage, and capable of degrading 
proteoglycans including aggrecan, and activating pro-collagenases (Peffers, 
Thornton et al. 2015). MMPs are also capable of degrading other ECM 
proteins including decorin, biglycan, fibromodulin and COMP (Peffers, 
Thornton et al. 2015). MMPs are induced by cytokines, predominantly IL-1β 
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and TNF-α, which activate the MAPK downstream signalling. Once MAPKs 
have translocated to the nucleus, they activate JNKs and ERKs which 
phosphorylate and activate C-Jun to induce expression of MMP genes, and 
ERK which activates transcription factors and drives MMP promotors 
(Vincenti and Brinckerhoff 2002). NF-κB is the second pathway to activate 
MMP genes and drive expression.  
 
MMPs cleave aggrecan within the IGD at two sites; DIPEN341!342FFGVG 
and SED441!442LVV. Proteinases including MMP1, -2, -3, -9, and -13 
preferentially cleave at the DIPEN341!342FFGVG site. Neoepitope antibodies, 
recognising unique specific newly formed N- or C- termini of the degradation 
products, allow identification of specific proteinase activity on aggrecan 
(Fosang, Last et al. 2010). These proteinases cleave matrix proteins at a 
later stage of OA than aggrecanases, possibly due to the delayed activation 
of the latent proteases (Durigova, Nagase et al. 2011).  
 
1.4.5.2  Aggrecanases  
There are over 28 different members of the ADAMTS family (A Disintegrin 
And Metalloproteinase with ThromboSpondin motif), and of these, a 
subgroup are aggrecanases with significant catabolic activity. These 
aggrecanases cleave aggrecan in particular, but can also degrade smaller 
ECM proteins. The ADAMTS family mainly cleave the aggrecan core protein 
within the IGD between the two globular domains G1 and G2. Here they 
cleave at the specific Glu373-Ala374 bond, giving rise to the N-terminal 
neoepitope 374ARGSV and the C-terminal neoepitope NITEGE373 (Fosang, 
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Last et al. 2010). However, they can also cleave aggrecan at four sites within 
the second chondroitin-sulphate rich domain (CS-2) (East, Stanton et al. 
2007, Fosang, Last et al. 2010). ADAMTS5 is thought to be responsible for 
cleavage within the IGD, whereas other aggrecanases cleave within the CS-
2 domain (East, Stanton et al. 2007). Aggrecanases can also effect other 
proteoglycans within the ECM such as biglycan, brevican, decorin and 
fibromodulin, and glycoproteins fibronectin and carboxymethylated transferrin 
(Gendron, Kashiwagi et al. 2007). Aggrecanases are now considered the 
principle proteases responsible for cartilage ECM proteolysis during OA 
rather than MMPs  (Durigova, Nagase et al. 2011, Zhang, Yan et al. 2013). 
This conclusion was reflected in a study which reported 90% reduction in IL-
1 induced aggrecanase activity after ADAMTS4 and -5 were 
immunodepleted from bovine cartilage explants (Tortorella, Malfait et al. 
2001). Lower MMP proteolytic activity, in comparison to aggrecanase 
activity, is thought to be due to the delayed activation of pro-MMPs, and the 
relatively low cleavage efficiency of these enzymes (Bakali, Gras-Masse et 
al. 2014). There are also certain members of the ADAMTS family which can 
cleave aggrecan but it is not their preferred substrate, these include 
ADAMTS 1, 8, 9 and 15 (Kataoka, Ariyoshi et al. 2013). However, the key 
mediators of OA within this family, are ADAMTS4 (aggrecanase-1) and 
ADAMTS5 (aggrecanase-2), and ADAMTS5 is thought to have 1000 times 
more aggrecanase activity than ADAMTS4 (Gendron, Kashiwagi et al. 2007). 
ADAMTS4 and -5 are produced as zymogens, and undergo intracellular 
activation by furin enzymes through cleavage of their pro-domain. Whether 
other pro-protein convertases have the same effect, or whether activation is 
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necessary for secretion from the cell, is so far unknown (Bondeson, 
Wainwright et al. 2013).  
 
The exact mechanisms of aggrecanase expression in chondrocytes and 
synoviocytes are yet to be determined in the horse. ADAMTS5 is thought to 
be the predominant mediator of aggrecanolysis in mice, whereas it is 
constitutively expressed by human synovium and chondrocytes (Bondeson 
2015). Human synoviocyte and chondrocyte ADAMTS4 gene expression 
was found to be significantly up-regulated by TNF-α and IL-1β in an NF-κB 
dependent manner (Bondeson, Wainwright et al. 2006), which may indicate 
ADAMTS4 is predominantly activated during OA. However when short 
interfering RNA (siRNA) was used to block both ADAMTS4 and ADAMTS5 
gene expression in human cartilage explants, both were found to facilitate 
aggrecanolysis either independently or concurrently (Song, Hua et al. 2007). 
These species-variations in gene expression cause us to ponder the 
question of whether the murine model should be used to investigate human 
OA. Much research has, so far, been carried out using murine models of OA, 
and as previously stated, ADAMTS5 has been found to cause the majority of 
aggrecanolysis and is therefore considered the pathologically inducing 
aggrecanase during murine OA (Bondeson, Wainwright et al. 2013). This has 
been proved through many different experimental studies, including those 
involving ADAMTS4 knock-out (KO) mice subjected to destabilisation of the 
medial meniscus (DMM) which developed instability-induced OA joint 
changes comparable to wild-type mice (Glasson, Askew et al. 2004). 
Whereas, ADAMTS5 KO mice experienced significantly less cartilage 
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degradation than wild-type mice. The role of ADAMTS5 aggrecanolysis was 
further supported by the lack of aggrecan fragments specific to ADAMTS5 
aggrecan cleavage sites found (Glasson, Askew et al. 2005).  
 
A variant of ADAMTS4 mRNA (ADAMTS4_v1) has been identified in human 
OA synovium. The protein it translates is identical to ADAMTS4 apart from 
the spacer domain, which is replaced with a non-homologous C-terminal 
domain. Both forms are produced as inactive pro-domain proteins, which are 
activated by furin-cleavage. ADAMTS4 is activated before being secreted, 
however ADAMTS4_v1 is secreted in its inactive form and associates with 
the cell membrane. It may then be activated by extracellular enzymes, by 
self-activation, or by an unknown mechanism (Wainwright, Bondeson et al. 
2013).    
 
Equine ADAMTS5 gene expression appears to contrast that of humans. 
Synoviocyte ADAMTS5 gene expression was found to be significantly up-
regulated during equine OA, whereas expression of ADAMTS4 remained 
unchanged. However equine chondrocytes significantly increased their 
ADAMTS4 gene expression during OA, but there was no increase in 
ADAMTS5 mRNA observed (Kamm, Nixon et al. 2010). This may indicate 
that equine synovium is the chief producer of ADAMTS5, however more 
insight into the regulation of ADAMTS5 is needed to confirm this. As 
previously mentioned, human synoviocyte ADAMTS4 gene expression has 
been found to be significantly up-regulated by both IL-1β and TNF-α 
cytokines, however ADAMTS5 expression remained unchanged (Bondeson, 
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Wainwright et al. 2006). A similar pattern of expression was observed in 
human chondrocytes, although a slight increase in ADAMTS5 occurred 
(Song, Hua et al. 2007). However, one study reported that human ADAMTS5 
mRNA was more abundant in both normal and OA cartilage compared to that 
of ADAMTS4 mRNA (Bau, Gebhard et al. 2002), although levels of 
ADAMTS4 mRNA and protein correlated with OA progression whereas 
ADAMTS5 levels did not. ADAMTS5 protein is rapidly cleared by endocytosis 
and degraded by low-density lipoprotein receptor-related protein (LRP-1) in 
cartilage, however this pathway is disrupted in OA as LRP-1 is lost 
(Yamamoto, Troeberg et al. 2013). These findings suggest that increased 
ADAMTS5 aggrecanolytic activity may result from a build up of extracellular 
ADAMTS5 protein rather than an increase in mRNA levels stimulated by the 
onset of OA and concurrent increases in cytokine levels.   
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Table 1.1 Aggrecanase gene expression levels observed in healthy joint cells exposed to inflammatory inducing agents.   
Gene Cell   Reason Species Expression Study 
      
ADAMTS4 Synoviocytes TGF-β Human Up-regulated (Yamanishi, Boyle et al. 2002) 
  LPS or IL-1β Equine Up-regulated (13-fold) (Ross, Kisiday et al. 2012) 
      
 Chondrocytes IL-1 Human Was induced by IL-1 but low level of expression. (Bau, Gebhard et al. 2002) 
  IL-1, TNF, OSM Human All induced expression  (Song, Hua et al. 2007) 
  TNF-α, OSM Murine Up-regulated expression but not aggrecanase activity. (Rogerson, Chung et al. 2010) 
  IL-1β, TNF-α Bovine Up-regulated, but undetected without induction (Tortorella, Malfait et al. 2001) 
  IL-1 induces aggre-
canase activity 
Bovine Constitutively expressed (Pratta, Scherle et al. 2003) 
  IL-1β Equine Up-regulated (27-fold) (Busschers, Holt et al. 2010) 
  LPS or IL-1β Equine Up-regulated (20-fold) (Ross, Kisiday et al. 2012) 
      
ADAMTS5 Synovium Not affected by  
IL-1, TNF-α, or  
TGF-β 
 
Human Constitutively expressed (Yamanishi, Boyle et al. 2002) 
  LPS or IL-1β Equine Unaffected (Ross, Kisiday et al. 2012) !
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 Chondrocytes IL-1 Human Not influenced by IL-1. Overall expression was much 
stronger than ADAMTS4.  
(Bau, Gebhard et al. 2002) 
  IL-1β, TNF-α,  
OSM 
 
Human All induced expression  (Song, Hua et al. 2007) 
   Human Constitutively expressed (Naito, Shiomi et al. 2007) 
  TNF-α, OSM, IL-6 Murine Up-regulated (Rogerson, Chung et al. 2010) 
  Not induced by  
IL-1β or TNF-α 
 
Bovine Constitutively expressed (Tortorella, Malfait et al. 2001) 
  IL-1β Equine Up-regulated (13-fold) (Busschers, Holt et al. 2010) 
  LPS or IL-1β Equine Up-regulated (3-fold) (Ross, Kisiday et al. 2012) 
      !
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Table 1.2 Aggrecanase gene expression levels observed in cells extracted from osteoarthritic joints.   
 
Gene Cell Reason Species Expression Study 
 
ADAMTS4 
 
Synoviocytes 
 
Driven by synovial 
macrophage-produced 
TNF-α and IL-1β 
 
Human 
 
 
Up-regulated 
 
 
(Bondeson, Wainwright et al. 2006) 
   Human Constitutively expressed (Yamanishi, Boyle et al. 2002) 
   Equine Unchanged (Kamm, Nixon et al. 2010) 
      
 Chondrocytes  
 
Human Four-fold higher than normal cartilage (Bau, Gebhard et al. 2002, Song, Hua et al. 
2007) 
   Human Increased with progression of OA (Bau, Gebhard et al. 2002) 
   Human Increased with progression of OA (Naito, Shiomi et al. 2007) 
 
   Equine Up-regulated (Kamm, Nixon et al. 2010) 
      
ADAMTS5 Synoviocytes Not driven by synovial 
TNF-α and IL-1β 
expression 
Human Constitutively expressed in OA synovium (Bondeson, Wainwright et al. 2006) 
   Human Constitutively expressed (Yamanishi, Boyle et al. 2002) 
   Equine Up-regulated in OA (Kamm, Nixon et al. 2010) 
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 Chondrocytes  Human Constitutively expressed         (Bau, Gebhard et al. 2002) (slight but significant 
increase found in late stage OA). 
   Human Constitutively expressed (Naito, Shiomi et al. 2007) 
   Human Two-fold higher than normal cartilage (Song, Hua et al. 2007) 
   Equine Unchanged  (Kamm, Nixon et al. 2010) 
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1.5  Disease Modifying Osteoarthritis Therapy     
 
1.5.1  Anti-Interleukin-1 Therapy 
Numerous targets are available to facilitate the inhibition of IL-1 activity.  
 
1.5.1.1  Interleukin-1 Receptor Antagonist  
Of the numerous IL-1β receptors expressed by each cell, only a low number 
require ligand binding to initiate the downstream signalling process, and 
potentiate IL-1β effects. IL-1RA binds to IL-1 membrane-bound receptors (IL-
1RI) to block the initiation of IL-1β activity. IL-1RA and IL-1β are produced at 
similar times and have equal affinity for IL-1RI . A high ratio of IL-1RA to IL-
1β is therefore required to have any therapeutic effect. Supplementing the 
intra-articular environment with IL-1RA may reinforce antagonistic actions. 
This can be performed using two methods; delivery of autologous IL-1RA 
protein (IRAP) into the joint space, or through gene therapy to up-regulate 
expression of the IL-1RA gene. The administration of IRAP is widely used in 
veterinary medicine. Autologous conditioned serum (ACS) is commonly 
termed IRAP in veterinary practice. The description IRAP, however, is 
incorrect; ACS is a mixture of many different anti- and pro-inflammatory 
mediators whereas IRAP refers to a single protein. ACS is produced through 
the incubation of whole blood with borosilicate glass beads for 24 hours. 
Interaction with the glass beads are believed to stimulate monocytes to 
produce cytokines and growth factors. Using human blood, ACS was first 
reported in 2003, to produce a 140-fold increase in IL-1RA, and a 2-fold 
increase in IL-4 and IL-10. No significant elevations of IL-1β or TNF-α were 
noted (Meijer, Reinecke et al. 2003). Positive symptom and disease 
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modifying effects on an equine OA model were observed through applied 
gene therapy designed to up-regulate the IL-1RA protein (Frisbie, Ghivizzani 
et al. 2002), validating the therapeutic effects of IL-1RA in equine OA. The 
clinical effects of ACS were then trialled on an equine osteochondral 
fragment model situated within the middle carpal joint. By day 70 post-
surgery, ACS-treatment of OA affected joints was associated with a lower 
lameness grade than those treated with a placebo (approximately 1 and 2 
out of 5 respectively; 0 represents normal gait, 5 represents severe 
lameness). However, there were no changes in carpal joint effusion or 
response to joint flexion, or difference seen in radiographic joint changes. A 
lower degree of cartilage erosion, synovial haemorrhage and subintimal 
hyperplasia within the synovial membrane was noted when treated with ACS. 
However, there were no changes in synovial membrane cellular infiltration, 
subintimal oedema, cartilage histopathology scores or GAG content evident 
(Frisbie, Kawcak et al. 2007). Similar observations were made when equine 
articular chondrocytes were exposed to recombinant human IL-1β. ACS had 
no significant beneficial effects on cartilage proteoglycan matrix metabolism 
(Carlson, Stewart et al. 2013). A second ACS preparation technique, called 
IRAP II (Arthrex Ltd, FL, USA), uses a similar system to that used to produce 
IRAP. IL-1RA levels in IRAP II ACS produced from human blood were 
reported to be 7x higher than levels in IRAP (Dechant, Baxter et al. 2003). 
ACS from both systems contained significantly elevated levels of IL-1RA, 
however IRAP II produced significantly higher levels of IL-1RA 
(approximately 350pg/ml) compared to IRAP. IRAP II, IRAP and 24h 
incubated control samples contained significantly higher levels of IL-1β 
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(approximately 150-200pg/ml) compared to 1h control samples 
(approximately 50pg/ml) (Hraha, Doremus et al. 2011). Levels of IL-1β in the 
three preparations other than the 1h control, were significantly higher than 
mean synovial fluid IL-1β concentrations reported in naturally occurring mild 
and advanced osteoarthritis (35.3pg/ml and 47.4pg/ml respectively) (Ehrle, 
Lischer et al. 2015). A 100-1000 fold increase of IL-1RA compared to IL-1β is 
required to effectively block the IL-1 receptors and prevent the activation of 
IL-1 signalling (Wehling, Moser et al. 2007). The ratio of IL-1RA:IL-1β  was 
significantly better with IRAP II, than IRAP and control samples 
(approximately 6 and 2.5 respectively). IRAP II also produced significantly 
higher levels of growth factors (TGF-β and insulin-like growth factor (IGF)-1) 
and IL-10 than 1h control samples (Hraha, Doremus et al. 2011). A recent 
study of IRAP and IRAP II preparations has reported levels of IL-1RA (both 
approximately 180ng/ml) and IL-1β (approximately 10ng/ml and 12ng/ml) 
respectively (Fjordbakk, Johansen et al. 2015). An estimated 10 fold 
difference between IL-1RA and IL-1β would therefore be present, and 
concentrations of pro-inflammatory cytokine IL-1β within ACS would be 
around 100 times higher than those found in naturally occurring OA. To 
conclude, most evidence for the use of ACS in equine OA is anecdotal 
(Moreira, Moraes et al. 2015), however, many veterinary clinicians 
recommend its use once corticosteroids fail to induce positive clinical effects 
(Textor 2011). Large variations in ACS IL-1RA concentrations have been 
reported, and ratios of IL-1RA:IL-1β required to block the effect of pro-
inflammatory IL-1β have not been produced. This may explain the lack of 
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substantial clinical evidence in favour of ACS; could favourable results have 
been influenced by a different mediator other than IL-1RA in ACS? 
Up-regulation of IL-1RA gene expression is the mainstay of equine anti-IL-1 
gene therapy research. Self-complementary adeno-associated virus (scAAV) 
IL-1RA equine serotype 2 is capable of markedly protecting a joint from 
developing surgically induced osteoarthritic pathology (Watson, Broome et 
al. 2014). This form of gene therapy proves promising, however it may be 
problematic to gain approval of its use in species which could potentially 
enter the food-chain.  
 
A recombinant form of IL-1RA, Anakinra (Kinaret, Sweden), is now a 
licensed product used for rheumatoid arthritis in humans and provides good 
anti-inflammatory action. However, intra-articular therapeutic concentrations 
are not achieved (Watson, Broome et al. 2013). In a double-blinded, placebo 
controlled, randomised trial in human patients suffering from knee OA, no 
differences were found between treatment groups (Chevalier, Goupille et al. 
2009).  
 
1.5.1.2  IL-1 Monoclonal Antibodies 
Monoclonal antibody (mAb) therapies designed to block IL-1 action include 
the monoclonal anti-IL-1β antibody Canakinumab (ACZ885, Ilaris, Novartis, 
Switzerland) which binds to and neutralizes IL-1β, and AMG108, a 
monoclonal antibody designed to bind to the IL-1RI. Canakinumab is 
licensed for use in cryopyrin-associated periodic syndrome and systemic 
juvenile idiopathic arthritis in humans. AMG108 has so far failed to improve 
! 60 
pain associated with knee OA in humans (Yu and Hunter 2015). Other 
monoclonal antibodies (gevokizumab and ABT-981) are presently in phase II 
clinical trials (Yu and Hunter 2015).  
 
1.5.1.3 Other Anti-Interleukin-1 Therapies 
The soluble decoy receptor Rilonacept (Regeneron pharmaceuticals, New 
York, USA) is a fusion protein consisting of the extracellular portion of the IL-
1 receptor and the Fc domain of human IgG1. This binds IL-1β preventing its 
interaction with IL-1RI (Kapoor, Martel-Pelletier et al. 2011). This is also 
licensed to treat cryopyrin-associated periodic syndrome in humans. Other 
alternative therapies include the overexpression of the IL-1RII (decoy 
receptor) to scavenge IL-1β (Kapoor, Martel-Pelletier et al. 2011). Diacerin, 
an anthraquinone derivative, inhibits the production of IL-1β and has 
generated a modest symptomatic benefit when used to treat OA. However it 
has been associated with higher rates of gastrointestinal toxicity when used 
long term (Panova and Jones 2015). ICE inhibitors, to prevent the activation 
of IL-1β, and MAPK inhibitors, to prevent the downstream signalling events 
that occur upon IL-1β binding to the receptor, are also being investigated.  
 
1.5.2  Anti-Tumour Necrosis Factor Therapy 
TNF-inhibitors have been used to treat rheumatoid arthritis, amongst other 
conditions, with great success. Monoclonal antibodies designed to bind to 
and neutralise TNF-α activity include infliximab (Remicade), adalimumab 
(Humira) and etanercept (Enbrel). However, in phase III clinical trials using 
adalimumab to treat hand OA, a lack of improvement in clinical symptoms 
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was observed (Verbruggen, Wittoek et al. 2012). Infliximab has been shown 
to offer a reduction in anatomical lesion radiographic score in patients with 
erosive hand OA, after 12 months (Fioravanti, Fabbroni et al. 2009). A fourth 
antibody, ESBA105, has been trialled in vivo in animals, and has been 
shown to have similar clinical efficacy to infliximab, but is able to penetrate 
joint tissues (Urech, Feige et al. 2010, Yu and Hunter 2015).  
   
1.5.3  Anti-Aggrecanase Therapy 
Several theoretical strategies to prevent aggrecanase activity exist; (1) 
introduce a molecule (mAb or small inhibitor) to bind to and block the 
aggrecanase, (2) block aggrecanase cleavage sites on aggrecan, mutate 
aggrecan therefore preventing aggrecanase binding, or (3) introduce a null-
aggrecanase to bind to and block aggrecan cleavage sites (Bondeson, 
Wainwright et al. 2015). A chimeric murine/human IgG4 monoclonal antibody 
(mAb, CRB0017), with high affinity for the ADAMTS5 spacer domain, and 
highly selective to the ADAMTS5 antigen, was created using intracellular 
antigen capture technology. This anti-ADAMTS5 mAb, administered into 
STR/ort mice (mice which develop spontaneous OA) joints, delayed cartilage 
breakdown (Chiusaroli, Visentini et al. 2013), and also reduced surgically 
induced OA histopatholoy in STR/ort mice (Caselli, Chiusaroli et al. 2015). 
This monoclonal antibody will enter phase I clinical trials in 2016. A second 
anti-ADAMTS5 mAb (GSK2394002) has been trialled systemically in mice 
subjected to DMM, it was administered after the onset of cartilage 
degeneration reflecting a therapeutic model. Mice were protected from 
cartilage degeneration and osteophyte formation, and were alleviated from 
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pain whilst still experiencing subchondral bone changes (Miller, Tran et al. 
2014). However, this mAb can cause prolonged cardiovascular side effects 
(Larkin, Lohr et al. 2014). Short interfering RNAs (siRNA) that have been 
chemically modified to enable access to the cell without requiring a 
transfection process, have been successfully used in vivo to target MMP13 
and ADAMTS5 expression in a murine model of surgically induced OA, 
resulting in decreased cartilage breakdown (Hoshi, Sasho et al. 2014). 
Engineered and synthetic small-molecule inhibitors of ADAMTS4 and 
ADAMTS5 are being designed to selectively and potently inhibit 
aggrecanase activity (Dancevic and McCulloch 2014). One in particular, 
AGG-523 (Wyeth/Pfizer, New York, USA), a reversible, non-hydroxamate, 
zinc-binding selective inhibitor, is currently under-going phase I clinical trials 
in patients with mild-moderate OA. It can reduce the release of aggrecanase 
generated aggrecan fragments in rat joints (Chockalingam, Sun et al. 2011). 
However, concerns over systemic effects of aggrecanase inhibition remain 
(Bondeson, Wainwright et al. 2015).  
 
MMP inhibitors (MMPi) were initially investigated for use as anti-tumour 
agents, due to their association with tissue remodelling and carcinogenesis. 
However, major systemic side effects halted this avenue of research. For use 
in locally contained diseases, such as OA, selectivity of MMPi poses a 
concern. Broader non-selective inhibitors have undergone clinical trials, but 
also produced adverse side effects (Li, Shi et al. 2011). There is new hope, 
however for the treatment of OA through selective MMP13 inhibition (Li, Shi 
et al. 2011). 
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1.6  Short Interfering RNA  
  
1.6.1  Introduction to Short Interfering RNA 
Short interfering RNA (siRNA) molecules are capable of inhibiting gene 
expression by cleaving mRNA at a specific site. These molecules are 
double-stranded RNA duplexes, which are 20-25 nucleotide base pairs in 
length with two nucleotide 3’ overhangs (Elbashir, Harborth et al. 2001). 
They are designed to complement target gene mRNA, and are synthetically 
produced. Several techniques facilitate introduction of the siRNA into the cell, 
known as transfection. Within the cytoplasm, the siRNA duplex is 
incorporated into the RNA-induced silencing complex (RISC). This contains 
an argonaute family protein with a Paz domain enabling interaction with the 
siRNA 3’ overhang, and a binding pocket which associates with the 5’ 
overhang (Deleavey and Damha 2012). The siRNA double helix is unwound, 
the sense strand released, and the now active RISC complex seeks out 
complementary 3’-untranslated regions (3’UTR) of mRNA. The ability of the 
RISC complex to differentiate between strands is crucial when selecting 
which strand to release, as incorrect selection can lead to reduced target 
gene silencing and the initiation of off-target gene silencing (Kanasty, 
Whitehead et al. 2012). Strand selection is determined by thermodynamic 
stability; the antisense strand is selected due to its low hybridisation stability 
at the 5’ end. Other characteristics, designed to increase strand asymmetry, 
such as A-U base pair content, also contribute to correct strand selection 
(Kanasty, Whitehead et al. 2012). The antisense strand anneals to the 
complementary sequence via Watson-crick base pairing, the phosphodiester 
! 64 
bonds between base pairs 10 and 11 are positioned within an RNase-H-like 
active site (Elbashir, Harborth et al. 2001, Deleavey and Damha 2012). 
RNase-H is an endogenous endonuclease which catalyses the enzymatic 
reaction that cleaves target mRNA and releases the RISC (Deleavey and 
Damha 2012). This prevents translation of the complementary mRNA into 
amino acid sequences, effectively silencing the gene.  
  
1.6.2  Use of Short Interfering RNA in Osteoarthritis 
SiRNA therapy has successfully decreased the expression of target pro-
inflammatory mediators in experimental OA models. Collagen-induced 
arthritis (CIA) in mice and rats has been ameliorated by anti-TNF-α and anti-
IL-1β siRNA delivered to cells via intra-articular electroporation (Inoue, 
Takahashi et al. 2005, Inoue, Takahashi et al. 2009), one study 
demonstrated siRNA localised to the synovium rather than the cartilage 
(Inoue, Takahashi et al. 2005). Intra-articular poly-lactide glycolic acid 
(PLGA) microspheres loaded with anti-TNF-α siRNA, used in a murine CIA 
model, have also successfully inhibited synovial TNF-α expression, as 
assessed by immunohistochemistry and intracellular staining of mononuclear 
cells (Présumey, Salzano et al. 2012). Treated joints had significantly lower 
joint swelling up to 15-28 days after induction of CIA, and radiographic and 
histological arthritis scores were significantly lower at 28 days (Inoue, 
Takahashi et al. 2009). Similar results were achieved with anti-TNF-α siRNA 
loaded PLGA microspheres in a murine CIA model at 10 days post-OA 
induction (te Boekhorst, Jensen et al. 2012).  
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LPS-stimulated (100µg/ml) equine primary chondrocytes transfected with 
anti-IL-1β siRNA via electroporation, experienced a significantly lower level 
of IL-1β gene expression than untreated cells. These siRNAs also decreased 
gene expression levels of MMP13, IL-1α and stromelysin (Nixon and 
Strassheim 2006). However, IGF-I and aggrecan gene expression 
significantly decreased through LPS exposure, were unaffected by IL-1β 
RNA interference (RNAi). Synovial cells, transfected with anti-IL1 siRNA and 
exposed to LPS in a similar manner, showed comparable gene expression 
levels to treated chondrocytes (Nixon, Goodrich et al. 2007). Using a 
polycistronic plasmid for ex vivo transduction of equine chondrocytes, 
simultaneous overexpression of IGF-1 and transcriptional silencing of IL-1 
using short hairpin RNA (shRNA) was achieved. This method maybe useful 
for a multi-targeting technique (Nixon, Strassheim et al. 2007). IGF-1 is a 
crucial mediator of anabolic chondrocyte metabolism, resulting in increased 
expression of aggrecan and collagen type II (Ortved, Begum et al. 2014). Ex 
vivo transduction of equine chondrocytes using a self-complementary adeno-
associated 5 vector overexpressing IGF-1, were implanted into full-thickness 
femoral chondral defects using a fibrin vehicle. After 8 months, histological 
scores were improved compared to contra-lateral defects filed with naïve 
chondrocyte-fibrin implants; increased chondrocyte numbers and collagen 
type II content were present (Ortved, Begum et al. 2014). The mechanical 
properties of cartilage produced by chondrocytes over-expressing IGF-1 
were also superior to naïve chondrocytes (Griffin, Ortved et al. 2015). These 
recombinant AAV vectors have been shown to be minimally immunogenic 
within equine joints, making them a potentially useful tool to target intra-
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articular tissues during OA (Ortved, Wagner et al. 2015).  
Vectors, including lentivirus and adeno-associated virus vectors, to transfect 
cells with shRNA for TNF knockdown, have successfully targeted dendritic 
cells, and FLS and synovial macrophages respectively. However, safety 
concerns reside over the use of viral vectors (Apparailly and Jorgensen 
2013).   
 
Delivery of siRNA to target cells has been a major limiting factors with 
regards to their clinical use. Successful results in OA models using viral 
vectors, electroporation and PLGA microspheres have already been 
described. Chemically modulated siRNA has been designed to enable siRNA 
transfection without the need of an agent. Studies investigating intra-articular 
administration of chemically modulated anti-MMP13 and anti-ADAMTS5 
siRNAs in a murine OA model, have shown successful inhibition of cartilage 
degradation in early OA (Hoshi, Sasho et al. 2014). 
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1.7  Biodegradable Polymer Microsphere as Drug Delivery Vehicles 
 
Intra-articular DMOADs to counteract pain and slow joint degradation driven 
by OA, are of major interest. Intra-articular therapies prevent systemic side 
effects, and optimise bioavailability and therapeutic efficacy to target cells. 
However, further optimisation is required to prevent drug clearance, by 
producing a delivery system providing targeted sustained release of the drug 
in order to generate a clinical effect.   
 
Targeted intra-articular OA therapies have been historically hindered by the 
lack of an effective drug delivery system (DDS). Interest in PLGA 
microspheres as DDS has been substantial since the 1980s (Janssen, Mihov 
et al. 2014). More specifically, investigating the use of this system to target 
intra-articular disease processes has been on going since the 1990s. 
Microspheres taken up by synovial macrophages offer a DDS which not only 
delivers the drug directly to the target inflammatory cell, but also provides 
sustained controlled release (Edwards 2011). Many obstacles have impeded 
the use of microspheres as DDS within the intra-articular environment; such 
as rapid hydrolysis of the drug by serum nucleases or failure of delivery/entry 
to the target cell. The following factors influence successful targeted drug 
delivery; microsphere size, resistance to intra-articular degradation, ability to 
retain the drug during delivery, sustained release of a therapeutic dose of the 
drug once at the target cell, and biocompatibility. Microspheres enter target 
cells through phagocytosis. PLGA microsphere phagocytosis appears to be 
size dependent; where 1-10µm was found to be optimal for synoviocyte 
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phagocytosis (Butoescu, Seemayer et al. 2009). PLGA microspheres have 
excellent biocompatibility, especially when used in horses and are degraded 
within the cell by both surface and bulk erosion (Bragdon, Bertone et al. 
2001, Larsen, Ostergaard et al. 2008). SiRNAs are high molecular weight 
hydrophilic molecules, unable to enter cells by passive diffusion, and rapidly 
degradable by nucleases. Consequently they have a short half-life in 
biological fluids (Khanna, Balgir et al. 2007). Their partnership with PLGA 
microspheres has been proposed to protect them from nuclease 
degradation, eliminate the need for a transfection agents, abolish their 
negatively charged hydrophilic nature preventing entry to the cell, and 
prolong their half life through sustained release. The arrangement of PLGA 
molecules around the drugs core due to ionic interactions between the basic 
amino acids of the siRNA and the terminal carboxylic anions of the PLGA, 
results in a rigid structure. This produces high encapsulation efficiency when 
PLGA is combined with a negatively charged drug such as siRNA (Murata, 
Takashima et al. 2008). The PLGA microsphere successfully releases the 
siRNA into the cytosol (Jensen, Cun et al. 2010), where the mechanisms for 
RNA interference are positioned (te Boekhorst, Jensen et al. 2012). There 
have been some successful reports of the use of siRNA-loaded PLGA 
microspheres, such as the down-regulation of TNF-α in experimental murine 
RA (Présumey, Salzano et al. 2012) and OA (Mountziaris, Sing et al. 2011). 
 
There have also been varying reports of success in using siRNA-PLGA 
nano/microsphere as DDS. One report suggests that carriers such as 
arginine or polyethylenimine (PEI) promote siRNA encapsulation efficiency to 
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64.3% and 80%, respectively from 48.6% using only PLGA (Murata, 
Takashima et al. 2008). These reported capsulation efficiencies are highly 
incomparable to the efficiencies found using solely PLGA in this study 70%. 
This previous study also found that both siRNA-PLGA microspheres with and 
without carriers significantly reduced tumour growth using VEGF-siRNA, with 
PEI-carriers being slightly more effective (Murata, Takashima et al. 2008). 
However, these carriers are associated with toxic effects and can delay the 
release of siRNA (Cun, Jensen et al. 2011). 
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1.8 Hypotheses and Aims 
 
1.8.1  General Hypotheses 
The experimental work described in this thesis aimed to design and test a 
novel therapy and therapy-delivery system intended to provide a sustained 
release, anti-cytokine therapy for equine OA. Interactions between the 
predominant cell populations present during synovitis were examined to help 
assess the effects of the therapy and therapy-delivery system on synoviocyte 
and cartilage health. It was hypothesised that an anti-cytokine therapy 
delivered to target synoviocytes would help prevent cartilage degradation 
driven by inflammatory stimulation.  
 
1.8.2  Aims 
 
To answer our hypotheses, this thesis aimed to: 
 
! Create a co-culture model to determine equine FLS gene expression 
profiles following exposure to an inflammatory stimulus and in the 
presence or absence of macrophages, and determine to what extent 
IL-1β and NF-κB signalling pathways were involved. 
! Optimise the extent of IL-1β gene knockdown in equine FLS and 
macrophages using an siRNA approach.  
! Determine the capacity of equine macrophages to phagocytose 
biodegradable polymer microspheres.  
! Determine the influence of synovitis on cartilage health, and 
subsequently investigate whether anti-IL-1β siRNA-loaded 
biodegradable polymer microspheres could effect synoviocyte gene 
expression and alter the effect of synovitis on cartilage health.  
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Chapter 2. Materials and Methods 
 
2.1  Cell Culture 
 
2.1.1  Equine Distal Limb Collection, Preparation and Scoring  
Equine distal limbs, disarticulated at the middle carpal joint or tarsus, were 
collected from abattoirs (Nantwich, Cheshire, and Swindon, Wiltshire) and 
processed within 6-8 hours. Each limb was secured in a table vice, 
positioning the dorsal aspect of the metacarpo/tarsophalangeal joint 
(MCPJ/MTPJ) upwards. Skin was removed with a no. 22 scalpel blade, the 
leg scrubbed with dilute chlorhexidine gluconate (Hibiscrub, Regent Medical 
Limited, Manchester, UK), and sprayed with surgical spirit. Using sterile 
gloves, rat-toothed tissue forceps, and a sterile no.10 scalpel blade, 
subcutaneous tissues overlying the dorsal aspect of the MCPJ/MTPJ were 
dissected and removed. The joint capsule, collateral ligaments and common 
digital extensor tendon were transected providing full access to the joint 
cavity. Gross macroscopic scoring of the MCPJ/MTPJ was recorded, and 
tissues were harvested from joints scoring 0 – 1 (Table 2.1).   
 
 
 
 
 
! 72 
Table 2.1 Macroscopic scoring system to describe gross changes 
located on the condyles of the equine third metacarpal bone 
(McIlwraith, Frisbie et al. 2010). 
 
Lesion 
 
Grade 
 
Description 
   
Wear lines 0 
1 
 
2 
 
3 
 
None 
1 or 2 partial-thickness wear lines/joint 
surface. 
3-5 partial-thickness or 1-2 full-thickness 
wear lines/joint surface. 
>5 partial thickness or >2 full-thickness wear 
lines/joint surface. 
 
Erosions 0 
1 
2 
3 
None 
Partial-thickness erosion, <5mm in diameter. 
Partial-thickness erosion, >5mm in diameter. 
Full-thickness erosion. 
 
Palmar arthrosis 
(osteochondral 
lesions distal palmar 
aspect of 
metacarpus) 
0 
1 
2 
 
3 
None 
Partial-thickness erosion, <5mm in diameter. 
Partial-thickness erosion, purple 
discoloration, >5mm in diameter. 
Full-thickness erosion, purple discoloration, 
5mm in diameter. 
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2.1.2  Tissue Harvesting 
 
2.1.2.1  Synovial Membrane Harvesting 
Synovial membrane from the dorsal and palmar/plantar pouches of the 
MCPJ/MTPJ was used. The synovial membrane was elevated using fine 
tissue forceps before being dissected with a no.11 scalpel blade, taking care 
to avoid the adjacent fibrous joint capsule (Figure 2.1 A and B). Dissected 
synovial membrane was placed in sterile 1 x phosphate buffered saline 
(PBS). A number of synovial membrane sections, approximately <5mm2, 
were placed in sterile 1 x PBS to be used as synovial membrane explants. 
 
2.1.2.2 Equine Cartilage Explant Harvesting 
Under sterile conditions, articular cartilage explants were harvested using 
fine smooth forceps and a no.10 scalpel blade. Explants were taken from the 
distal condyles of the third metacarpal bone, taking care not to include the 
underlying subchondral bone. Explants were approximately 5mm x 10mm, 
and were immediately placed into sterile PBS.  
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Figure 2.1 Synovial membrane harvesting and digestion. Synovial membrane 
was dissected from the dorsal (A) and palmar/plantar (B) pouches of the equine 
metacarpo/tarsophalangeal joints. Synovial membrane was finely diced and digested 
first in 0.25% (w/v) trypsin/0.1% (w/v) EDTA, and secondly in 2mg/ml collagenase 
type 2 solutions (C), whilst incubated at 37°C under continuous agitation (D).  
A. B. 
C. D. 
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2.1.3  Isolation and Culture of Equine Fibroblast-like Synoviocytes 
In a cell culture hood, the synovium was finely diced, immersed in 25ml 
sterile PBS, thoroughly mixed and centrifuged at 453 – 805g for 10 minutes. 
The PBS was removed without disturbing the synovium pellet, before the 
process was repeated to wash the tissue. Synovium was then mixed with 
12ml 0.25% (w/v) trypsin/0.1% (w/v) ethylenediaminetetraacetic acid (EDTA) 
in PBS, and agitated at 250rpm at 37°C for one hour. One and a half 
millilitres of foetal bovine serum (FBS, Gibco, Thermofisher Scientific, 
Massachusetts, USA) was added to the trypsin/EDTA solution to deactivate 
it. The contents were thoroughly mixed and centrifuged at 805g for 10 
minutes. The trypsin/EDTA solution was discarded and the synovium re-
suspended in 10ml sterile 2mg/ml collagenase type 2 (Worthington 
Biochemicals, Berkshire, UK) in Dulbeccos’ Modified Eagle Medium (DMEM, 
Life Technologies, California, USA) with 10% FBS, 100U/ml 
penicillin/streptomycin (Penstrep, Life Technologies, California, USA) and 
500ng/ml amphotericin B (Life Technologies, California, USA). This media 
will be referred to as standard culture media. Overnight, the suspension was 
agitated and incubated at 37°C, at which point the majority of the tissue had 
been digested (Figure 2.1). The suspension was centrifuged, media 
discarded and cells re-suspended in standard culture media. The cell 
suspension was strained through a 70µm cell strainer (SLS, Yorkshire, UK) 
to remove any remaining tissue. Cells were then washed, suspended in 25ml 
fresh standard culture media and seeded at approximately 1 x 106 cells per 
cell culture flask (175cm2). Flasks were incubated at 37°C, in 5% CO2. 
Standard culture media was changed every 3 days, and cells were passaged 
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when 80-90% confluent. Cultures were considered predominantly equine 
fibroblast-like synoviocytes (EFLS) by passage 3 (Rosengren, Boyle et al. 
2007).  
 
2.1.4  Canine Macrophage-Monocyte (DH82) Cell Line Culture 
DH82 cells (Sigma-Aldrich, Missouri, USA), a macrophage-monocyte cell line 
isolated from a dog with malignant histiocytosis, were suspended in 25ml 
standard culture media and seeded at approximately 1 x 106 cells per cell 
culture flask (175cm2). They were incubated at 37°C in 5% CO2. The 
standard culture media was changed every 3 days, and cells were passaged 
when 80-90% confluent.  
 
2.1.5  DH82 and EFLS Passage 
Used standard culture media was discarded before the cell layer was gently 
washed twice with PBS to remove any traces of FBS. Cells were then 
covered with 0.05% trypsin-EDTA (Lonza, Slough, UK), 5ml for a 175cm2 cell 
culture flask, and incubated at 37°C in 5% CO2. After 5-10 minutes, the 
flasks were vigorously agitated before an equal volume of standard culture 
media containing FBS was added to the suspension to deactivate the trypsin. 
The cell suspension was centrifuged at 290g for 4 minutes, and the cell pellet 
re-suspended in fresh standard culture media. Cells were seeded at 1 x 106 
cells in 25ml standard culture media in a 175cm2 cell culture flask.  
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2.1.6  Equine Venous Blood Collection  
Equine venous blood was collected from inpatients at the University of 
Liverpool’s Philip Leverhulme Equine Hospital (PLEH) and from an abattoir 
(Swindon, Wiltshire). The University of Liverpool Veterinary Research Ethics 
Committee granted ethical approval (VREC91) based on the following 
stipulations. Excess blood collection from PLEH inpatients only occurred if 
the owner had given informed consent, the horse had an intravenous 
catheter in situ, blood was being collected for diagnostic or therapeutic 
reasons, the horse was free from systemic illness, the horse was over 6 
months old, or if the horse was euthanised under general anaesthesia and 
used for blood bank purposes. Blood was collected in lithium heparin 
vacutainer tubes. At the abattoir blood was free caught at the time of 
exsanguination. Half a litre was collected in a glass-jar containing 100ml 
acid-citrate dextrose solution (7.35g glucose, 2.2g sodium citrate and 730mg 
citric acid). The blood and acid-citrate dextrose solution were thoroughly 
mixed and processed within 24 hours.  
 
2.1.7  Density Gradient Separation to Isolate Equine Mononuclear 
Cells  
A solution of polysucrose (57g/L) and sodium diatrizoate (90g/L) adjusted to 
an approximate density of 1.077g/ml (Histopaque-1077, Sigma-Aldrich, 
Missouri, USA) was used to isolate mononuclear cells from equine blood. 
PBS and Histopaque-1077 were used at room temperature. In a cell culture 
hood, the blood was thoroughly re-mixed following separation into blood cell 
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conical centrifuge tubes, and spun at 1200g for 15 minutes at room 
temperature, with no brake. Whole blood separates into 3 distinct fractions 
(bottom to top); the darkly coloured red blood cell layer, a white layer lying on 
top of this called the buffy coat containing white blood cells and platelets, 
and the plasma layer above this (Figure 2.2A). The buffy coat was removed 
from all tubes using a glass pipette, without disturbing the red blood cell 
layer, and combined. Twenty-five millilitres buffy coat was diluted with 25ml 
PBS, and half of the suspension was carefully layered onto 15ml 
Histopaque-1077 in a falcon 50ml conical centrifuge tube; this was repeated 
in duplicate (Figure 2.2B). Tubes were centrifuged at 1811g for 25 minutes 
with the brake off. The density gradient media separated the buffy coat into 3 
layers (bottom to top); any red blood cells that were contaminating the buffy 
coat, a white cloudy mononuclear cell layer, and a clear layer of histopaque 
(Figure 2.2C). Using a pipette, the mononuclear cell layer was transferred 
into a clean 50ml centrifuge tube and diluted with PBS (50ml total). Tubes 
were centrifuged at 600g for 15 minutes at 4°C with the brake on. The 
supernatant was discarded and the white cell pellet re-suspend in fresh PBS. 
The tubes were centrifuged at 400g with the brake on. The supernatant was 
discarded and the cells were re-suspended in a known volume of fresh 
culture media. Cells were then counted using a haemocytometer. Cells were 
either cultured (see below), or frozen at -80°C in RPMI-1640 culture media 
with 20% FBS, containing 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, 
Missouri, USA). These cells were known as equine peripheral blood 
mononuclear cells (EPBMCs). 
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Plasma 
Mononuclear cell 
layer 
Histopaque- 
1077 
RBC 
Figure 2.2 Density gradient separation of equine blood to isolate equine mononuclear 
cells. (A) Equine whole blood mixed with acid-citrate dextrose solution, the red blood cells 
(RBC) were in the process of settling at the bottom of the centrifuge tube. (B) Once the whole 
blood was centrifuged, the buffy coat was removed, diluted with PBS and layered onto 
Histopaque-1077. This sample had a large degree of RBC contamination which was unusual. 
(C) The buffy coat and Histopaque-1077 are centrifuged for 25 minutes to isolate the 
mononuclear cell layer.  
A. B. C. 
Plasma 
RBC 
Buffy 
Coat 
Diluted 
Buffy 
Coat 
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2.1.8  Equine Peripheral Blood Mononuclear Cell Culture 
EPBMCs were seeded in 24-well cell culture plates at 5 x 104 cells per well in 
1ml RPMI-1640 medium with L-alanyl-L-glutamine (RPMI 1640 Medium, 
GlutaMAX™ Supplement, Life Technologies, California, USA). This was 
supplemented with 10% horse serum (New Zealand origin, Life 
Technologies, California, USA), 100U/ml penicillin/streptomycin (Penstrep, 
Life Technologies, California, USA), 500ng/ml amphotericin B (Life 
Technologies, California, USA) and 50ng/ml recombinant human 
granulocyte-macrophage colony stimulating factor (rhGMCSF 300-03, 
Peprotech, New Jersey, USA). This media will be referred to as standard 
EPBMC culture media. Half of the standard EPBMC culture media (500µl) 
was replenished every 3 days, to avoid wasting non-adherent cells. Within 7 
days to 2 weeks cells adhered to the cell culture plate.  
 
2.1.9  Stimulating a Cellular Inflammatory Response In Vitro 
To stimulate a cellular response in vitro comparable to that found in an 
inflammatory environment in vivo, 10µg/ml LPS from Escherichia coli 
(026:B6) (Sigma-Aldrich, Missouri, USA) was added to culture media. The 
addition of LPS represented day 0 in all experiments.  
 !
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2.2  Cell Labelling and Analysis 
 
2.2.1  Fluorescent Labelling of EFLS Cells  
Cell Proliferation Dye eFluor® 670 (eBioscience Inc., San Diego, USA) is a 
fluorescent dye which binds to all cellular proteins containing primary 
amines. The dye is detectable in cells for up to 6 cells divisions. This 
fluorescent dye was used to label EFLS. The dye was dissolved at a 
concentration of 5mM in anhydrous DMSO, aliquoted for storage at -20°C 
and protected from light. A suspension of EFLS cells at double the desired 
cell number/ml were washed twice with PBS to remove any serum present, 
and re-suspended in PBS. To optimise the concentration of dye required to 
produce maximum fluorescence, six different dye concentrations were 
trialled; 10, 9, 8, 7, 6 and 5µM. All concentrations produced very similar 
fluorescence intensities, however the 8µM dye solution produced optimum 
labelling. An equal volume of the 8µM dye solution was mixed with the cell 
suspension, and vortexed thoroughly. It was incubated for 10 minutes at 
37°C in the dark. Approximately four to five times the final volume of cold 
complete standard culture media was added, and the cells were incubated 
on ice to stop the labelling process. Cells were washed three times with 
standard culture media (at room temperature) and cultured as normal.  
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2.2.2  Lentiviral-Mediated Generation of GFP Expressing DH82 Cells 
A multiplicity of infection (MOI) optimisation experiment determined the ideal 
number of particles required to produce effective transfection; for example a 
MOI of 1 represents 40,000 lentiviral particles used to transfect 40,000 cells. 
DH82 cells were seeded into 24-well plates at a density of 2.1 x 104/cm2 in 
1ml standard culture media. Each well received 1µl of sterile filtered 8mg/ml 
hexadimethrine bromide 1000x (Sigma-Aldrich, Missouri, USA), which was 
then mixed thoroughly, taking care not to spill contents. Lentiviral particles 
expressing a constitutively active green fluorescent protein gene (CMV 
promoter) and a puromycin resistance cassette (Sigma, Missouri, USA) were 
added to the DH82 cells at MOI 0.5, 1, 2 and 4. Wells were incubated at 
37°C for 24 hours, after which the standard culture media was replaced with 
fresh standard culture media and transfection was assessed using 
fluorescent microscopy. Standard culture media was replenished every 3-4 
days and wells were incubated for a further 10 days. Cells successfully 
transfected with the GFP-expressing plasmid were selected using 2µg/ml 
puromycin (Life Technologies, California, USA) for ten days with standard 
culture media changes every three days. Following selection it was evident 
that wells using a MOI of 0.5 and 1 had not been effectively transfected with 
the GFP-expressing lentivirus. Wells containing cells exposed to an MOI of 2 
and 4 were 70-80% confluent, and were 90-100% GFP positive. These cells 
were passaged, expanded in cell culture flasks and frozen for later use.  
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2.2.3  Fluorescence-Activated Cell Sorting  
To determine the proportion of each cell population within a mixed co-culture, 
EFLS labelled with the cell proliferation dye eFluor® 670 or DH82 cells 
expressing GFP were analysed using a BD Accuri C6 Flow Cytometer (BD-
Biosciences, New Jersey, USA). The Cell Proliferation Dye eFluor® 670 has 
a peak excitation of 647nm, excited by the red laser line (633nm), and a 
peak emission wavelength of 670nm which is detected using a 675/25 
interference filter. GFP has a peak emission wavelength of 507nm and is 
detected by a 533/30nm interference filter. Peak emission wavelengths of 
these fluorophores were sufficiently different to ensure no overlap in 
detection between the interference filters occurred (Figure 2.3). 
Fluorescence-Activated Cell Sorting (FACS) analysis was performed by the 
BD AccuriTm C6 Analysis Software 1.0.264.21.  
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Figure 2.3 FACS analysis demonstrates two separate fluorophores present within a mixed culture of 
DH82 and EFLS cells. (A) Density plot graph displaying two discernable plots, consistent with the two 
fluorophores used. The plot with maximum fluorescence intensity detected by the 533/30nm and 675/25nm 
interference filter represents the GFP-DH82 cells and efluor-labelled EFLS respectively. The third, less dense 
area, represents background fluorescence. (B) Peak fluorescence intensity detected by the 675/25nm filter is 
consistent with efluor-labelled EFLS (purple line). The GFP-DH82 cells (green line) and unlabelled EFLS cells 
(black line) only emit fluorescence at a wavelength consistent with background fluorescence, as detected by 
this filter. (C) Peak fluorescence intensity detected by the 533/30nm filter is consistent with GFP-DH82 cells 
(green line). The efluor-labelled EFLS (purple line) and unlabelled EFLS (black line) only emit fluorescence at 
a wavelength consistent with background fluorescence, as detected by this filter.  
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2.3  Short Interfering RNA Transfection 
 
Short interfering RNA (siRNA) duplexes and transfection reagents were 
purchased from Life Technologies (California, USA); Silencer Cyanine (Cy3) 
labelled negative control siRNA (Life technologies, California, USA), and 
Silencer Select Custom Designed siRNA to target certain cytokines. SiRNA 
was reconstituted to 100µM (100pmol/µl) concentration using nuclease-free 
water, then aliquoted and frozen at -20°C as stock solution. 
 
Cells were transfected in 6-well plates once they had reached 60-80% 
confluence. For each well, 9µl lipofectamine RNAiMAX reagent was mixed 
with 150µl Opti-MEM medium. A working stock solution of 10µM siRNA 
(10pmol/µl) was made for immediate use; 3µl was mixed with 150µl Opti-
MEM. The diluted siRNA suspension was then added to the diluted 
lipofectamine RNAiMAX solution (at a 1:1 ratio), mixed thoroughly and 
incubated for 5 minutes at 37°C. SiRNA-lipid solution (250µl)  containing a 
final quantity of 25pmol siRNA and 7.5µl lipofectamine, was added to the 
well, and contents were thoroughly mixed. Cells were exposed to the siRNA-
lipid complex for 6-12 hours, before it was removed and cells were 
replenished with fresh culture media.  
 
The ability of each synthetic siRNA sequence, to silence the target gene was 
measured through gene expression analysis via qRT-PCR, and protein 
expression analysis via western blotting.  !
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2.4  ELISA Analysis 
 
2.4.1  Equine IL-1β ELISA 
An equine IL-1β ELISA kit (Bethyl Laboratories, Texas, USA) was used to 
measure the IL-1β protein concentration within culture media. A standard 
curve was produced using recombinant equine IL-1β ranging from 3.125 – 
200ng/ml as a standard. Media sample or standard of 100µl were added, in 
duplicate, to a 96-well microplate, coated with anti-equine IL-1β capture 
antibody. The plate was sealed and incubated for 2 hours at room 
temperature. All contents were discarded and the plate washed four times, 
before blotting thoroughly to remove waste fluid. Detection antibody was then 
added, 100µl per well, to all wells before sealing and incubating the plate for 
one hour at room temperature. Contents were once again discarded and 
washing steps repeated preceding the addition of 100µl horseradish 
peroxidase (HRP) solution to each well. The plate was sealed and incubated 
for 30 minutes at room temperature. Contents were once again discarded 
and washing steps repeated preceding the addition of 100µl 
tetramethylbenizidine (TMB) substrate to each well. The plate was incubated 
for 30 minutes in the dark at room temperature, before the addition of 100µl 
of stop solution to each well. The plate was agitated and absorbance’s 
immediately read at a wavelength of 450nm (Figure 2.4). 
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 2.4.2  Equine TNF-α ELISA 
An equine TNF-α ELISA kit (R&D Systems, Minneapolis, USA) was used to 
measure the TNF-α protein concentration within culture media. A standard 
curve was produced using 31.3 - 2000pg/ml recombinant equine TNF-α. The 
goat anti-equine TNF-α capture antibody was diluted with PBS; 100µl per 
well was used to coat a 96-well microplate before sealing and incubating the 
plate overnight. The plate was washed twice with wash buffer (0.05% 
Tween® 20 in PBS, pH 7.2-7.4) before blocking the plates with 300µl per 
well of reagent diluent (1% bovine serum albumin (BSA) in PBS, pH 7.2-7.4, 
0.2um filtered) for 1 hour. The contents of all wells were aspirated and the 
wells were washed twice, before 100µl media sample and standard were 
added, in triplicate, into individual wells of the 96-well microplate previously 
coated with anti-equine TNF-α capture antibody. The microplate was sealed 
and incubated for 2 hours at room temperature. The plate was aspirated and 
washed as previously described before detection antibody was added at 
100µl per well, to all wells before sealing and incubating the plate for two 
hours at room temperature. Contents of all wells were then aspirated and the 
plate washed twice with wash buffer before 100µl diluted streptavidin-HRP 
was added to all wells, the plate sealed and incubated in darkness at room 
temperature for 20 minutes. Wells were once again aspirated and washed 
before 100µl substrate solution (1:1 mixture of H2O2 and TMB) was added to 
each well. The plate was sealed, incubated in darkness at room temperature 
for 20 minutes before 50µl stop solution (2NH2SO4) was added to each well. 
After ensuring the contents were thoroughly mixed, absorbances were read 
spectrophotometrically at a wavelength of 450nm (Figure 2.4). 
! 88 
 
 
 
Figure 2.4 Typical ELISA standard curve for extracellular equine (A) 
IL-1β and (B) TNF-α protein quantification in culture media. 
Concentrations of recombinant equine (A) IL-1β and (B) TNF-α ranging 
from 3.125 – 200ng/ml and 31.3 - 2000pg/ml respectively, were used as 
known standard concentrations, in duplicate and triplicate respectively. 
Absorbance was read spectrophotometrically at a wavelength of 450nm. 
Lines of best fit, in both cases a polynomial curve, were applied to the 
readings.  
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2.5  Glycosaminoglycan Assay 
Sulphated glycosaminoglycan (sGAG) concentrations within culture media 
were measured using the 1-9 dimethylmethylene blue (DMMB) assay 
(Farndale, Buttle et al. 1986). DMMB is a thiazine chromotrope agent which, 
when bound to sGAG, induces metachromasia which causes a change in its 
absorption spectrum. Samples were diluted 10-fold using nuclease-free 
water and 40µl of each sample was added, in duplicate, to wells of a flat-
bottomed transparent 96-well plate. DMMB dye (16mg 1-9 
dimethylmethylene blue, 2g sodium formate, 2ml formic acid, 1L water, pH 
3.5) was added to each well at 200µl per well. Absorbance was immediately 
measured spectrophotometrically at a wavelength of 570nm, and unknown 
sGAG concentrations were calculated using a standard curve. Standard 
concentrations ranging from 0-70µg/ml were made using chondroitin 
sulphate (shark cartilage, C-4384, Sigma-Aldrich, Missouri, USA) dissolved 
in ultrapure water using a stock solution of 5mg/ml (Figure 2.5).  
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Figure 2.5 Constituents of the standard concentrations (A), and 
typical standard curve (B) used for the GAG Assay. (A) Table 
displaying relative volumes of chondroitin sulphate stock solution (5mg/
ml) and water combined to produce known standard concentrations 
ranging from 0-70µg/ml. (B) Standard curve using absorbance 
measurements for standard concentrations. A linear line of best fit was 
used to calculate unknown GAG concentrations.   
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2.6  Intra- and Extracellular Protein Analysis Through Western 
Blotting 
 
2.6.1  Sample Collection and Processing 
Intracellular proteins were analysed within cell lysates, and extracellular 
proteins within cell culture media. For cell lysate protein extraction, the media 
was removed and the cell layers were gently washed with PBS before 200µl 
Novex tris-glycine sodium dodecyl sulfate (SDS) sample buffer 1X (Life 
Technologies, California, USA) was added to each well of a 6-well plate and 
the cell layer was detached using a cell scraper. Samples were sonicated 
(10Hz, 50% power) on ice three times for 10 seconds, a process that was 
repeated three times with >1 minute intervals for each sample. Following 
sonication, samples were then centrifuged at 20817g at 4°C for 10 minutes. 
The supernatant was transferred to a clean microcentrifuge tube, taking care 
not to disturb the pellet of cell debris. Samples were stored at -20°C.  
 
2.6.2  PierceTm 660 Protein Assay 
This colorimetric assay spectrophotometrically measures absorbance at a 
wavelength of 660nm, allowing the quantitation of total protein within a 
sample. The protein assay reagent is a dye-metal complex in an acidic 
buffer. At an acidic pH, the dye undergoes deprotonation becoming 
negatively charged and binding to positively charged amino acids. These 
protein-binding interactions aid in a stable colour change, due to 
deprotonation of the dye, from a reddish-brown to green. A series of known 
BSA dilutions (0-2000µg/ml) were produced from a BSA stock solution 
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(2mg/ml), and were assayed and measured alongside unknown samples, 
providing a standard curve of absorbance and protein concentrations, with 
which to reference unknown protein concentrations (Figure 2.6). Protein 
sample and protein standards (10µl) were entered, in duplicate, into a 
transparent flat-bottomed 96-well plate. The PierceTm 660 protein assay is 
compatible with most detergents and reducing agents. However, the 
concentration of SDS in the cell lysate samples (>0.0125%) required the 
addition of an ionic detergent compatibility reagent (IDCR, Life Technologies, 
California, USA) to treat the protein assay reagent prior to use. One gram of 
IDCR was diluted in 20ml of the PierceTm 660 protein assay reagent before 
performing the assay. Each well received 150µl of protein assay reagent 
(Thermo Fisher Scientific, Maryland, USA), with or without the IDCR 
depending on the samples assayed. The plate was covered, agitated for 1 
minute and incubated at room temperature for 5 minutes. Absorbance was 
immediately measured by a plate reader at a wavelength of 660nm.  
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Figure 2.6 Constituents of the standard concentrations (A), and 
standard curve (B) used for the Pierce 660 Protein Assay. (A) Table 
displaying relative volumes of BSA stock solution (2mg/ml) and water 
combined to produce known standard concentrations ranging from 
0-2000µg/ml. (B) Standard curve using absorbance measurements for 
standard concentrations. A linear line of best fit was used to calculate 
unknown protein concentrations.   
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2.6.3  Deglycosylation of aggrecan in media with Chondroitinase 
ABC 
The anti-aggrecan ARG antibody (BC-3) recognises the N-terminal 
neoepitope of aggrecan formed through aggrecanase cleavage between 
amino acids Glu373-Ala374 within the interglobular domain. The antibody is 
specific for aggrecanase cleaved (ARG) neoepitopes and will not bind to 
ARG sequences within the intact aggrecan protein core. Media samples 
were treated with proteinase inhibitors 1 tablet/10ml media (Complete 
ULTRA tablets, EDTA-free, Roche, Basel, Switzerland) to remove soluble 
degradation products of varying lengths from protein breakdown, which 
would contaminate the protein preparation. Media samples were mixed with 
a solution containing 250mM Tris HCl and 300mM Sodium Acetate Buffer 
with 0.05% (w/v) BSA, ph 8.0, with chondroitinase ABC (from proteus 
vulgaris; c2905, Sigma-Aldrich, Missouri, USA) at 0.001U chABC/10µg 
sGAG, and incubated at 37°C overnight. This de-glycosylates the samples 
for optimal neoepitope recognition by the antibody.  
 
2.6.4  Extraction of Protein from Cell Media using Protein-Resin 
Binding 
StrataCleanTm Resin was used to concentrate protein secreted into cell 
culture media. The protein concentration of each sample was determined 
using the PierceTm 660 Protein Assay; the volume of sample containing the 
desired protein content (40µg) was transferred to a new eppendorph tube. 
Ten µl StrataCleanTm Resin was added to each sample, vortexed and 
centrifuged at 805g for 1 minute. The silica-based solid phase resin binds to 
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proteins through its hydroxyl groups. The supernatant above the resin pellet 
was discarded, and the pellet washed with 1ml double distilled water 
(DDH2O). The vortex and centrifuge stages were repeated, the supernatant 
removed and the pellet re-suspend in 15µl diluted (1X) Novex tris-glycine 
SDS sample buffer (Life Technologies, California, USA).  
 
2.6.5  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS PAGE) 
Samples of equal protein content (40µg) were prepared as described above 
and suspended in 15µl diluted (1X) Novex tris-glycine SDS sample buffer 
(Life Technologies, California, USA). Samples were reduced by adding 1µl 2-
mercaptoethanol (Sigma-Aldrich, Missouri, USA) to each, following which 
they were mixed thoroughly by vortexing and then the proteins denatured by 
heating at 100°C for 5 minutes. 
 
A NuPAGE 4-12% Bis-Tris Gel cassette (Novex Life Technologies, 
California, USA), was rinsed with water, before the spacer comb and 
adhesive strip protecting the exposed gel, were removed. The gel cassette 
was locked in place within the gel tank, by a gel tension wedge. Running 
buffer (1x) (NuPAGE MES SDS Running Buffer, Novex Life Technologies, 
California, USA) filled the upper and lower buffer chambers of the gel tank, 
ensuring exposed gel at the top and bottom of the gel cassette were 
covered. Ten µl Novex Sharp Pre-Stained Protein Standard (Life 
Technologies, California, USA) was loaded into the first well in the gel 
cassette, to allow identification of molecular weight in unknown samples. The 
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samples were centrifuged and 15µl of each sample (total amount) was 
loaded individually into their assigned well using loose gel tips. The gel tank 
lid was fixed into position, ensuring that the connections were correctly 
aligned, and connected to an electrical power source (Powerpac 300, Biorad, 
Hertfordshire, UK). The SDS detergent attaches to the proteins, resulting in a 
negative charge proportional to the protein size being produced. Once 
electrophoresis begins, the proteins migrate through the gel towards the 
positive cathode. Larger proteins will move more slowly through the 
polyacrylamide gel. For cell lysate samples, the gel was subjected to 100V 
for approximately 10 minutes, then 150V for approximately 50 minutes, or 
until the samples had moved sufficiently distal to separate proteins of 
different molecular weights, without allowing them to contact the exposed gel 
strip. Cell culture media samples were subjected to 200V for 50 minutes.  
 
2.6.6  Western Blotting 
Once electrophoresis was complete the gel was removed from its plastic 
cassette and laid against a similarly sized piece of nitrocellulose transfer 
membrane which had been pre-soaked in NuPAGE Transfer Buffer (Novex 
Life Technologies, California, USA). The gel/membrane were sandwiched 
between pieces of filter paper which had also been pre-soaked with Transfer 
Buffer. Care was taken to remove any bubbles between the gel and 
nitrocellulose transfer membrane, as these inhibit protein transfer. This was 
then packed into an X-Cell II blot module (Invitrogen, California, USA) 
amongst foam pads (which had also been pre-soaked in Transfer Buffer) 
with the nitrocellulose membrane positioned closest to the anode. The tank 
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was filled with NuPAGE Transfer Buffer (Novex Life Technologies, California, 
USA), and the unit connected to an electrical power source (Powerpac 300, 
Biorad, Hertfordshire, UK). The module was subjected to 35V for 90 minutes, 
after which the nitrocellulose membrane was carefully removed. The side 
which had been in contact with the gel, was placed upwards in a tray filled 
with a blocking buffer appropriate for the antibody of intended use. The 
blocking buffers used within this thesis were non-fat milk blocking buffers 
(see Table 2.2), prepared with 1g or 2g non-fat milk powder diluted in 100ml 
(1x) tris-buffered saline (TBS) respectively. The membrane submerged in 
blocking buffer was agitated at room temperature for 1 hour.   
 
2.6.7  Antibody Detection 
TBS stock solution (10x) was prepared using a 0.2M trizma base (Sigma-
Aldrich, Missouri, USA) and 1.37M sodium chloride (NaCl) solution; pH 7.6. 
TBS working solution (1x) was prepared using 50ml TBS (10x) mixed with 
450ml ultrapure water, and in a second batch, 500µl Tween® (Sigma-
Aldrich, Missouri, USA) was added to make TBS (1x) with 0.1% Tween®. As 
previously stated, nitrocellulose transfer membranes were submerged in an 
appropriate blocking buffer, depending on the specific protein of interest and 
antibody used (see Table 2.2). The primary antibody was then added to the 
blocking buffer at the recommended concentration, making sure it was 
thoroughly diluted, and the membrane was incubated overnight at 4°C under 
gentle agitation. The following day, the membrane was washed four times 
with; TBS (1x), TBS (1x) with 0.1% Tween® (twice) and TBS (1x), each 
wash lasting 5 minutes. The membrane was then incubated for 1 hour at 
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room temperature, in a suitable blocking buffer containing the secondary 
HRP-conjugated antibody at an appropriate concentration (see Table 2.2). 
The four-step washing process was repeated before the membrane was 
exposed to a 1:1 combination of Oxidising Reagent Plus and Enhanced 
Luminal Reagent Plus (Western Lightening-Plus ECL Enhanced 
chemiluminescence substrate, Perkin Elmer, Massachusetts, USA) for one 
minute under gentle agitation. Excess fluid was blotted from the membrane 
before it was placed in a plastic cover, with the protein ladder situated on the 
left hand side. Membranes were exposed to chemiluminescence using a 
UVP ChemiDoc-it imaging system. Trial images were taken and exposure 
time adjusted as required to produce optimal band intensity. Images were 
assessed and modified using VisionWorksLS image acquisition and analysis 
software. Images were superimposed using Microsoft Powerpoint, to enable 
the molecular weight ladder to be observed on the same blot as the bands. 
 
2.6.8  Stripping of Blots and Reprobing with Loading Control 
Antibody 
Control antibodies were used on membranes analysing intracellular proteins 
extracted from cell lysates. The primary antibody was stripped from the 
membrane by immersing it in stripping buffer (7.6g/L Tris hydrochloric adid 
(HCl), 7ml 2-mercaptoethanol, 2-g/l SDS, pH 6.7) for 30 minutes at 50°C 
under gentle agitation. After repeated washing (3x) of the membrane in TBS 
(1x) with 0.1% Tween®, the membrane was incubated in 2% (w/v) milk 
blocking buffer for 1 hour at room temperature. It was re-probed with an 
HRP-conjugated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
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antibody, and incubated at 4°C overnight under gentle agitation. The four-
wash procedure was carried out, and the membrane was exposed to the 1:1 
combination of Oxidising Reagent Plus and Enhanced Luminal Reagent Plus 
and imaged as detailed above.  
 
! 100 
Table 2.2 Primary and secondary antibody concentrations used in western blot.  
Primary Antibody Manufacturer 
(Cat. No.) 
Conc. Blocking buffer Secondary Antibody Manufacturer 
(Cat. no.) 
Conc.  
Aggrecan interglobular doman 
(IGD) aggrecanase site-specific 
neoepitope monoclonal (BC-3) 
 
Kind gift from Prof. 
B Caterson,  
Cardiff University. 
1:200 1% non-fat milk 
blocking buffer 
Anti-mouse IgG-
peroxidase monoclonal  
Sigma-Aldrich 
(A4416) 
1:2000 
Sheep anti-mouse ADAMTS5 
monoclonal 
 
 
Kind gift from Prof. 
A Fosang, 
Melbourne, AUS. 
1:500 2% non-fat milk 
blocking buffer 
Anti-goat/sheep IgG-
peroxidase conjugated 
monoclonal 
Sigma-Aldrich 
(A9452) 
1:1000 
Equine IL-1 beta/IL-1F2 
monoclonal (Clone 424823)  
R&D Systems 
(MAB3340) 
 
1:500 2% non-fat milk 
blocking buffer 
Anti-rat IgG peroxidase 
conjugated monoclonal 
Sigma-Aidrich 
(A9037) 
1:1000 
Anti-GAPDH peroxidase 
monoclonal 
Sigma-Aldrich  
(G9295) 
1:5000 2% non-fat milk 
blocking buffer 
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2.7  Gene Expression Analysis Through qRT-PCR 
 
2.7.1  The Design, Validation and Testing of Species-Specific 
Primers 
The mRNA sequences associated with the equine and canine genes listed in 
table 2.3 alongside their gene accession numbers, were acquired from the 
NCBI Genebank database. Equine and canine mRNA sequences were 
directly compared for similarity through the NCBI BLAST facility 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Species-specific primers were 
designed using Primer Express 2.0 (Applied Biosystems, California, USA) 
against non conserved sequences.  
 
Equine and canine primers were validated using serial doubling dilutions (0 = 
undiluted, (1) 1:2 dilution, (2) 1:4 dilution, (3) 1:8 dilution, (4) 1:16 dilution, (5) 
1:32 dilution) of EFLS and DH82 cDNA respectively, from cells that had been 
cultured individually and exposed to 10µg/ml LPS (Figures 2.7 and 2.8).  
 !
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Table 2.3 Equine and Canine primers. 
 
  
Equus Caballus Primers 
 
  
Gene Gene 
Accession No. 
Sequence R Effici
-ency 
     
GAPDH NM_001163856.1 F:TGACCCCCTAACATATTGAGAGTCT 
R: GCCCCTCCCCTTCTTCCTG 
 
1 
 
108% 
 
IL-1β NM_001082526.1 F: GAGCCCAATCTTCAACATCTATGG 
R: ATACCAAGTCCTTTTACCAAGCCTG 
 
0.99 
 
91% 
 
IL-6 NM_001082496.1 F: CCTGGTGATGGCTACTGCTTTC 
R: GGATGTACTTAATGTGCTGTTTGGTT 
 
0.99 
 
92% 
 
ADAMTS4 NM_001111299.1 F: CAGCCTGGCTCCTTCAAAAA 
R: ATGTGGTCACTATTCCTGCGG 0.99 
 
 
106% 
 
ADAMTS5 XM_003364218.2 F: ACCGATCCTGCAGTGTCACA 
R: AAATCTTTTCGCCATGAGCAG 1 
 
 
101% 
 
MMP3 NM_001082495.1 F: TCTTGCCGGTCAGCTTCATATAT 
R: CCTATGGAAGGTGACTCCATGTG 
 
0.99 
 
97% 
 
MMP13 NM_001081804.1 F: CTGGAGCTGGGCACCTACTG 
R: ATTTGCCTGAGTCATTATGAACAAGAT  >90% 
 
Canis Lupus Primers  
 
  
Gene Gene Accession 
No.  
Sequence R Effici
-ency 
     
GAPDH NM_001003142.1 F: AACTGCTTGGCTCCTCTAGCC 
R: CCACGATGCCGAAGTGGT 
 
0.99 
 
123% 
 
IL-1β NM_001037971.1 F: CTATCATCTGCAAAACAGATGCG 
R: GCATGGCTGCATCACTCATAAA 
 
1 
 
94% 
 
IL-6 NM_001003301.1 F: CCTGGTGATGGCTACTGCTTTC 
R: TGGCATCATCCTTGGAATCTC 
 
1 
 
95% 
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Figure 2.7 Equine primer validation and 
dissociation curves. (A-F) Equine primers 
were validated using serial doubling dilutions (0 
= undiluted, 1; 1:2 dilution, 2; 1:4 dilution, 3; 1:8 
dilution, 4; 1:16 dilution, 5; 1:32 dilution) of 
EFLS cDNA. qRT-PCR was then performed 
using each primer. (G) A typical dissociation 
cu rve p roduced f rom equ ine p r imer 
amplification products.  
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Figure 2.8 Canine primer validation and dissociation curves. (A-C) Canine primers were validated 
using serial doubling dilutions (0 = undiluted, 1; 1:2 dilution, 2; 1:4 dilution, 3; 1:8 dilution, 4; 1:16 dilution, 
5; 1:32 dilution) of DH82 cDNA. qRT-PCR was then performed using each primer. (D) A typical dissociation 
curve produced from canine primer amplification products.  
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2.7.2  RNA Extraction  
For each well of a 6 well plate culture media was transferred to a 1.5ml 
centrifuge tube for storage at -20°C, and then 1ml Tri-reagent (Ambion, 
Warrington, UK) was added to the cell layers. Cells were exposed to the Tri-
reagent for 1-2 minutes before being pipetted vigorously to ensure complete 
homogenisation. Suspensions were transferred to RNAse-free centrifuge 
tubes and stored at -80°C. The guanidinium-thiocyanate-phenol-chloroform 
technique (Chomczynski and Sacchi 1987) with ethanol was used to extract 
RNA from Tri Reagent lysates. Each sample had 100µl chloroform (Sigma-
Aldrich, Missouri, USA) added to it, and samples were thoroughly mixed. 
Samples were rested for 5 minutes, allowing the suspension to separate into 
a pink-coloured bottom layer and a clear upper layer. Samples were then 
centrifuged at 20817g for 15 minutes at 4°C. This process separates the 
suspension further into three distinct layers; the bottom pink-coloured layer 
contains protein, the white layer overlying this contains DNA, and the clear 
layer above these contains RNA. The upper clear aqueous layer was 
transferred to a new centrifuge tube, taking care not to disturb the other 
layers. The aqueous layer, approximately 400µl, was mixed with an equal 
volume of 2-propanol (Sigma-Aldrich, Missouri, USA) to precipitate the RNA 
and the suspension was centrifuged at 20817g, for 10 minutes at 4°C. The 
suspension was discarded and the centrifuge tube carefully blotted to 
remove as much of the 2-propanol-chloroform mixture as possible, taking 
care not to disturb the RNA pellet. The pellet was then washed with 1ml 70% 
ethanol (prepared using diethylpyrocarbonate(DEPC)-water). Samples were 
centrifuged again at 20817g for 5 minutes before the 70% ethanol solution 
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was discarded, the tube blotted and the samples allowed to air dry for 20 
minutes. The RNA pellet was then dissolved in 20µl 0.1% DEPC-water and 
stored at -80°C.  
 
2.7.3  Reverse Transcription 
The RNA content of each sample was quantified using a Nanodrop ND-100 
spectrophotometer (Labtech, East Sussex, UK). One µl (0.5µg) random 
hexadeoxynucleotides (Random Primers, Promega, Wisconsin, USA) were 
added to 1µg RNA of each sample. 0.1% DEPC-water was also added to the 
samples to equalise sample volumes to 13.4µl. Samples were then 
subjected to 70°C heat for 5 minutes, to uncoil the RNA secondary structure. 
Samples were immediately rested on ice for >1 minute. A volume containing 
100µM nucleotide triphosphates (dNTP mix, Promega, Wisconsin, USA) 
which includes 25µM of each dATP, dCTP, dGTP, and dUTP, was combined 
with 200U moloney-murine leukaemis virus (M-MLV) reverse transcriptase 
(200U/µl), 5µl M-MLV reverse transcriptase 5x reaction buffer (50mM Tris-
HCl, 75mM potassium chloride (KCl), 3mM magnesium chloride (MgCl2) and 
10mM Dithiothreitol (DTT)), and 24U rRNasin Plus ribonuclease inhibitor 
(40U/µl) (Promega, Wisconsin, USA). This mixture was added to each 13.4µl 
sample to result in a total volume of 25µl. Complementary DNA was then 
synthesised under standard reverse transcription conditions.  
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2.7.4  Quantitative Real-Time Polymerase Chain Reaction 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed 
using 160ng cDNA in a total volume of 20µl containing SYBR Green master 
mix (GoTaq qPCR Master Mix, Promega, WI, USA) at 1X, 300µM forward 
primer and 300µM reverse primer. Reactions were performed on a ABI 7300 
Real Time PCR system (Applied Biosystems, California, USA), under the 
following standard amplification conditions; 2 minutes at 50°C, 10 minutes at 
95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. 
Using the Sequence Detection Systems (SDS) software system (Applied 
Biosystems, California, USA), PCR products were quantified using the 
number of thermal cycles (Ct) required for each PCR product to produce the 
amount of fluorescence needed to reach a defined threshold. The relative 
quantification of each gene normalised to the GAPDH reference gene was 
calculated using the 2-ΔCt method (Livak and Schmittgen 2001).  
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2.8  Poly Lactic-co-Glycolic Acid Microspheres 
 
PLGA microspheres were created by Dr Rui Chen and Professor John Hunt, 
at the Centre for Materials and Structures within the Institute of Ageing and 
Chronic Disease, University of Liverpool, using the technique outlined below,  
 
2.8.1  Emulsion Solvent Evaporation Technique; Water-in-Oil-in-
Water (W1/O/W2)  
PLGA microspheres were constructed from the biodegradable polymers; 
lactide and glycolide. The emulsion solvent evaporation technique; water-in-
oil-in-water (W1/O/W2) method was used to create the PLGA microspheres 
(Chen, Curran et al. 2006). The polymeric coat material (PLGA) is dissolved 
in a volatile organic solvent; dichloromethane. Fluorescein isothiocyanate-
dextran or equine anti-IL-1β siRNA were dissolved in pure water and added 
to the polymer solution as an inner-water phase (10%w/w). The water in oil 
emulsion (W1/O) was prepared with a micro-homogenizer in a 25ml flask at 
20W for 30 seconds at 4°C. The prepared emulsion was then added to 
100ml 1% polyvinyl alcohol (PVA) solution. The emulsion was stirred at 
1000rpm for 30 minutes to obtain the water-in-oil-in-water emulsion 
(W1/O/W2). This was added to 100ml 0.1% PVA solution to prevent 
coagulation, and to evaporate the solvent (dichloromethane). Microspheres 
were suspended in 0.1M PBS (pH 7.4) at 10mg/ml for use in cell culture 
experiments, and frozen at -20°C.  
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2.9  Histology 
 
2.9.1  Tissue Explant Preparation 
Synovial explants, which had been cultured with fluorescein isothiocyanate-
dextran-loaded microspheres, were embedded in Tissue-TEK OCT (Sakura 
Finetek, CA, USA) on a cork disc. A plastic vessel containing 2-propanol 
(Isopentane, Sigma-Aldrich, Missouri, USA) floating above liquid nitrogen 
within a dewer, was used to snap freeze the explants. Both embedded 
synovial explants and cartilage explants were immersed within the 2-
propanol for approximately 30 seconds, before being transferred to a 
labelled conical falcon tube or eppendorph tube and frozen at -80°C. 
Synovial explants were sectioned using a cryostat (Leica CM 1900). Sections 
10µm thick were adhered to glass slides, dried, and labelled. Sections were 
stored at -20°C. Synovial sections were incubated with 4’,6-diamidino-2-
phenylindole (DAPI) (1:1000 diluted in PBS) (Invitrogen, Massachusetts, 
USA) and mounted under coverslips using Vecatshield mounting media 
(Vector laboratories, California, USA).  
 
2.9.2  Cartilage Explant Preparation and Sectioning 
Cartilage explants were fixed in 4% neutral buffered paraformaldehyde (PFA) 
for 48 hours, before being immersed in 70% ethanol. Explants were 
embedded in paraffin wax, cut into 10µm sections and mounted onto glass 
slides.  
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2.9.3  Osteochondral Wedge Biopsy Preparation 
Osteochondral wedge biopsies were fixed in 4% neutral buffered PFA for at 
least 24 hours. Samples were then de-calcified in 7.4% EDTA for one month. 
Water within the sample was first replaced with alcohol by dehydrating the 
samples; the tissue was passed through increasing concentrations of ethyl 
alcohol (0 to 100%). The alcohol was then replaced by xylene, which is 
miscible with paraffin wax, in the clearing step. Finally, the tissue was 
impregnated with, and embedded in, paraffin wax. Explants were cut into 
10µm sections using a microtome, and mounted onto glass slides.   
 
2.9.4  Tissue Staining and Histological Scoring 
All histological cartilage, synovial membrane and osteochondral sections 
were stained with either Haematoxylin and Eosin (H&E), or celestine blue, 
0.5% fast green and 1% Safranin-O stains. Sections were visualised using a 
Nikon Eclipse 80i microscope, and images were acquired using a Nikon DS-
L2 standalone control unit. Cartilage explant sections were scored using a 
modified version of the cartilage histopathologic scoring system (McIlwraith, 
Frisbie et al. 2010). Osteochondral sections and synovial sections were 
scored using unmodified scoring systems (McIlwraith, Frisbie et al. 2010). 
Sections were scored twice by two users blinded to section identity. Inter- 
and intra- variability was assessed using Cohen’ kappa coefficient (Cohen 
1960). Cartilage explant depth was measured at three different locations on 
each explant, using lines drawn perpendicular to the long axis of the explant.  
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2.9.5  Cell Mounting and Staining 
Cells (EFLS, DH82 or EPBMCs) were cultured on sterile poly-l-lysine 
(Sigma-Aldrich, Missouri, USA) coated glass coverslips within 6-well plates, 
and non-adherent cells were cyto-spun onto glass slides.  
 
2.9.5.1  Adherent Cells  
Glass coverslips were soaked in 70% ethanol, placed into wells of a 6-well 
tissue culture plate and allowed to air dry within a cell culture hood. 
Coverslips were then covered with 400µl 0.01% poly-l-lysine solution 
(Sigma-Aldrich, Missouri, USA) and incubated at room temperature for 15 
minutes. Excess poly-l-lysine was removed and wells air dried within a cell 
culture hood. Adherent cells on coverslips were gently washed with PBS 
before being fixed with 500µl 4% PFA. Plates were incubated at room 
temperature for 20 minutes. Coverslips were then washed twice with PBS 
and once with wash buffer (0.1% BSA in PBS) before being air dried within a 
cell culture hood. Vectashield mounting medium containing DAPI was 
dispersed over the coverslip which was then mounted onto a slide. 
Coverslips were permanently sealed around the perimeter with nail polish. 
 
2.9.5.2  Non-adherent Cells 
Non-adherent cells and culture media were transferred to 1.5ml 
eppendorphs, spun in a microfuge at 20817g for 30 seconds, and the 
supernatant discarded. Cells were fixed in a solution containing 250µl PBS 
and 250µl 4% paraformaldehyde, and incubated for 20 minutes at room 
temperature. Cells were then washed twice with PBS and once with wash 
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buffer (0.1% BSA in PBS) before finally being re-suspended in 50µl PBS. A 
volume of  cell suspension, 25µl, was transferred onto each slide. Slides 
were placed at the bottom of whatmann paper-lined centrifuge buckets. 
Slides were spun at 1811g for 2 minutes and allowed to air dry. Vectashield 
mounting medium containing DAPI (Vector laboratories, California, USA) 
was dispersed over the cells and covered with a coverslip. Coverslips were 
permanently sealed around the perimeter with nail polish.  
 
2.9.6  Fluorescence Microscopy 
Cells and tissue sections were imaged using a three channel confocal 
microscope (Zeiss LSM510 Meta Confocal microscope, Axioplan 2 stand); 
the fluorescein isothiocyanate-dextran microspheres were imaged using the 
Cy3-fluorescein isothiocyanate (FITC) filter (488-532nm), and the DAPI 
stained nuclear material with the blue filter (364nm).  
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Chapter 3. 
Testing Short-Interfering RNA Mediated Gene Silencing and 
Biodegradable Polymer Microspheres As Delivery Vehicles on Equine 
Synoviocytes 
 
3.1  Introduction 
Synovial inflammation, or synovitis, has been reported to play a major role in 
both the structural and symptomatic progression of osteoarthritis (OA). 
Whether it predisposes the joint to OA or is a secondary result of OA is so far 
unknown. It is characterised by an increase in catabolic cytokines such as 
TNF-α and IL-1β, both of which are produced by FLS and synovial 
macrophages.   
A joint capsule surrounds every diarthrodial joint. It consists of 3 layers and 
the synovial membrane (intima) is the innermost layer overlying the 
subsynovium. This membrane is one to four FLS thick and acts as a 
macromolecular sieve (Caron 2011) allowing molecules, such as glucose, 
oxygen, carbon dioxide, and small proteins, to move from plasma into the 
synovial fluid (Frisbie 2012), whereas larger components of synovial fluid are 
directly secreted by FLS into the joint (Yielding, Tomkins et al. 1957, Jay, 
Britt et al. 2000). When the synovial membrane becomes inflamed, this 
highly regulated process is compromised. Changes to synovial fluid protein 
content, cell numbers and subsequent fluid consistency occur. Two major 
cell populations reside within the synovial membrane: FLS and synovial 
macrophages. Characterisation of each population has determined these 
populations to be mutually exclusive (Edwards 1994) although some reports 
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suggest the presence of an intermediate cell population (Caron 2011). 
Resident synovial macrophages are produced by precursors within the 
synovial membrane, whereas infiltrating mononuclear cells present in the 
synovium during synovitis originate from bone marrow (Edwards 1994). FLS 
produce collagen, hyaluronan, lubricin and various cytokines including TNF-α 
and IL-1β. Resident synovial macrophages, which comprise between 10 - 
20% of the synoviocyte population, carry out phagocytosis, and also produce 
cytokines, eicosanoids (PGE2) and proteinases (Caron 2011). They are the 
chief producers of both TNF-α and IL-1β, and expression of these cytokines 
increases in all degrees of equine OA (Kamm, Nixon et al. 2010). 
TNF-α and IL-1β, play a substantial role in the pathogenesis of OA (Sellam 
and Berenbaum 2010). Alongside other cytokines, such as IL-6 and IL-18, 
they stimulate the NF-ĸB and MAPK intracellular signalling pathways, which 
in turn cause an increase in the transcription of several different MMPs, 
cycloxygenase (COX-2) and inducible nitric oxide (Kamm, Nixon et al. 2010). 
These cause joint pain and inflammation. IL-1β can also stimulate an 
increase in aggrecanases which cause cartilage matrix destruction through 
proteolysis (Kamm, Nixon et al. 2010).  
Synovitis has many causes including bacterial infection and systemic 
autoimmune inflammatory disorders. However, the condition referred to in 
this thesis, is synovitis triggered by an initial trauma to the joint. Events 
predisposing the joint to OA and/or synovitis are comparable. Much like the 
chicken and egg argument, whether innate immunity responses from 
synoviocytes cause deleterious effects on articular cartilage, or primary 
cartilage damage releases matrix fragments and pro-inflammatory mediators, 
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stimulating an inflammatory response by synoviocytes, is yet to be 
determined. Initial trauma could reflect an acute episode of excessive force, 
or frequent episodes of recurrent low-grade excessive force experienced by 
the joint. Alternatively, it can arise from normal forces exerted on an 
abnormal joint; be it through incorrect conformation or developmental 
orthopaedic disease resulting in disproportionate forces experienced by the 
joint, or from defects in joint tissue integrity. Whichever way synovitis is 
initiated, it has the potential to progress to OA. Synovial inflammation is 
characterised by a mononuclear cell infiltration of neutrophils, T lymphocytes 
and monocytes; as well as vascularisation and hyperplasia of the synovium 
(Sutton, Clutterbuck et al. 2009). In osteoarthritis, acute synovitis may be one 
of the first changes to occur during which synovial tissue has been shown to 
over-express inflammatory mediators such as pro-inflammatory cytokines 
(Benito, Veale et al. 2005); especially IL-1β and TNF-α (Todhunter, Kincaid 
et al. 1996). Reducing the action of IL-1β and TNF-α has been shown to be 
therapeutically beneficial for inflammatory joint disease in humans.  
 
RNA interference (RNAi) facilitates manipulation of target gene expression, 
resulting in post-transcriptional gene silencing (PTGS). Double stranded 
synthetic siRNA molecules are between 20-25 nucleotide base pairs long, 
and are incorporated into a RISC once inside the cell. The siRNA sense 
strand is released from the complex, and the anti-sense strand binds to 
complementary mRNA. Cleavage of mRNA at this site inhibits its translation 
to a protein, effectively silencing the gene. However, in vivo delivery of this 
molecule to the target cell is problematic. Optimal PTGS requires (1) siRNA 
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protection from nuclease degradation, (2) an efficient method of siRNA 
transportation into the cells cytoplasm (siRNA duplex is negatively charged 
and can therefore not move across the cell membrane), and (3) sustained 
siRNA release from the delivery vehicle, at an appropriate dose to ensure an 
effective therapeutic response. The delivery vehicle must also be 
biodegradable, non-toxic and able to be loaded with an siRNA concentration 
sufficient to permit sustained release over the required period.  
 
Interest in PLGA microspheres as drug delivery systems has been 
substantial since the 1980s (Janssen, Mihov et al. 2014). More specifically, 
investigating the use of this system to target intra-articular disease processes 
has been on-going since the 1990s. It has previously been proved that the 
DH82 cell line (a canine macrophage-like cell line) can phagocytose PLGA 
microspheres (Wasserman, Diese et al. 2012). Unpublished data from our 
laboratory has demonstrated the effective use of PLGA (65:35 lactide: 
glycolic acid) microspheres for the delivery of siRNA molecules to DH82 
cells. PLGA microspheres were shown to encapsulate siRNA with 70% 
efficiency and this was uniformly distributed throughout a <20µm 
microsphere. Degradation of the microsphere occurred over 6 weeks, 
releasing the siRNA in a controlled manner, resulting in 30-40% remaining in 
the microsphere at 6 weeks. IL-1β and TNF-α siRNA-loaded microspheres 
were successfully phagocytosed by DH82 cells. When challenged with LPS, 
a decrease in the release of IL-1β and TNF-α, as analysed by ELISA assays, 
occurred at 8 days and 2 weeks of culture.  
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Building on our laboratory’s findings, this chapter describes a series of 
investigations into RNAi of catabolic cytokines produced by equine fibroblast-
like synoviocyte (EFLS) and equine peripheral blood mononuclear cells 
(EPBMC), using siRNA and siRNA-loaded PLGA microspheres.  
 
 
3.1.1 Aims 
! Determine EFLS and EPBMC gene expression profiles following 
exposure to an inflammatory stimulus. 
! Optimise the extent of IL-1β gene knockdown in EFLS and EPBMC 
using an siRNA approach.  
! Determine the capacity of EPBMCs to phagocytose PLGA 
microspheres.  
! Determine the in vitro effectiveness of siRNA-loaded microspheres on 
reducing synoviocyte IL-1β gene expression. 
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3.2  Study Design  
 
An overview of the experimental design can be found in Schema 3.1. 
 
3.2.1  Synoviocyte Gene Expression in Response to Inflammatory 
Stimulation  
EFLS and EPBMCs were isolated from equine synovium and peripheral 
equine venous blood respectively, as described in Chapter 2 Materials and 
Methods, section 2.1.  
 
3.2.1.1  LPS Concentration Optimisation 
The responses of EFLS (n=3) and EPBMCs (n=3) to LPS (Escherichia coli 
026:B6, Sigma-Aldrich, Missouri, USA) exposure were tested using 0-
100µg/ml and 0-10µg/ml LPS respectively. EFLS were seeded in 6-well 
plates at 3.3 x 105 cells per well in 2ml standard culture media. Once cells 
had adhered, media was replaced with fresh media containing either 0, 0.1, 
0.5, 1, 5, 10, 50 or 100µg/ml LPS. EPBMCs were seeded in 96-well plates at 
7 x 104 cells per well in 300µl standard EPBMC culture media. Once 
adhered, media was removed and replaced with fresh media containing 0, 
0.1, 1 or 10µg/ml LPS. In each case cells were exposed to LPS for 24 hours. 
EFLS were harvested in tri-reagent and underwent RNA extraction, reverse 
transcription and qRT-PCR. Cytokine mRNA levels were normalised to 
GAPDH, and calculated using the 2-ΔCt method (Livak and Schmittgen 2001) 
(Figure 3.2). EPBMC culture media was analysed for secreted TNF-α and 
IL-1β protein concentrations using TNF-α and IL-1β ELISA assays 
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respectively (Figure 3.3). A curve of best fit was positioned among the optical 
density readings produced by the standards (of known concentrations) for 
both equine IL-1β and TNF-α assays, yielding a linear regression equation 
from which unknown sample IL-1β and TNF-α protein concentrations could 
be deduced respectively. 
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EFLS & EPBMC  
•  The concentration of LPS which provides sufficient cytokine up-
regulation was investigated.  
siRNA design 
and testing 
•  siRNA Sequence Design 
•  Testing of optimal concentration of siRNA for transfection 
•  Measurement of post-transcriptional gene silencing using anti-
cytokine siRNA  to treat EFLS and EPBMC 
•  PCR analysis 
•  Western Blot analysis 
•  Different primers trialled for PCR analysis 
PLGA 
Microsphere 
work 
•  Optimal microsphere size for EPBMC phagocytosis investigated 
•  Microsphere culture with synovial explants investigated 
•  EPBMC culture with Anti-IL-1β siRNA loaded PLGA microspheres 
Schema 3.1 Experimental strategy for work within Chapter 3. An overview of 
order of experimental investigations included in Chapter 3.  
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3.2.2  RNA Interference Optimisation 
 
3.2.2.1  Short Interfering RNA Sequence Design 
As described in Chapter 2 Materials and Methods, section 2.7, equine IL-1β 
and TNF-α mRNA sequences were acquired from the NCBI Genbank 
database. Custom made synthetic siRNA duplexes were designed by 
Ambion (Life technologies, California, USA) to complement these mRNA 
sequences (Table 3.1). BLAST searches were performed on all siRNA 
sequences to determine their compatibility with the equine genome, and to 
detect any compatibility to non-target genes.  
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Table 3.1 SiRNA sequences used to target equine IL-1β and 
TNF-α mRNA sequences. The antisense strand anneals to the 
complementary fragment of the target mRNA sequence. 
Sequence not disclosed in the 
interest of intellectual property 
protection 
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3.2.2.2  Determining what Concentration of SiRNA will Produce 
Optimal Post-Transfection Intracellular SiRNA Levels 
Initial optimisation experiments were conducted to ensure maximal 
intracellular post-transfection siRNA levels. EPBMCs (n=4 horses, 2 
bioloigcal replicates) were seeded in 96-well plates at 7 x 104 cells per well in 
300µl standard EPBMC culture media. Cells were incubated overnight and 
allowed to adhere. Cells were then transfected with 0, 0.2 or 1pmol/µl 
silencer Cy3 labelled negative control siRNA (Life technologies, California, 
USA). To create the transfection reagents, 2µl Lipofectamine 2000 (Thermo 
Fisher Scientific, California, USA) reagent was diluted in 50µl serum free 
OPTI-MEM medium (Life Technologies, California, USA). Separately, Cy3 
labelled negative control siRNA (Life technologies, California, USA) was 
diluted at either 0.2pmol/µl or 1pmol/µl in OPTI-MEM media. The 
lipofectamine and siRNA dilutions were combined at a 1:1 ratio, and 
incubated for 25 minutes to allow the formation of siRNA-lipid complexes. 
Cell culture media was replenished with standard EPBMC culture media and 
the siRNA-lipid complexes added. An equivalent volume of OPTI-MEM was 
added to wells which did not receive siRNA-lipid complexes. Four hours 
later, wells were analysed microscopically using the FITC filter, as the 
fluorescein derivative Cy3 has a peak excitation and emission at 
wavelengths of 547nm and 563nm respectively. The percentages of 
fluorescent cells were calculated in four different areas of each well, and the 
average value used to determine the optimum siRNA concentration to be 
used during transfection. 
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3.2.2.3  Measurement of Post-Transcriptional Gene Silencing 
Produced by SiRNA  
Gene and protein levels of target cytokines, from both EFLS and EPBMCs, 
were analysed. The majority of experiments compared the effects of custom 
designed anti-cytokine siRNA (Ambion, Thermofisher Scientific, UK) to that 
of control cells transfected with silencer select negative control no.1 siRNA 
(Ambion, Thermofisher Scientific, UK), and all cells were stimulated with 
10µg/ml LPS. Messenger RNA expression and extracellular secreted protein 
levels were analysed through qRT-PCR, and western blot and ELISA assays 
of culture media, respectively.  
 
3.2.2.4  The Effects of Anti-cytokine SiRNA on Extracellular 
Secreted Protein  
EPBMCs (n=3 horses) and EFLS (n=3 horses) were seeded separately into 
96-well plates in 300µl standard EPBMC culture media, and standard culture 
media respectively, and cultured until 80% confluent. Cells were either 
transfected with 1pmol/µl silencer select negative control no.1 siRNA 
(Ambion, Thermofisher Scientific, UK), anti-IL-1β (1) or anti-IL-1β (2) siRNA, 
or anti-TNF-α (1) or anti-TNF-α (2) siRNA (Ambion, Thermofisher Scientific, 
UK). Lipofectamine-siRNA complexes were diluted in OPTI-MEM before 
being added to wells for 6 hours. Culture media was then replenished with 
normal media containing 10µg/ml LPS for 12 hours. Media was stored at -
20°C before being analysed using an equine IL-1β and TNF-α ELISA assay.  
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3.2.2.5  EFLS IL-1β mRNA Interference by Anti-IL-1β (2) SiRNA  
EFLS (n=3 horses, 2 biological replicates) were seeded in 12 well plates at 
1.5 x 105 cells per well in 1ml standard culture media and incubated 
overnight. When cells were 80% confluent, media was replaced with serum-
free standard culture media. Cells were transfected with 1pmol/µl siRNA in 
8µl lipofectamine 2000 reagent for 6 hours. Cells were either transfected with 
silencer select negative control no.1 siRNA or anti-IL-1β (2) siRNA. Media 
was then exchanged for serum-free standard culture media containing 
10µg/ml LPS. Cells were incubated for 3 hours before being harvested. 
Media was stored at -20°C. Cells layers were exposed to 0.5ml Tri-reagent 
(Sigma-Aldrich, Missouri, USA) for two minutes before cell lysates were 
thoroughly pipetted and collected.  
 
3.2.2.6  EFLS IL-1β Gene Expression After Treatment with Anti-IL-
1β SiRNA 
Cell lysates underwent RNA extraction using the Guanidinium-thiocyanate-
phenol-chloroform technique (Chomczynski and Sacchi 1987), reverse 
transcription, and qRT-PCR using two different equine IL-1β primers. Equine 
IL-1β gene expression was normalised to GAPDH.  
Two equine IL-1β primer pairs were used to analyse post-siRNA IL-1β 
mRNA expression. The first pair was designed to anneal to sequences 
towards the 5’ end of reverse transcribed IL-1β cDNA, whilst the second pair 
annealed towards the 3’ end. Figure 3.1. shows the relative complementary 
primer positions on the IL-1β mRNA sequence in comparison to the anti-IL-
1β siRNA antisense strand binding site.  
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Primer 1 Primer 2 
Anti-IL-1β (2) siRNA 
AAAAAA  3’ 5’ 
1545 nucleotides 
Figure 3.1 Locations of primer and siRNA complementary binding sites on the Equine IL-1β mRNA sequence.  
(A) Two equine IL-1β primer sequences. (B) The relative locations of primer and siRNA binding sites on the equine IL-1β 
mRNA sequence. 
A. 
B. 
Forward 
 
Reverse 
 
Primer 1  
 
5’-GCAGTACCCGACACCAGTGA-3’ 5’-TTTGGGCCATCCTCCTCA-3’ 
  
Primer 2 5’-GAGCCCAATCTTCAACATCTATGG-3’ 
  
5’-ATACCAAGTCCTTTTACCAAGCCTG-3’ 
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3.2.2.7  Western Blot Analysis of Protein Secreted by Anti-IL-1β 
EFLS    
Protein concentrations within culture media samples were measured using 
the PierceTm 660 protein assay kit. Protein was then extracted from the 
culture media using StrataClean resin (Agilent, California, USA) and re-
suspended in 20µl of (1X) Novex tris-glycine sodium dodecyl sulfate (SDS) 
sample buffer (Life Technologies, California, USA). Each sample was loaded 
onto a 4-12% Bis-tris gel and proteins were separated under reducing 
conditions using electrophoresis. Proteins were transferred to a nitrocellulose 
membrane, which was stained with ponseau stain to test for the presence of 
protein. Membranes were probed with equine IL-1beta/IL-1F2 MAb (Clone 
424823) 1:500 (R&D Systems, Minnesota, USA) and anti-rat peroxidase 
conjugated anti-immunoglobulin antibody 1:1000 (Sigma-Aldrich, Missouri, 
USA). Membranes were exposed to chemiluminescence using a UVP 
ChemiDoc-it imaging system.  
 
A PierceTm 660 protein assay was performed on three samples at three 
points; (1) media post-incubation with StrataClean resin, (2) SDS 
supernatant post-boiling, (3) resin-SDS suspension loaded into the gel.  !
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3.2.3  Phagocytosis of PLGA Microspheres 
 
3.2.3.1  Investigating the Optimal Microsphere Size for EPBMC  
 Phagocytosis 
EPBMCs (n=2 horses, 2 biological replicates) were seeded onto poly-l-lysine 
coated glass coverslips at 3 x 106 cells per well of a 6-well tissue culture 
plate, and in 2ml standard EPBMC culture media. Cells were cultured for one 
week; 1ml standard EPBMC culture media was replenished every 3 days. 
Small (2-6µm diameter) or medium (6-20µm diameter) fluorescein 
isothiocyanate-dextran microspheres were added to the media at 1mg/ml in 
0.1M PBS (pH 7.4), and cultured for a further week. Again, 1ml standard 
EPBMC culture media was replenished every 3 days, taking care not to 
disturb the cells or microspheres.  
 
Non-adherent EPBMCs were cyto-spun onto glass slides, and all slides and 
coverslips were processed, and permanently sealed to enable imaging. Cells 
were imaged using a three channel confocal microscope (Zeiss LSM510 
Meta Confocal microscope, Axioplan 2 stand); the fluorescein 
isothiocyanate-dextran microspheres were imaged using the Cy3-FITC filter 
(488-532nm), and the DAPI stained nuclear material with the blue filter 
(364nm).  
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3.2.3.2  Culture of Microspheres with Synovial Explants 
Synovial explants, approximately 5mm2 were cultured in 6 well-plates, in 2ml 
standard culture media containing 1mg/ml fluorescein isothiocyanate-dextran 
microspheres (2-100µm diameter). Explants were incubated with the 
microspheres for 3 days before being washed with PBS three times. 
Explants were processed for cryosectioning. Sections 10-30µm thick were 
stained with DAPI and imaged using a three channel confocal microscope 
(Zeiss LSM510 Meta Confocal microscope, Axioplan 2 stand).  
 
3.2.4  RNA Interference of EPBMC Gene Expression using Anti-IL-
1β-siRNA Loaded PLGA Microspheres 
EPBMCs (n=2 horses, 2 biological replicates) were seeded in 24-well plates 
at 1 x 105 cells per well in 500µl standard EPBMC culture media. Cells were 
cultured for 7 days during which 50% of the media was replenished every 3 
days. One pmol/µl of either anti-IL-1β microspheres or anti-IL-1β siRNA was 
added to the media bathing the cells. The microspheres were incubated with 
the EPBMCs for 48 hours prior to LPS (10µg/ml) exposure. EPBMC were 
transfected with anti-IL-1β siRNA for 6 hours before exposure to LPS 
(10µg/ml). Cells were harvested in tri-reagent at 4 and 8 days post-LPS 
exposure. Half the media was replenished every 3 days. EPBMC IL-1β 
mRNA expression was analysed through RT-qPCR. 
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3.2.5  Statistical Analysis 
A minitab general linear model was used to perform comparisons between 
EFLS mRNA levels produced by different concentrations of LPS. Paired two-
tailed t tests were used to investigate the EPBMC transfection efficiency 
using fluorescent siRNA between paired groups, and to investigate EFLS IL-
1β gene expression when treated with anti-IL-1β (2) siRNA. One-tailed t tests 
with bonferroni post hoc corrections were used to investigate the difference 
in secreted protein concentrations of EPBMCs and EFLS when transfected 
with anti-cytokine siRNA 
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3.3  Results  
 
3.3.1  Synoviocyte response to LPS Stimulation  
 
3.3.1.1  EFLS mRNA Expression in Response to LPS Exposure 
EFLS IL-1β and TNF-α mRNA expressions in response to LPS 
concentrations ranging 0 - 100µg/ml varied (Figure 3.2A & B respectively). 
Exposure to all concentrations of LPS increased the level of IL-1β and TNF-
α mRNA expression compared to EFLS unexposed to LPS. Whilst direct 
comparisons cannot be performed quantitatively between different genes, it 
was clear from the scale of the 2-ΔCt values that TNF-α mRNA expression 
was approximately 100-fold lower than IL-1β mRNA expression. It was also 
clear that 10µg/ml LPS stimulated the largest increase in EFLS IL-1β mRNA 
expression compared to unexposed cells. This concentration also stimulated 
a moderate to high level of increased TNF-α mRNA expression. Two outliers 
of both TNF-α and IL-1β EFLS mRNA expression were removed due their 
values being between 3 x 103 – 9 x 103 fold lower than the mean values at 
10 and 50µg/ml LPS. Using a Multitab general linear model, a statistically 
significant increase in TNF-α mRNA expression (p<0.0005) was stimulated 
by LPS, whereas the increase in IL-1β mRNA expression was not statistically 
significant.  
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Figure 3.2 EFLS gene expression levels when exposed to different concentrations of LPS. Individual EFLS donor 
(n=3) IL-1β (A) and TNF-α (B) mRNA expression levels when exposed to a range of LPS concentrations for 24 hours, are 
displayed. Cytokine gene expression was normalised to GAPDH. The horizontal band represents the mean expression 
level, and error bars represent 95% confidence intervals. 10μg/ml LPS produced a good degree of IL-1β and TNF-α mRNA 
expression in EFLS compared to cells unexposed to LPS.  
A. B. 
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3.3.1.2  EPBMC Protein Secretion in Response to LPS  
The levels of cytokine protein secreted by EPBMCs into culture media when 
exposed to different LPS concentrations varied between samples (Figure 
3.3). Levels of both cytokines tended to increase upon exposure to 
increasing concentrations of LPS. Secreted IL-1β protein ranged from 0.17 – 
0.46ng/ml to 0.23 – 1.1ng/ml, when cells were exposed to 0 or 10µg/ml LPS 
respectively. Secreted TNF-α protein ranged from 47.55 – 52.6pg/ml to 67.5 
– 308.9pg/ml, when cells were exposed to 0 or 10µg/ml LPS respectively. 
The mean cytokine response when cells were exposed to each LPS 
concentration (Figure 3.3C & D) clearly shows a general trend of increased 
extracellular secreted cytokine protein on exposure to increased LPS 
concentrations. Levels of both secreted cytokines are significantly greater 
when EPBMCs are exposed to 10µg/ml LPS compared to EPBMCs 
unexposed to LPS. !
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Figure 3.3 EPBMC extracellular secreted protein levels released on exposure to different LPS concentrations. Individual EPBMC (n=3) 
IL-1β (A) and TNF-α (B) protein concentration profiles display the degree of variation between each donor (n = 3) on exposure to each LPS 
concentration. The mean IL-1β (C) and TNF-α (D) concentration clearly shows a general trend of increased extracellular cytokine protein on 
exposure to increased LPS concentrations. When taking into consideration the wide margin of error, secreted protein levels of both cytokines 
are greater at 10µg/ml LPS compared to those unexposed to LPS. Error bars represent SEM. 
A. 
B. D. 
C. 
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Based on the responses of EPBMC at the mRNA and protein level, it was 
decided that 10µg/ml Escherichia coli LPS provided adequate simulation to 
investigate RNA interference of equine IL-1β within these cell populations. 
Due to the relatively low degree of EFLS TNF-α gene expression, and 
EPBMC TNF-α secreted protein, further analyses concentrated on IL-1β 
post-transcriptional gene silencing.  
 
 
3.3.2  RNA Interference Optimisation 
 
3.3.2.1  A Higher Concentration of SiRNA Produces Higher 
Transfection Efficiency 
To optimise the intracellular delivery of our siRNA molecules to EPBMCs, we 
investigated the effects of different siRNA concentrations on transfection 
efficiency by using a non-targeting Cy3 labelled siRNA (Figure 3.4). 
Significantly more EPBMCs were transfected with this siRNA when using a 
concentration of 1pmol/µl (69.5-79.0%, mean ± SD: 72.1±6.7%) compared to 
0.2pmol/µl (24.5-50.0%, mean ± SD: 39.4±14.0%) (p<0.005, paired two 
tailed t-test).  !
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0.2pmol/µl siRNA 1pmol/µl siRNA 
Figure 3.4 EPBMCs transfected with two concentrations of Cy3 labelled 
negative control siRNA. Microscopy images; phase contrast images (top), FITC 
filter (middle), two images overlaid (bottom). Using 1pmol/µl fluorescent siRNA 
72.1±6.7% (mean ± SD) cells were transfected compared to 39.4±14.0% (mean ± 
SD) of cells when using 0.2pmol/µl fluorescent siRNA  (p<0.005, paired two tailed t-
test).  
 
40µm  40µm  
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3.3.3  Measurement of Post-Transcriptional Gene Silencing 
Produced by SiRNA  
 
3.3.3.1  EPBMCs and EFLS Secrete More IL-1β than TNF-α  
 Protein in Response to LPS  
After transfection with control or anti-IL-1β siRNA, EPBMCs secreted 5.6 and 
5.0ng/ml, and EFLS secreted 4.42 and 3.5ng/ml IL-1β protein respectively. 
After transfection with control or anti-TNF-α siRNA, EPBMCs secreted 100.5 
and 68.5pg/ml, and EFLS secreted 31.9 and 20.0pg/ml TNF-α protein 
respectively. 
 
Extracellular secreted IL-1β and TNF-α protein levels are shown as fold 
differences in comparison to those of cells transfected with negative control 
siRNA (Figure 3.5). Knockdown of secreted proteins was observed in both 
cell types for each siRNA, although the extent of knockdown was greater in 
the EFLS. Both EPBMCs and EFLS transfected with anti-IL-1β (2) siRNA 
demonstrated a trend toward reduced levels of secreted IL-1β protein. EFLS 
transfected with anti-IL-1β (1) siRNA secreted less IL-1β protein than control 
cells, however, EPBMCs showed a slight increase in secreted protein (Figure 
3.5A). EFLS transfected with either anti-TNF-α (1) or (2) siRNA displayed 
lower concentrations of secreted TNF-α within the media, compared to 
those of control cells. Whereas the concentration of TNF-α within anti- TNF-
α EPBMC media was comparable to those of control cells, leading to the 
conclusion that treatment with anti-TNF-α (2) siRNA had minimal effect on 
the level of TNF-α protein translation and secretion (Figure 3.5B). One-tailed 
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t tests with bonferroni post hoc corrections did not show statistically 
significant reduction in gene expression using the anti-cytokine siRNA 
compared to control siRNA.  
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Figure 3.5 EPBMC and EFLS secreted protein concentrations after RNA interference 
with different siRNA sequences. Fold changes of secreted IL-1β (A) and TNF-α (B) 
protein by EPBMCs (black bars; n=3) and EFLS (grey bars; n=3) treated with two different 
anti-IL-1β and anti-TNF-α siRNA sequences, when compared to cells treated with negative 
control siRNA. All cells were exposed to 10µg/ml LPS for 12 hours. No statistically 
significant reductions in gene expression found. Error bars represent SEM.  
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3.3.3.2  SiRNA Sequence Comparison to Equine mRNA Sequences 
BLAST searches between all siRNA sequences and the Equus Caballus 
genome only detected 100% similarity between the anti-IL-1β (2) siRNA 
sequence and the genome. The other siRNA sequences were less optimally 
matched. All further investigation was therefore carried out using the equine 
anti-IL-1β (2) siRNA. 
 
3.3.4  EFLS IL-1β mRNA Interference by Anti-IL-1β (2) siRNA 
 
3.3.4.1  Anti-IL-1β (2) SiRNA Significantly Reduced EFLS IL-1β 
mRNA Levels 
The IL-1β gene expression of EFLS treated with negative control siRNA was 
compared to those treated with anti-IL-1β (2) siRNA, exposed to 10µg/ml 
LPS for 3 hours. Significantly different 2-ΔCt values were produced when 
using equine IL-1β primer 1 and primer 2 (p = 0.01). EFLS IL-1β mRNA 
expression was normalised to EFLS GAPDH mRNA expression. EFLS 
treated with negative control siRNA and anti-IL-1β (2) siRNA, produced 
0.008 and 0.003, and 0.018 and 0.019 2-ΔCt values respectively, when primer 
1 and 2 were used respectively. Primer 1 demonstrated a large reduction in 
IL-1β mRNA expression when EFLS were treated by anti-IL-1β (2) siRNA in 
comparison to cells treated with negative control siRNA. The change in IL-1β 
mRNA expression did not represent a statistically significant decrease, 
however it did represent a 65.7% reduction, which is considered a good 
reduction (Figure 3.6).  
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Figure 3.6 EFLS IL-1β gene expression after treatment with either negative control 
siRNA or anti-IL-1β (2) siRNA. Two different IL-1β primers were used to analyse the IL-1β 
gene expression of EFLS (n = 3) treated with negative control siRNA (circle and black bars) 
compared to those treated with anti-IL-1β (2) siRNA (square and grey bars). IL-1β gene 
expression is displayed as 2-ΔCt values (A) and as fold changes (B) in comparison to EFLS 
gene expression after treatment with negative control siRNA. A 65.7% reduction in IL-1β 
gene expression was found using primer 1, however there was no statistically significant 
difference found. Error bars represent SEM.  
B. 
A. 
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3.3.5  Analysis of Protein Secreted by EFLS 
 
3.3.5.1  Successful Protein Extraction from Culture Media 
Average protein concentrations within the serum-free culture media of EFLS 
treated with negative control siRNA or anti-IL-1β siRNA, were 533 and 
508µg/ml respectively. Following incubation with Strataclean resin, the 
average culture media protein concentration decreased to 198µg/ml. Once 
protein-bound resin was reconstituted in SDS loading buffer, the average 
protein concentration was >2000µg/ml which reflected successful extraction 
of protein from the culture media. 
 
3.3.5.2  Presence of Culture Media Protein on the Nitrocellulose 
Membrane 
The nitrocellulose membrane stained positive for ponseau stain, which 
inferred that protein had been successfully transferred onto the membrane. 
Two bands are evident for each sample of EFLS treated with both negative 
control siRNA and anti-IL-1β siRNA. These bands reflect the presence of 
protein of approximately 57 and 65kDa (Figure 3.7). It was hypothesised that 
a much bigger range of proteins, with different molecular weights, would be 
extracted from the culture media.  
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Figure 3.7 Protein secreted from EFLS transfected with either 
negative control (-) or anti-IL-1β (+) siRNA. EFLS (n=3) were 
transfected with siRNA for 6 hours before being exposed to 10µg/ml 
LPS for 3 hours. Secreted protein was extracted from serum-free 
culture media and run on an SDS-PAGE gel. Successful protein 
transfer to a nitrocellulose membrane is evident by positive 
Ponseau staining at 57 and 65kDa.  
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3.3.5.3  Equine IL-1β Protein was Undetected within EFLS Culture 
Media 
Using an equine IL-1β mAb the nitrocellulose membrane was probed. There 
was no evidence of protein consistent with either pro-IL-1β (33kDa) or active 
secreted IL-1β (17.5kDa) protein within the culture media of EFLS 
transfected with either negative control or anti-IL-1β siRNA.  
 
3.3.6   EPBMCs Successfully Phagocytose Microspheres  
EPBMCs carried out successful phagocytosis of fluorescein isothiocyanate-
dextran microspheres, between 2-6µm diameter. This was displayed using 
multichannel scanning confocal laser microscopy to create a colour 
composite z-stack series of transverse images spanning the entire cell 
volume (Figure 3.8). A close association between intracellular fluorescent 
microsphere particles and the cell nucleus was evident. Intracellular co-
localisation of phagocytosed microsphere particles and the cell nucleus was 
further demonstrated by three channel confocal imaging (Figure 3.9). 
Between one and seven fluorescent particles were present within 71% of 
EPBMCs, reflecting positive intracellular presence of the microspheres. 
Microspheres larger than 6µm failed to be phagocytosed by the EPBMCs.  
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Figure 3.8 A series of z-sections demonstrating extensive phagocytic uptake of fluorescein isothiocyanate-
dextran microspheres by an equine macrophage, imaged using multichannel scanning confocal laser 
microscopy. Three channels were merged to create a colour composite z-stack series (100x); 488nm (green) to visualise 
the microsphere, 364nm (blue) to visualise the nucleus, and a transmitted light channel (grey) to visualise the 
macrophage. The series of images (top left to bottom right) represent transverse sections from the bottom to the top of the 
cell, allowing visualisation of intracellular components throughout the entire cell.  
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Figure 3.9 Confocal microscopy images of EPBMCs phagocytosis of 2-6µm fluorescein isothiocyanate-dextran 
microspheres (A-D). Transmitted light image (top left), 488nm channel detects the fluorescein isothiocyanate-dextran 
microsphere (top right), 364nm channel detects the DAPI stained cell nucleus (bottom left), and all three images 
overlaid (bottom right). A. x100, B. x63, C. x63, D. x63. Images C and D are on the next page.  
A.  B.  
8μm  8μm  
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3.3.7  Microspheres Cultured with Synovial Explants were 
Associated with Synovicoytes 
Close association of the microspheres and synovial explants, after a 
vigorous washing procedure and histological sample preparation, was 
evident when samples were visualised through confocal microscopy (Figure 
3.10). This supports the presence of successful phagocytic activity within the 
explant. Additionally, multiple fluorescent particles, smaller than the 
microspheres that were originally added to the culture, were detected within 
the explant. These are consistent with small digested particles of the 
fluorescent microsphere within multiple intracellular phagosomes (Figure 
3.10).  !
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Figure 3.10 Synovial explant section associated with fluorescein isothiocyanate-dextran microspheres. Transmitted 
light image (top left), 488nm channel detects the fluorescein isothiocyanate-dextran microsphere (top right), 364nm channel 
detects the DAPI stained cell nucleus (bottom left), and all three images overlaid (bottom right).  
8μm  
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3.4  Discussion  
 
Severe synovitis is characterised by the presence of a marked mononuclear 
cell infiltration, marked increase in vascularity, subintimal oedema and 
fibrosis, and intimal hyperplasia (McIlwraith, Frisbie et al. 2010). When cells 
from the synovium are isolated and cultured, the proliferation of FLS quickly 
exceeds that of synovial macrophages. Previous reports have suggested by 
passage 3-4, cultures contain solely FLS (Rosengren, Boyle et al. 2007). 
This study incorporated both cell types to investigate the cellular interactions 
that would arise within synovial membrane during synovitis.  
LPS was chosen to stimulate synoviocytes because it activates the same cell 
signalling pathways as those which initiate the inflammatory response during 
early OA. LPS binds to the cell surface TLR-4, which is the same receptor 
that DAMPs (Scanzello and Goldring 2012, Houard, Goldring et al. 2013), 
such as extracellular matrix components (Nair, Kanda et al. 2012), bind to. 
This activates the NF-κB pathway, subsequently up-regulating transcription 
of cytokines and chemokines responsible for the mononuclear cell infiltration 
characterising synovitis (Scanzello and Goldring 2012, Houard, Goldring et 
al. 2013). Up-regulation of TLR-4 and DAMPs have been observed in OA 
synovial tissue (Goldring, Otero et al. 2011).  
To allow testing of cytokine RNAi in synoviocytes, cytokine expression had to 
be sufficiently up-regulated. The optimal LPS concentration for the 
stimulation of both IL-1β and TNF-α production in EFLS and EPBMCs was 
10µg/ml. This was a high concentration compared to previous reports. 
However, this concentration stimulated good expression of EFLS IL-1β and 
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TNF-α mRNA expression respectively, when compared to LPS 
concentrations ranging from 0-100µg/ml. Exposing EFLS to 100µg/ml LPS 
produced the highest level of TNF-α mRNA expression, however this 
concentration has been reported to cause a decrease in cell viability (Sharifi, 
Hoda et al. 2010). Ten µg/ml LPS also produced the highest concentration of 
secreted IL-1β (1.1ng/ml) and TNF-α (203.3pg/ml) protein from EPBMCs 
when compared to concentrations between 0 - 10µg/ml LPS. The equine IL-
1β ELISA kit (Bethyl Laboratories, TX, USA) and equine TNF-α ELISA kit 
(R&D Systems, MN, USA) used standard concentrations of recombinant 
equine IL-1β and TNF-α between 3.125–200ng/ml and 31.3–2000pg/ml 
respectively. The IL-1β protein concentrations are below the lower threshold 
of this assay, therefore there maybe a larger degree of error in the 
quantitation of IL-1β protein. Using a lower concentration (<10µg/ml) of LPS 
may have led to undetectable IL-1β protein concentrations. For future 
investigations, proteins within culture media would be extracted and 
concentrated if intended to be used with ELISA kits. 
A slight increase in EPBMC secreted IL-1β protein was observed when cells 
were transfected with anti-IL-1β (1) siRNA using the lipofectamine 
transfection reagent. Lipofectamine, a cationic lipid carrier, is required to 
facilitate intracellular delivery of the large anionic hydrophilic siRNA 
molecules, due to the negative hydrophilic extracellular surface of the cell 
membrane. Lipid-delivered siRNAs bind to the cell membrane, and are 
internalised through endosomal formation (Dominska and Dykxhoorn 2010). 
During this process the innate immune system can be activated through 
endosomal TLRs and intracellular cytoplasmic receptors, which can detect 
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and react to siRNA in a sequence independent manner (Kanasty, Whitehead 
et al. 2012). TLR3 has been identified in macrophages (Rehli 2002, Kawai 
and Akira 2008) and is expressed on cell membranes in endosomes. This 
receptor can activate pathways leading to the production of inflammatory 
cytokines. This may explain the small increase in secreted IL-1 protein.  
Of the two IL-1β siRNA molecules examined, the anti-IL-1β (2) siRNA 
sequence provided the strongest degree of gene expression knockdown, 
causing a 65.7% reduction in EFLS IL-1β transcript abundance. EPBMCs 
showed a moderate decrease in the secretion of IL-1β protein when 
transfected with anti-IL-1β (2) siRNA, as analysed via ELISA. These assays 
were performed on cells which had been exposed to LPS for different lengths 
of time; EFLS and EPBMCs were exposed to LPS for 3 and 12 hours 
respectively. Once cells were stimulated, IL-1β intracellular signalling 
mechanisms caused a rapid increase in IL-1β mRNA and secreted IL-1β 
protein within 1-3 hours (Wang, Olschowka et al. 1997) and >3 hours 
respectively (Lee, Yuk et al. 2012). It has been reported that IL-1β mRNA 
has a half life of 4-5 hours in monocytes and macrophages (Herzyk, Allen et 
al. 1992), however many factors can affect this.  A period of <3 hours of 
exposure to LPS facilitated detection of a true positive decrease in mRNA 
expression. However, exposure to LPS for 12 hours may have resulted in a 
false negative decrease in secreted IL-1β protein concentration. IL-1β protein 
is produced as an inactive precursor protein (31-33kDa) which accumulates 
within the cell cytosol and has a half life of 2.5 hours (Moors and Mizel 2000). 
The intracellular converting enzyme (ICE) cleaves this protein to produce the 
17.5kDa active form (Lopez-Castejon, Brough et al. 2011). Both the 
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precursor and active forms of IL-1β protein are released by human 
monocytes (Moors and Mizel 2000), and both forms are detected by the 
ELISA. The active IL-1β protein has a half life of 2 - 2.5 hours in plasma 
(Kudo, Mizuno et al. 1990). IL-1β protein release is unusual as it bypasses 
the endoplasmic reticulum and golgi apparatus (Lopez-Castejon, Brough et 
al. 2011), and is released approximately 2 hours after synthesis (Moors and 
Mizel 2000). To detect a strong decrease in EBMC secreted IL-1β protein 
caused by anti-IL-1β siRNA, a sampling time of 6 hours post-LPS exposure 
may have provided a more sensitive reflection of the siRNA effects on 
protein translation. Interestingly, previous studies have demonstrated that 
LPS is capable of inducing IL-1β transcription without effecting translation 
(Sung and Walters 1991), contrasting other reports suggesting that LPS can 
stabilise IL-1β mRNA, resulting in increased translation (Caput, Beutler et al. 
1986).  
The siRNA used within this study fulfilled design criteria recommended to 
ensure optimal RNA interference. Low G/C content (24%), A/U base pairs 
within nucleotide positions 15-19, and certain sense strand base preferences 
at positions 3 (A), 10 (U), and 19 (A, no G or C). A/U base pair content is a 
simple measure of local internal stability of the siRNA molecule. Presence of 
these base pairs towards the 3’ end of the duplex correlates well with 
functionality of the siRNA (Reynolds, Leake et al. 2004). Specific sequence-
related determinants, such as the inclusion or exclusion of certain 
nucleotides at specific positions along the sense strand, also correlates with 
siRNA functionality (Reynolds, Leake et al. 2004).  
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When analysing gene silencing via qRT-PCR, it was noted that the relative 
siRNA and primer positions on the target mRNA sequence were highly 
important. Messenger RNA fragments produced through siRNA-mediated 
cleavage are usually cleared through normal cellular mRNA degradation 
pathways. However the 5’ and 3’ mRNA fragments do not share the same 
routes of degradation (Valencia-Sanchez, Liu et al. 2006). One study has 
suggested that the 3’ mRNA fragments may fail to be effectively degraded by 
these cellular mechanisms, and can subsequently act as a template for 
cDNA synthesis. Primers designed to complement cDNA towards the 3’ end 
of the gene, will detect these transcripts during qRT-PCR and false negative 
reductions in gene expression will occur (Holmes, Williams et al. 2010). It is 
hypothesised that this failure of degradation may occur due to the presence 
of particular RNA binding proteins, to the secondary structure of the mRNA, 
or to the accumulation of 3’ mRNA cleavage products reported during siRNA 
treatment (Holmes, Williams et al. 2010). The difference between 2-ΔCt values 
produced by anti-IL-1β (2) siRNA using primer 1 compared to primer 2 were 
significant. Primer 1 demonstrated a 65.7% reduction in EFLS IL-1β mRNA 
transcripts compared to those treated with control siRNA, whereas primer 2 
demonstrated no reduction. Primer pair 1, which is complimentary to a region 
toward the 5’ end of the IL-1β mRNA, was able to detect a significant effect 
of the siRNA mediated knockdown whereas primer pair 2 which is located 
towards the 3’ end, could not detect the knockdown. These results would 
suggest the presence of un-degraded 3’ mRNA fragments within EFLS.  
EPBMCs were also cultured with anti-IL-1β siRNA loaded microspheres, and 
exposed to LPS. The RNA derived from these cultures was highly 
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contaminated and qRT-PCR produced no Ct results. Further work is required 
to investigate whether presence of the PLGA microspheres hinders the 
extraction of good quality pure RNA. 
To provide gold-standard proof of effective silencing by siRNA, analysis of 
intracellular and secreted protein via western blot analysis is required. 
However this was not achieved. Each stage of the culture media protein 
extraction process was tested by performing serial PierceTm 660 protein 
assays. This verified successful protein-resin binding. Protein transfer to the 
nitrocellulose membrane also tested positive using the Ponseau staining. 
However, ponseau staining revealed only two protein bands of around 57 
and 65kDa, it was hypothesised that a far greater dispersity in protein size 
would be present. Once the membranes had been probed with the anti-IL-1β 
monoclonal antibody and appropriate secondary antibody, there was no 
evidence of either the pro- or active forms of IL-1β protein within the culture 
media. This may be due to unsuccessful binding of the primary anti-IL-1β 
monoclonal antibody, the absence of secreted IL-1β in the cell culture media, 
or the concentration of secreted IL-1β protein may be undetectable. To 
investigate this further, a sample of recombinant equine IL-1β would have 
been probed with the anti-IL-1β monoclonal antibody, to test for compatibility.  
The most popular vector to potentiate gene-therapy under current 
investigation is the adeno-associated virus (Goodrich, Phillips et al. 2013, 
Hemphill, McIlwraith et al. 2014). This has been extensively tested in equine 
arthritis models, using the IL-1 receptor antagonist gene (Goodrich, Phillips 
et al. 2013). Whether IL-1β is the target of choice to aid in the reduction of 
clinical symptoms and pathology caused by osteoarthritis, is ambiguous. It is 
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well known that IL-1β plays a major causative role, however, the deletion of 
this gene has also been found to accelerate osteoarthritis (Clements, Price et 
al. 2003). It may be yet another factor involved in the modulation, rather than 
solely inciting, osteoarthritis.  
Further identification of the macrophages, using macrophage-specific 
surface receptors, would have been preferred. Attempts to label this 
population using primary antibodies to the macrophage markers CD14 and 
CD68 (Bartok and Firestein 2010) were unsuccessful due to a lack of equine 
cross-reactive antibodies to these proteins. The lack of such reagents thus 
continues to make the examination of equine monocytes extremely 
challenging. However, the highly efficient manner in which the EPBMCs 
phagocytosed the 2-6µm fluorescein isothiocyanate-dextran microspheres 
provides convincing evidence supporting their nature. This agreed with 
previous studies which found that 1-10µm microspheres were optimal for 
synoviocyte phagocytosis (Butoescu, Seemayer et al. 2009).  
 
3.4.1  Conclusion 
To conclude, we have demonstrated successful siRNA-mediated reduction of 
EFLS IL-1β transcripts, and a moderate decrease in the levels of IL-1β 
protein secreted from equine synoviocytes. Successful equine macrophage 
phagocytosis of PLGA microspheres is a positive step towards the provision 
of a drug-delivery vehicle. Further investigation into the effects of siRNA-
loaded microspheres on equine synoviocyte cultures is required to advance 
this synoviocyte-targeted anti-OA therapy.   
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Chapter 4. 
Species-Specific Co-Culture Synovitis Model to Investigate Intercellular 
Signalling Between Cellular Populations: Macrophages Attenuate 
Fibroblast-Like Synoviocyte ADAMTS5 Gene Expression.  
 
4.1  Introduction  
Synovitis is a key mediator of osteoarthritis (Goldring, Otero et al.), and of 
the perpetuation of cartilage degradation (Sellam and Berenbaum 2010). 
Synovial inflammation is characterised by increases in catabolic cytokines, 
especially IL-1β and TNF-α, which are predominantly produced by synovial 
macrophages. These cytokines cause changes in FLS gene expression, 
including up regulation of damaging cartilage matrix degrading proteinases 
and further cytokines (Bondeson, Wainwright et al. 2006). In 1991 it was 
reported that the major aggrecan fragment detected in synovial fluid of 
arthritic joints, had been cleaved between the Glu373 - Ala374 peptide bond, 
within the interglobular domain of the aggrecan core protein (Sandy, 
Flannery et al. 1992). This differed from the cleavage site of MMPs, which 
had initially been thought to be primarily responsible for aggrecan 
breakdown. This new group of proteases were termed aggrecanases, and 
are the principle proteinases of aggrecan degradation during articular 
cartilage destruction (Zhang, Yan et al. 2013). The ADAMTS family (A 
Disintegrin And Metalloproteinase with ThromboSpondin motif) have 
aggrecanase activity and mainly cleave between the Glu373-Ala374 peptide 
bond; ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2) are key 
players in cartilage destruction (Bondeson, Wainwright et al. 2013). A recent 
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study has identified the transcription factor RelA/p65 as a potent activator of 
ADAMTS5 in chondrocytes during osteoarthritis. It binds to the promoter 
region, and influences expression in the NF-κB pathway (Kobayashi, Hirata 
et al. 2013). The ADAMTS-5 full-length protein has a predicted mass of 
101kDa. Once secreted, it is cleaved in a furin-dependent manner and 
becomes proteolytically activated, although it can exist in two isoforms, 
active and inactive (Bondeson, Wainwright et al. 2013). Increased 
proteoglycan breakdown in articular cartilage was associated with increased 
immunohistochemical staining of PACE4 and furin, suggesting that the post-
transcriptional activation of these factors may be important in the 
pathophysiology of arthritis (Wylie, Ho et al. 2012). Extracellular ADAMTS5 
proteolytic activity is predominantly inhibited by TIMP-3 through its N-
terminal inhibitory domain (Bondeson, Wainwright et al. 2013, Bakali, Gras-
Masse et al. 2014). Extracellular active ADAMTS5 protein is also reduced by 
lipoprotein receptor-related protein 1 (LRP-1) mediated endocytic clearance 
(Yamamoto, Troeberg et al. 2013, Bakali, Gras-Masse et al. 2014). 
ADAMTS5 gene expression is thought to be constitutively expressed by both 
normal and OA human chondrocytes (Bau, Gebhard et al. 2002, Naito, 
Shiomi et al. 2007) and synovial cells (Yamanishi, Boyle et al. 2002, 
Bondeson, Wainwright et al. 2006), however one study reports induction of 
chondrocyte expression by IL-1, TNF-α and oncostatin-M (OSM) (Song, Hua 
et al. 2007). However, normal bovine (Patwari, Gao et al. 2005) and murine 
chondrocyte (Rogerson, Chung et al. 2010) ADAMTS5 mRNA levels respond 
to IL-1 and TNF-α (Bondeson, Wainwright et al. 2013). One report does 
contradict these findings, suggesting bovine chondrocyte ADAMTS5 mRNA 
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expression is constitutive (Tortorella, Malfait et al. 2001). Human synoviocyte 
(Yamanishi, Boyle et al. 2002) and chondrocyte (Bau, Gebhard et al. 2002, 
Song, Hua et al. 2007) ADAMTS4 gene expression is up-regulated by IL-1β 
and TGF-β (Bondeson, Wainwright et al. 2006) and during OA (Bau, 
Gebhard et al. 2002, Bondeson, Wainwright et al. 2006, Naito, Shiomi et al. 
2007, Song, Hua et al. 2007). Previous reports suggest ADAMTS5 is the 
central aggrecanase responsible for cartilage degradation in the murine 
model; ADAMTS5 KO, and normal mice treated with a potent anti-ADAMTS5 
monoclonal antibody, subjected to DMM experienced significantly less 
cartilage destruction than wild type mice (Glasson, Askew et al. 2005, 
Chiusaroli, Visentini et al. 2013, Miller, Tran et al. 2014). In addition to 
cartilage, equine synovium also expresses both ADAMTS4 and -5 (Ross, 
Kisiday et al. 2012); normal synoviocytes co-cultured with injured cartilage 
were found to express significantly lower levels of ADAMTS5 mRNA 
compared to synovium in co-culture with normal cartilage (Lee, Kisiday et al. 
2013). Normal equine synoviocyte ADAMSTS5 mRNA expression was found 
to be unaffected by IL-1 or LPS (Ross, Kisiday et al. 2012), whereas 
chondrocyte expression was up-regulated by these mediators  (Busschers, 
Holt et al. 2010, Ross, Kisiday et al. 2012). However equine OA synoviocyte 
ADAMTS5 gene expression was found to be up-regulated, whereas 
chondrocyte expression was unchanged (Kamm, Nixon et al. 2010). These 
factors suggest a central role for this aggrecanase in equine cartilage 
degeneration, with a possible synovial protective component. ADAMTS5 
presents a potential disease-modifying target for OA, however further insight 
into the regulation of this aggrecanase is needed.  
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A co-culture system modelling synovitis was designed to allow cell-specific 
responses to an inflammatory environment to be identified. The EFLS 
response to LPS stimulation, and to direct macrophage contact, and indirect 
contact through macrophage conditioned-media, were analysed. The 
signalling pathway responsible for macrophage-mediated regulation of EFLS 
ADAMTS5 gene expression was found to be NF-κB-independent, and non-
responsive to macrophage-secreted IL-1β.  
 
4.1.1  Aims  
! To investigate the EFLS response to inflammatory stimulation.  
! To analyse how EFLS cytokine and aggrecanase gene expression is 
affected by macrophages in an inflammatory environment, in a 
temporal and quantitative manner.  
! To examine the influence of IL-1β and NF-κB signalling pathways on 
macrophage and EFLS gene expression.  
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4.2  Study Design  
 
4.2.1  Isolation of Equine Fibroblast-like Synoviocytes  
As described in Chapter 2 Materials and Methods, section 2.1. EFLS from 
three horses were used (passage number <4) from 
metacarpo/tarsophalangeal joints without orthopaedic disease.  
  
4.2.2  Western Blot Analysis; Response of EFLS ADAMTS5 Protein 
to LPS Exposure 
EFLS cells were cultured in 6-well plates at 3.3 x 105 cells per well in 2ml 
standard culture media for 24 hours to allow cells to adhere. Media was 
replaced with fresh media, with and without serum, and with and without 
10µg/ml LPS (E. Coli 026:B6, Sigma-Aldrich, Missouri, USA). Cells were 
harvested at 6 or 16 hours post-LPS exposure. Media was collected and 
stored at -20°C. The cell layer was washed using 1x PBS, before being lysed 
with 200µl 1x SDS sample-loading buffer (62.5mM Tris-HCl, pH 6.8 at 25°C, 
2% w/v SDS, 10% glycerol, 50mM DTT, 0.01% w/v bromophenol blue or 
phenol red). Samples were processed to remove cell debris and sonicated 
as described in Chapter 2 Materials and Methods, section 2.6. Cell layer and 
culture media protein concentrations were measured using the PierceTm 660 
Protein Assay (Life Technologies, Carlsbad, USA). Protein (40µg) was 
extracted from each media sample using StrataCleanTm Resin according to 
the manufacturer’s protocol and eluted by boiling in 15 µl 1x SDS sample 
buffer. Cell layer and culture media protein samples were analysed by SDS-
PAGE and western blotting using primary sheep anti-mouse ADAMTS5 mAb 
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1:500 (a kind gift from Prof. A Fosang, Melbourne, Australia) and monoclonal 
anti-goat/sheep IgG-peroxidase antibody 1:1000 (A9452, Sigma-Aldrich, 
Missouri, USA). Visualisation of the antibody was achieved using a 1:1 
combination of Oxidising Reagent Plus and Enhanced Luminal Reagent Plus 
(Western Lightening-Plus ECL Enhanced chemiluminescence substrate, 
Perkin Elmer, Massachusetts, USA), and a UVP ChemiDoc-it imaging 
system. The primary antibody was stripped from the cell layer membrane by 
immersing it in stripping buffer before being re-probed with an HRP-
conjugated GAPDH antibody 1:5000 (Sigma-Aldrich, Missouri, USA) to serve 
as a control.  
 
4.2.3  Design of the Inter-species Co-culture Model  
 
4.2.3.1  EFLS Cells were Labelled with Cell Proliferation Dye Efluor® 
670 
As described in Chapter 2 Materials and Methods, section 2.2, EFLS cells 
were labelled with the cell proliferation dye eFluor® 670 (eBioscience Inc., 
San Diego, USA). To determine the concentration of dye with maximum 
EFLS labelling efficiency, concentrations ranging from 5 - 10µM were tested. 
Once labelled, cells were cultured in 6-well plates at 3.3 x 105 cells per well 
in 2ml standard culture media, for 24 and 48 hours. Cell layers were then 
washed with PBS, before being exposed to 0.05% trypsin-EDTA (Lonza, 
Basel, Switzerland) and incubated at 37°C in 5% CO2. After 5-10 minutes, 
the wells were vigorously agitated before an equal volume of standard 
culture media containing FBS was added to the suspension to deactivate the 
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trypsin. The cell suspension was centrifuged at 290 x g for 4 minutes, and 
the cell pellet re-suspended in fresh media. Fluorescence emission at each 
concentration was analysed using an AccuriTm C6 flow cytometer (BD 
Biosciences, California, USA).  
 
4.2.3.2  Lentiviral-Mediated Generation of GFP Expressing DH82 
Cells  
The canine macrophage derived cell line DH82 was obtained from American 
Tissue Culture Collection (ATCC, Virginia, USA) and cultured under the 
same conditions as EFLS. These cells were exposed to 8mg/ml 
hexadimethrine bromide (1000x) before being mixed with four different 
multiplicity of infections (MOI) of lentiviral particles expressing a constitutively 
active green fluorescent protein gene (CMV promoter) and a puromycin 
resistance cassette (Sigma, Missouri, USA). Successfully transfected cells 
containing the GFP-expressing plasmid were selected using 2µg/ml 
puromycin (Life Technologies, Carlsbad, USA) and expanded in culture.  
  
4.2.3.3  Determining Cell-proliferation Characteristics within a Co-
Culture Environment 
After seeding cells, cultures were incubated for 24 hours to allow cells to 
attach. When using mixed co-cultures in experiments, it is imperative to know 
the relative proportions of each population within the culture, to fully elucidate 
cellular interactions. EFLS cells labelled with 8µM cell proliferation dye 
eFluor® 670 (eBioscience Inc., California, USA) and GFP-expressing DH82 
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cells were cultured together at different proportions for 24 hours. Cell 
numbers and proliferation characteristics were determined by flow cytometry.  
Cells were seeded in 6-well plates at 3.3 x 105 per well in 2ml standard 
culture media at the following proportions: (1) EFLS, (2) DH82 cells, (3) 33% 
EFLS and 67% DH82 cells, (4) 50% EFLS and 50% DH82 cells, (5) 67% 
EFLS and 33% DH82 cells. Cells were incubated at 37°C in 5% CO2. 
Proliferation characteristics of each population were analysed using an 
Accuri™ C6 flow cytometer (BD Biosciences, California, USA). The 
fluorescence emission intensities of the GFP-expressing DH82 cells and 
efluor-EFLS were measured by the 533/30nm interference filter (FL-1/GFP-
filter) and the 675/25nm interference filter (FL-4/Efluor-filter) respectively. 
Fluorescence emission wavelengths of these fluorophores were sufficiently 
different to ensure that no overlap in detection between the interference  
filters occurred.  
Fluorescent microscopy was conducted using a Nikon eclipse 80i 
microscope to visualise GFP-expressing DH82 cells using a GFP-filter. GFP-
expressing DH82 cell confluence within the mixed co-cultures was recorded. 
Both populations were imaged simultaneously using a three channel 
confocal microscope (Zeiss LSM510 Meta Confocal microscope, Axioplan 2 
stand); the GFP-expressing DH82 cells were excited using a green 
(488/532nm) laser line and detected with a FITC band pass filter. Efluor-
labelled EFLS were excited using a far red (633nm) laser line and detected 
with a 660/20nm band pass filter. Confluence of both populations were 
observed and recorded.  
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4.2.3.4  Design, Validation and Testing of Species-Specific qPCR 
Assays 
Equine and canine mRNA sequences for the following genes; GAPDH, IL-
1β, TNF-α, IL-6, ADAMTS4, ADAMTS5, were located from the NCBI 
Genbank database (Table 4.2). Equine and canine mRNA sequences, for the 
genes of interest, were directly compared using an NCBI BLAST search to 
find areas of dissimilarity, which were then used for primer design. All 
primers were designed using Primer Express 2.0 software (Applied 
Biosystems, California, USA) and obtained from Eurogentec (Liege, 
Belgium). BLAST searches, using the entire Equus caballus genome and 
Canis lupus genome, were performed with all primer sequences to establish 
gene specificity. Primer pairs were validated using serial 2-fold dilutions of 
either EFLS or DH82 cDNA, extracted from cells which had been cultured 
individually (Figures 4.8 and 4.9). Primers were also tested on cDNA from 
EFLS, DH82, and mixed EFLS and DH82 cultures (n=3) at 0, 1, 3, 6, 12 and 
24 hours to investigate their species-specificity (Figures 4.6 and 4.7). QRT-
PCR analysis was performed for both the validation and species-specificity 
tests. Dissociation curves for all PCR reactions were analysed to ensure 
primers were producing one single amplicon (Figures 4.6 and 4.7). 
 
4.2.3.5  EFLS and DH82 Co-cultured With Direct Contact 
EFLS (n=3 horses, 2 biological replicates) and DH82 cells were seeded 
either independently, or as co-cultures within the same well, in 6-well plates 
at 1.5 x 105 cells per well in 2ml standard culture media (Figure 4.1). Cells 
were cultured overnight. Cells were then exposed to 10µg/ml LPS and 
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harvested at 0 (no LPS exposure), 1, 3, 6, 12, and 24 hours post-LPS 
exposure. Media was removed and stored at -20°C. Cell layers were 
exposed to Tri-reagent (Ambion, Warrington, UK) for 1-2 minutes then 
pipetted vigorously to ensure all cells had detached. Samples were 
transferred to RNA-free eppendorphs and stored at -80°C. Where necessary 
prior to co-culture, DH82 cells were transfected with 25pmol custom 
designed anti-canine IL-1β siRNA (Life technologies, California, USA) or 
silencer Cy3 labelled negative control siRNA (csiRNA) (Life technologies, 
California, USA). DH82 cells were first seeded at 150,000 cells per well of a 
6-well plate, before undergoing transfection using the lipofectamine 2000 
transfection reagent (Life Technologies, Carlsbad, USA). Alternatively EFLS 
in co-culture were pre-treated with either 0.8µM Bay 11-7082 (B5556, 
Sigma-Aldrich, Missouri, USA) or 200µM Pyrrolidinedithiocarbamic acid 
(PDTC) (Enzo Life Sciences, New York, USA) for 1 hour prior to LPS 
exposure.  
 
4.2.3.6  EFLS and DH82 Co-cultured Without Direct Contact 
The influence of DH82 cells on EFLS in the absence of direct cell contact 
was examined in experiments using conditioned medium from DH82 cells or 
by compartmentalised co-culture of the cells. For the former, DH82 cells 
were stimulated with 10µg/ml LPS for 24h and conditioned media was 
collected (CM). To examine the effect of protein denaturation on conditioned 
media activity, aliquots were heated to 100°C for 10 mins prior to further use. 
This was referred to as denatured conditioned medium (DCM). EFLS cells 
were seeded at 5 x 104 cells per well in 24-well plates for 24h hours before 
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being exposed to either unconditioned media, CM or DCM, with and without 
10µg/ml LPS. Compartmentalised culture was performed by seeding 20,000 
DH82 cells into a 0.45µm cell culture insert (Merck Millipore, Darmstadt, 
Germany) for 24 hours to attach. Inserts were then transferred to a well 
containing a monolayer of EFLS (Schema 4.1). The co-cultures were 
stimulated with 10µg/ml LPS. EFLS cell layers from indirect co-culture 
experiments were harvested using Tri-reagent (Ambion, Warrington, UK) at 6 
and 12 hours post-LPS exposure. 
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EFLS DH82 
MEDIA 
EFLS Anti-IL1β DH82 
(1) (2) 
(3) (4) 
EFLS co-cultured with DH82  EFLS exposed to DH82 
conditioned media   
EFLS co-cultured with anti-IL1β 
DH82    
EFLS co-cultured with DH82 
in transwells  
Schema 4.1 Different co-culture conditions. EFLS (n = 3 horses, 2 technical replicates) were co-
cultured with DH82 cells using a variety or direct and indirect co-culture conditions.  
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4.2.4  Reverse Transcription and Quantitative Real-time PCR  
Total RNA was purified from tri-reagent extracts using the Guanidinium-
thiocyanate-phenol-chloroform technique (Chomczynski and Sacchi 1987), 
and measured using a Nanodrop ND-100 spectrophotometer (Labtech, 
Florida, USA). Reverse transcription was carried out on 1µg RNA using M-
MLV reverse transcriptase (Promega, Wisconsin, USA) primed with random 
hexadeoxynucleotides (Random Primers, Promega, Wisconsin, USA). The 
qRT-PCR was performed with 160ng cDNA using SYBR Green master mix 
(GoTaq qPCR Master Mix, Promega, Wisconson, USA) and each primer at 
300nM concentration on an ABI 7300 Real Time PCR system (Applied 
Biosystems, California, USA). The relative quantification of each gene 
normalised to the GAPDH reference gene was calculated using the 2-ΔCt 
method (Livak, Schmittgen et al. 2001).  
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4.2.5   Statistical Analysis 
Two tailed t-tests were used to compare fold changes in EFLS mRNA 
expression when cultured independently in standard culture media, 
compared to those cultured with DH82, in conditioned media, in denatured 
conditioned media, and with DH82 cells in well-inserts, and also to compare 
the gene expression of DH82 cells cultured alone and in co-culture with 
EFLS. One-tailed t tests with bonferroni post hoc corrections were used to 
compare DH82 gene expression when treated with control siRNA compared 
to anti-IL-1β siRNA, and EFLS ADAMTS5 gene expression when cultured 
with DH82 cells either treated with control siRNA or anti-IL-1β siRNA, or 
when pre-treated with NF-κB inhibitors. 
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4.3  Results 
 
4.3.1  LPS Stimulated EFLS Secreted Increased Levels of ADAMTS5 
Protein 
We were initially interested in the levels of ADAMTS5 protein in the cell layer 
and media of EFLS exposed to inflammatory stimulation. We therefore 
cultured EFLS in the presence or absence of LPS for 6 or 16 hours. We 
analysed proteins in the cell layer and culture media by western blotting 
using an antibody raised to murine ADAMTS5. Preliminary analysis (not 
shown) had established that this antibody also recognised the human 
ADAMTS5 protein, and these experiments demonstrate that it also cross-
reacts with equine ADAMTS5 protein. The predominant form of ADAMTS5 in 
cell layers, had a molecular weight of 75kDa, however different forms of the 
protein (55-60kDa and 100kDa) were also present. No notable induction of 
ADAMTS5 protein was observed in cell layers following exposure to LPS. 
We detected ADAMTS5 protein secreted in to the culture media with a 
molecular weight of approximately 55kDa. Its levels were increased upon 
exposure of the cells to LPS and appeared to accumulate with time (Figure 
4.1). 
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4.3.2  Design of the Inter-Species Co-Culture Model 
We were interested in how the ADAMTS5 response of EFLS was affected by 
interactions with inflammatory cells that they might encounter in vivo. We 
therefore generated a multi-species co-culture model to allow us to 
investigate cell interactions whilst being able to specifically measure the 
response of the EFLS at the mRNA expression level. We fluorescently 
labelled EFLS with the Cell Proliferation Dye eFluor® 670 (eBioscience Inc., 
California, USA), and generated canine DH82 macrophage cells that 
expressed GFP so that we could examine their proliferation characteristics 
when cultured together. 
 
4.3.2.1  Optimal Fluorescent Labelling of EFLS for a 24 Hour 
Experiment 
All concentrations of cell proliferation dye eFluor® 670 (eBioscience Inc., 
California, USA) successfully labelled EFLS, producing fluorescence 
intensity (FI) >105 from peak cell numbers after 24 and 48 hours of culture. 
EFLS labelled with 8µM and 9µM cell proliferation dye eFluor® 670 
concentrations, produced the highest number of cells emitting optimal FI 
after 24 and 48 hours of culture respectively (Figure 4.2). After 24 hours of 
culture, the highest number of cells were emitting at a FI of approximately 
106, whereas after 48 hours culture this had decreased to approximately 105. 
This is consistent with a decrease in the amount of dye contained in each 
cell due to cell division. On analysis of EFLS gene expression profiles 
(Figure 4.10), it was noted that peak expression of the cytokines and 
aggrecanases of interest occurred within 12 hours of LPS-exposure. Co-
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culture models were therefore designed to extend a 24 hour time course and 
8µM proliferation dye was used to label EFLS.  
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Figure 4.2 Flow cytometric analysis of EFLS labelled with different µM concentrations of Cell 
Proliferation Dye eFluor® 670. Fluorescence intensity (x-axis) detected using a 675/25nm 
interference filter (FL4-A) against cell count (y-axis); unlabelled EFLS (black line) demonstrate 
background fluorescence intensity (<105). Labelled EFLS emit a higher fluorescence intensity 
(>105) at a wavelength detected by the 675/25nm interference filter. Cells harvested at 24 hours 
emit at a higher intensity (approx. 106) than those harvested at 48 hours (approx. 105). The 
coloured lines represent different µM concentrations of the cell proliferation dye, used to label 
EFLS, as shown in the legend.  
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10µM 
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4.3.2.2 GFP-Expressing DH82 Cells 
DH82 cells were infected with four different multiplicities of infection (MOI) 
conditions; an MOI of 2 and 4 were found to produce the most effective 
lentiviral transfection (Figure 4.3). Populations of GFP expressing DH82 cells 
were then selected through exposure to puromycin, and successfully 
expanded in culture. 
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Figure 4.3 DH82 cells infected with different MOIs of lentiviral particles 
expressing an active GFP gene at. DH82 cells were transfected with differing 
ratios of lentiviral particle numbers compared to number of cells, otherwise known as 
multiplicity of infection (MOI). MOI 2 and 4 cultures produced a sufficient number of 
GFP-expressing DH82 cells and were expanded. Phase contrast image (left), 
fluorescent microscopy using the green fluorescence filter (right), scale bar =  
100µm, x10 .  
MOI 
0.5 
1 
2 
4 
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4.3.2.3  Visualising Fluorescence Emission from Labelled EFLS 
and DH82 
When analysing co-culture samples using a confocal microscope, it was 
clear that both labelling techniques had been successful. However, the cell 
proliferation dye produced less discernable EFLS borders, possibly due to 
the large cell area and subsequent low intracellular concentration of proteins 
(Figure 4.4). After 24 hours of culture, it was clear that neither cell population 
had expanded to full confluence, EFLS and DH82 cell populations appeared 
approximately equal at all co-culture proportions. Flow cytometric analysis 
enabled specific comparisons of cell proliferation rates to be made. 
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Figure 4.4 Confocal microscopy of GFP-expressing DH82 and Efluor-
labelled EFLS cells in 1:1 Co-Culture. (A) Efluor-labelled EFLS (purple) 
excited using a far red (633nm) laser line and detected with a 660/20nm band 
pass filter. (B) GFP-expressing DH82 (green) were excited using a green 
(488/532nm) laser line and detected with a FITC band pass filter. (C) An 
overlay image of A and B. (D) Plain contrast image of DH82 (arrow) and EFLS 
(arrowhead) cells in co-culture.  
A. B. 
C. D. 
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4.3.2.4  Seeding Density of Equal Proportions of DH82 and EFLS 
Resulted in a Co-Culture Containing 40% DH82 and 60% 
EFLS after 24 Hours   
During flow cytometry, side scatter (SSC) and forward scatter (FSC) describe 
the direction of light refracted by cells obstructing the path of the laser beam. 
SSC and FSC are consistent with intracellular complexity, sometimes 
referred to as granularity, and cell size respectively. SSC versus FSC density 
plots identified two groups of cells with differing morphological characteristics 
within the mixed culture. After analysis of individual cultures, EFLS were 
identified to be smaller and less granular than DH82 cells (Figure 4.5A & B). 
Once populations were identified, the two populations within the mixed 
culture were gated on the SSC vs FSC density plot (G1 = EFLS, G2 = DH82) 
(Figure 4.5C). The majority of cells within the G1 gated area emitted at a FI 
>105, detected by the 675/25nm interference filter, consistent with efluor-
labelled EFLS (Figure 4.5D).  The majority of cells within the G2 gated area 
emitted at a FI >105, detected by the 533/30nm interference filter, consistent 
with GFP-expressing DH82 cells (Figure 4.5E).  
Once populations were identified, proliferation rates of each population in co-
culture were analysed. A slightly higher rate of EFLS proliferation compared 
to DH82 proliferation, when co-cultured over 24 hours was observed, and 
EFLS mitosis was stimulated by co-culture with DH82 cells (Figure 4.5F & G, 
and Table 4.1). When efluor-labelled EFLS were cultured independently, the 
majority of cells (67%) emitted at a FI of 105.3 – 106.7. The efluor cell 
proliferation dye 670 therefore has a binding efficiency of 67% after 24 hours 
of culture, when applied to EFLS. The remainder of the cells emitted at a FI 
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consistent with background fluorescence. Background fluorescence can be 
due to the auto-fluorescence of the sample, vessel or media. When 
structures within the cell, such as mitochondria or lysosomes absorb light, it 
is also emitted at a low FI, otherwise known as auto-fluorescence. 
The efluor cell proliferation dye binds to primary amine side chains, found on 
polypeptides. As the cell undergoes mitosis, the dye is distributed equally 
between the two daughter cells, and this can be measured by the FI halving. 
Within mixed co-cultures, fluorescence detected by the 675/25nm 
interference filter identified two sub-populations of EFLS consistent with the 
two peaks in cell numbers. Sub-populations emitting FI at 105.3-106.7 and 
103.3-105.3 FI, are consistent with the primary and secondary generation of 
EFLS respectively (Figure 4.5F). The sum of both populations is equal to the 
total EFLS cell number. On comparison of EFLS cultured independently and 
co-cultured with DH82 cells, a secondary EFLS population was only 
identified upon co-culture. This could indicate that the addition of DH82 cells 
stimulates EFLS mitosis.  
The number of labelled DH82 and EFLS cells within each co-culture was 
analysed to calculate the proportion of each population after 24 hours. 
Fluorescence intensities corresponding to peaks in cell numbers were gated; 
the primary (G3) and secondary (G4) generations of EFLS, and DH82 cells 
(G5) (Figure 4.5F&G). Cell numbers can be found in Table 4.1. The initial 
seeding ratio of 50% EFLS and 50% DH82, produced a culture of 60% EFLS 
and 40% DH82 after 24 hours. An infiltration of cells into the synovial 
membrane, resulting in 25-50% of the synovial cell population consisting of 
mononuclear cell, has been classified as a moderate (grade 3 out of 4) 
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synovitis (McIlwraith, Frisbie et al. 2010). This proportion of cells was 
therefore deemed appropriate to replicate a moderate synovitis after 24 
hours in culture.  
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Figure 4.5 Graphs displaying GFP-expressing DH82 and efluor-labelled EFLS cellular characteristics and fluorescence 
intensities emitted in co-culture. A-C. Density plot diagrams of DH82 (A) and EFLS (B) cultured individually and in co-culture (C); 
EFLS (G1) and DH82 (G2) populations were gated. D & E. Fluorescence intensity emitted from cells within the gated areas (D = G1, 
E = G2). F & G. Fluorescence intensity emitted by labelled DH82 and EFLS after 24 hours in co-culture at different proportions, 
detected by two different interference filters, 675/25nm and 533/30nm respectively. Gates corresponding to EFLS primary (G3) and 
secondary (G4) generations, and DH82 cells (G5) were applied to enable cell numbers within each co-culture to be determined.  
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Table 4.1 Cell numbers of DH82 and EFLS within gated regions.  
 
  
 EFLS DH82  
 
 
Relative proportion of 
each population 
(EFLS:DH82) 
 
 
Proportion of each 
population in co-culture 
Cell number  
emitting FI at 
103.3 – 105.3 
(G4) 
Cell number 
emitting FI at 
105.3 – 106.7 
(G3) 
Total EFLS cell 
number emitting 
FI >103.3 
Cell number 
emitting FI at 105.6 
– 107.2 
(G5) 
      
EFLS - 66,750 66,750 - 100% 
DH82 - - - 68,312 100% 
33% EFLS and 67% DH82 66,150 8,448 74,598 59,260 55.7:44.3% 
50% EFLS and 50% DH82 59,926 15,255 75,181 51,191 59.5:40.5% 
67% EFLS and 33% DH82 52,068 15,255 78,096 43,051 64.5:35.5% !
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4.3.2.5  Production of Species-Specific qRT-PCR Assay 
To allow us to specifically measure expression of genes in each cell type 
when they were cultured together we designed species-specific qRT-PCR 
assays. To analyse primer performance, cycle threshold (Ct) values from 
samples (n=3) harvested at each time point (0, 1, 3, 6, 12, and 24 hours) 
were amalgamated to produce total Ct values for each condition. The mean 
total Ct values produced by EFLS, DH82 and co-culture cDNA are displayed 
using histograms in figures 4.6 and 4.7. Primers met the following criteria 
and were thus deemed to be species-specific.  
 
4.3.2.6  Testing the Species Specificity of each Primer  
Firstly, all primers measured robust expression, reflected by low Ct values 
when used on cultures of the same species (equine and canine primer Ct 
values were 18.0-25.2 and 15.8-23.6 respectively) which was conserved 
when analysing the co-cultures (equine and canine primer Ct values were 
16.7-25.6 and 15.6-26.9 respectively) (Figure 4.6A-E & 4.7A-C). Low 
expression of genes, reflected by high Ct values (equine and canine primer 
Ct values were 32.8-36.1 and 32.2-38.9 respectively) or undetected Ct 
values (producing a Ct value of 0), were evident when primers were used on 
mRNA of a different species. However the canine GAPDH primer did 
produce a Ct value of 26.2, which is consistent with good gene expression, 
when it was used on equine cDNA.  
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Figure 4.6 Equine primer species-specificity testing. A – E. Histograms display the mean sum 
of Ct values produced when equine primers were used on EFLS, DH82 or co-culture cDNA 
samples (n=3) harvested at 0, 1, 3, 6, 12 and 24 hours. Error bars represent SEM. F – J. 
Dissociation curves of amplicon products produced when equine primers were used on EFLS, 
DH82 and co-culture cDNA samples (n=3) harvested at 0, 1, 3, 6, 12 and 24 hours.  
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Secondly, dissociation curves of PCR products displayed a single peak when 
analysing both cells of the correct species, and co-cultures. Single peaks are 
often considered to reflect specific binding of the primer, resulting in the 
production of a single amplicon product. However, it has been shown that 
peaks at two different temperature can also be produced by the same 
amplicon product. Peaks were either not evident (Figure 4.6G & J), or very 
small (Figure 4.6F, H & I. Figure 4.7D-F) and peaking at the same 
temperature as those produced by cDNA of the same species, when primers 
were used on cultures of solely the opposite species. Small peaks at the 
same temperature are consistent with a low level of amplicon product from 
one species produced by the primer of a different species, however levels 
were insignificant. Canine GAPDH (Figure 4.7D) and to a much lesser 
degree IL-1β (Figure 4.7E) primers, also revealed some annealing to equine 
cDNA. The dissociation curve produced by the canine GAPDH primer used 
on EFLS cDNA had two peaks, one large peak at a higher temperature 
(>80°C) than the peak produced by DH82 and co-culture cDNA, and a 
second smaller peak at the same temperature as the large peak produced by 
the other cDNA (<80°C). The peak at >80°C may represent the same 
amplicon as the peaks <80°C, or a second amplicon may have been 
produced by non-specific binding of the canine GAPDH primer to equine 
cDNA. Canine GAPDH was used as a housekeeping gene, however, relative 
quantification of canine genes normalised to this housekeeping gene, may 
be underestimated. Analysis of canine specific ADAMTS4 and ADAMTS5 in 
DH82 cells was eventually omitted from the study as repeated iterations of 
primer design failed to identify a specific assay. 
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Figure 4.7 Canine primer species-specificity testing. A – C. Histograms display the mean sum 
of Ct values produced when canine primers were used on EFLS, DH82 or co-culture cDNA 
samples (n=3) harvested at 0, 1, 3, 6, 12 and 24 hours. Error bars represent SEM. D – F. 
Dissociation curves of amplicon products produced when canine primers were used on EFLS, 
DH82 and co-culture cDNA samples (n=3) harvested at 0, 1, 3, 6, 12 and 24 hours.  
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4.3.2.7  Primer Validation  
Primer pairs were validated using serial 2-fold dilutions of cDNA from the 
same species (either EFLS or DH82 cDNA), extracted from cells which had 
been cultured individually. Standard curves were created for all primers 
(Figure 4.8A-E & Figure 4.9A-C). Using the linear regression equation 
produced by the standard curve, the primer amplification efficiency was 
calculated. The co-efficiency of determination (R) value produced by the 
standard curve was also recorded (Table 4.2). All equine primers, canine IL-
1β and canine IL-6 annealed to cDNA from the same species (equine and 
canine cDNA respectively) with excellent amplification efficiency (91-108%). 
The canine GAPDH primer was less efficient (123%) at amplifying the target 
gene. Dissociation curves of cDNA at each dilution were produced. Equine 
primer dissociation curves displayed comparable peaks at all dilutions 
(Figure 4.8F-J). However dissociation curves produced by canine primer 
were variable (Figure 4.9D-F). Canine GAPDH and IL-1β primers produced a 
second dissociation peak from the more dilute canine cDNA samples (1:16 
and 1:32 dilutions). The canine IL-6 primer produced a second peak from all 
dilutions of cDNA; the less dilute canine cDNA samples (0, 1:2, 1:4 and 1:8 
dilutions) had a second peak at a higher temperature than more dilute cDNA 
samples (1:16 and 1:32 dilutions).  
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Figure 4.8 Standard curves and dissociation curves for all equine primers tested on EFLS 
cDNA. A-E. EFLS cDNA (n=3) was diluted in serial 2-fold dilutions and mixed with equine primers. 
The standard curves are presented as Ct values (y-axis) against the dilution of cDNA (x-axis); 
concentrated cDNA (0), 1:2 dilution (1), 1:4 dilution (2), 1:8 dilution (3), 1:16 dilution (4), 1:32 (5). F-
J. Dissociation curves produced by each primer mixed with cDNA at all dilutions are displayed.  
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Figure 4.9 Standard curves and dissociation curves for all canine primers tested on DH82 
cDNA. A-C. DH82 cDNA was diluted in serial 2-fold dilutions and mixed with canine primers. The 
standard curves are presented as Ct values (y-axis) against the dilution of cDNA (x-axis); 
concentrated cDNA (0), 1:2 dilution (1), 1:4 dilution (2), 1:8 dilution (3), 1:16 dilution (4), 1:32 (5). 
D-F. Dissociation curves produced by each primer mixed with cDNA at all dilutions are displayed.  
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Table 4.2 Equine and Canine primers. Equine and canine gene sequences, corresponding to the 
accession numbers displayed, were located within the NCBI Genbank database. The nucleotide 
sequences for the primer pairs designed are displayed. The efficiencies and co-efficiencies of 
determination (R) of all primer pairs were calculated using serial 2-fold dilutions of either EFLS or 
DH82 cDNA, extracted from cells which had been cultured individually.   
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4.3.3  Comparative Gene Expression of EFLS and DH82 Cells when 
Cultured in the Co-Culture Model  
 
4.3.3.1  Macrophages Attenuate EFLS ADAMTS5 Gene  
 Expression. 
EFLS cultured independently demonstrated rapid increases in IL-1β, IL-6, 
ADAMTS4 and ADAMTS5 mRNAs in response to 10µg/ml LPS (Figure 
4.10A-D). Peak expression of each mRNA occurred 3 to 6 hours post-LPS 
exposure. Fold changes in EFLS gene expression were normalised to the 
gene expression of independently cultured EFLS at 0 hours with no LPS 
exposure. Maximum fold changes in mRNA levels of EFLS cultured 
independently and with DH82 cells respectively, were 10 x (at 6 hours) and 
14 x (at 3 hours) for IL-1β mRNA, 50 x (at 6 hours) and 27 x (at 6 hours) for 
IL-6 mRNA, 18 x (at 3 hours) and 16 x (at 3 hours) for ADAMTS4 mRNA, 
and 4 x (at 6 hours) and 1.4 x (at 6 hours) for ADAMTS5 mRNA. 
Interestingly, the increased expression of ADAMTS5 mRNA over this time 
period was significantly (p <0.05) lower in EFLS that were co-cultured with 
DH82 cells (Figure 4.10D). Although ADAMTS4 and IL-6 mRNA levels 
tended to be lower when EFLS were in co-culture, lack of a consistent effect 
across the three biological replicates prevented us from concluding that they 
were also stastically significantly affected (Figure 4.10B & C).  
 
 
! 194 
!
0 10 20 30
0
5
10
15
20
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
-Δ
Ct
 
0 10 20 30
0
20
40
60
80
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
-Δ
Ct
 
0 10 20 30
0
10
20
30
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
-Δ
Ct
 
0 10 20 30
0
2
4
6
8
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
-Δ
Ct
 
0 10 20 30
0
5
10
15
20
EFLS IL-1β gene expression 
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
^-
dC
t  
0 10 20 30
0
20
40
60
80
EFLS IL-6 gene expression
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
^-
dC
t  
EFLS
EFLS with DH82
0 10 20 30
0
10
20
30
EFLS ADAMTS4 gene expression
Time (hours)
Fo
ld
 C
ha
ng
e 
of
 2
^-
dC
t  
0 10 20 30
0
2
4
6
8
Time (hrs)
Fo
ld
 C
ha
ng
e 
of
 2
^-
dC
t  
EFLS ADAMTS5 gene expression
Figure 4.10 Fold changes of EFLS gene expression when cultured independently or in co-culture with DH82 macrophages. 
EFLS (A) IL-1β, (B) IL-6, (C) ADAMTS4 and (D) ADAMTS5 gene expression when cultured independently (clear circles) or in co-
culture with DH82 (black circles) is displayed as fold changes (n=3) compared to the gene expression of independently cultured 
EFLS at 0 hours with no LPS exposure. Gene expression was measured at 1, 3, 6, 12 and 24 hours post-LPS exposure. Error bars 
represent SEM. Increased expression of ADAMTS5 mRNA over the 24 hour period was significantly (* p<0.05) lower when EFLS 
were cultured with DH82.  
A. B. 
C. D. 
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4.3.3.2  DH82 Cell Gene Expression when Co-Cultured with EFLS  
DH82 cells cultured independently or in co-culture with EFLS, experienced a 
repeatable and rapid increase in their gene expression of the cytokines IL-1β 
and IL-6 upon exposure to LPS (Figure 4.11A-B). Fold changes in DH82 
gene expression were normalised to the gene expression of independently 
cultured DH82 cells at 0 hours with no LPS exposure. Peak fold change in 
IL-6 gene expression occurred earlier than IL-1β (3 hours and 12 hours 
respectively), and the mean expression of both cytokines were higher when 
co-cultured with EFLS, although this was not statistically significant using 
two-tailed t tests. Maximum fold changes in DH82 mRNA expression when 
cultured independently and in co-culture, were 103 x (at 12 hours) and 175 x 
(at 12 hours) for IL-1β mRNA, and 129 x (at 3 hours) and 182 x (at 3 hours) 
for IL-6 mRNA.  !
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Figure 4.11 Fold changes of DH82 gene expression when cultured independently or in co-culture with 
EFLS. DH82 (A) IL-1β and (B) IL-6 gene expression when cultured independently (clear circles) or in co-culture 
with EFLS (n=3) (black circles) is displayed as fold changes (n=3) compared to the gene expression of 
independently cultured DH82 cells at 0 hours with no LPS exposure. Gene expression was measured at 1, 3, 6, 
12 and 24 hours post-LPS exposure. Error bars represent SEM. Fold changes of the different conditions were not 
statistically different. 
 197 
4.3.3.3  Macrophage Attenuation of EFLS ADAMTS5 is Not Driven 
by Macrophage IL-1β expression 
When IL-1β binds to the IL-1 membrane bound receptor, it activates several 
pathways including the NF-κB pathway. RelA/p65, an NF-κB family member, 
is a strong transcriptional activator of ADAMTS5 in chondrocytes (Kobayashi, 
Hirata et al. 2013). It was hypothesised that DH82 IL-1β gene expression 
may influence EFLS ADAMTS5 gene expression. Statistically significant 
down-regulation of macrophage IL-1β gene expression was achieved at 6h 
(p<0.05) and 12h (p<0.01) post-LPS exposure, using anti-IL-1β siRNA 
compared to control siRNA (csiRNA) (Figure 4.12A). When anti-IL-1β DH82 
cells were co-cultured with EFLS, EFLS ADAMTS5 gene expression was 
similar to that of EFLS cultured with normal DH82 cells (Figure 4.12B). !
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Figure 4.12 Histograms demonstrating DH82 and EFLS gene expression when in direct co-culture. DH82 
were transfected with either csiRNA (light grey bars), or with canine anti-IL-1β siRNA (dark grey bars), and co-
cultured with EFLS (n=3) in the presence of 10µg/ml LPS. Cultures were harvested at 0, 6 and 12 hours post-LPS 
exposure. Histograms display (A) DH82 IL-1β gene expression and (B) EFLS ADAMST5 gene expression. Error 
bars represent SEM. Statistically significant down-regulation of macrophage IL-1β gene expression was achieved 
at 6h (*p<0.05) and 12h (*p<0.01) post-LPS exposure, using anti-IL-1β siRNA compared to control siRNA 
(csiRNA), calculated using one-tailed t tests with bonferroni post hoc corrections. 
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4.3.3.4  A Soluble Mediator Produced by Macrophages is 
Responsible for the Attenuation of ELFS ADAMTS5 Gene 
Expression 
Experiments were conducted to investigate whether the EFLS ADAMTS5 
gene expression attenuation caused by DH82 cells was mediated through 
direct contact, or through a soluble mediator. EFLS gene expression is 
described as fold changes compared to the gene expression of EFLS 
cultured in standard culture media containing LPS for 12 hours. EFLS 
cultured in DH82 conditioned media (CM) expressed lower levels of 
ADAMTS5 mRNA following LPS exposure for 12 hours (Figure 4.13) 
compared with those cultured in LPS-containing unconditioned media (NM). 
This suggests that the attenuation of ADAMTS5 in the co-culture system is 
mediated by a soluble factor. Interestingly, EFLS expression of ADAMTS5 
mRNA was also lower when the cells were cultured in denatured conditioned 
media (DCM) (p < 0.01), indicating that this soluble factor is thermally stable 
(Figure 4.13). Consistent with these findings, indirect co-culture culture of 
EFLS with DH82 using well inserts, also led to repressed ADAMTS5 mRNAs 
(p < 0.01) (Figure 4.13). 
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Figure 4.13 Histograms demonstrating EFLS ADAMTS5 gene expression when 
cultured in DH82 conditioned media, or with DH82 cells within well-inserts. 
Fold changes in EFLS ADAMTS5 gene expression are compared to EFLS cells 
cultured in LPS-containing normal media (NM). EFLS expression when cultured with 
DH82 conditioned media (CM) and DH82 denatured conditioned media (DCM) (** = 
p < 0.01), and with DH82 cultured in well inserts (** = p < 0.01) is displayed. Cells (n 
= 3) were harvested at 12 hours post-LPS exposure. All conditions were exposed to 
10ug/ml LPS. Error bars represent SEM.   
** 
** 
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4.3.3.5  Co-Culture Does Not Influence EFLS ADAMTS5 Gene 
Expression Through NF-κB Signalling 
To investigate the influence of the NF-κB signalling pathway on EFLS 
ADAMTS5 gene expression, EFLS in co-culture with DH82 cells were pre-
treated with NF-κB inhibitors before being exposed to LPS (Figure 4.14). 
EFLS gene expression was compared to non-NF-κB inhibitor treated EFLS 
gene expression at 0h, and expressed as fold changes. Neither inhibitor 
prevented the suppression of ADAMTS5 induction in co-cultures. The 
presence of the inhibitor PDTC led to an overall suppression of EFLS 
ADAMTS5 gene expression levels, whilst the inhibitor Bay 11-7082 led to 
similar levels of ADAMTS5 mRNA compared to non-treated EFLS in co-
culture, however these changes were not statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
! 202 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Fold changes in EFLS ADAMTS5 gene expression after pre-
treatment with NF-κB inhibitors. EFLS (n =3) in direct co-culture with DH82 cells 
were pre-treated with NF-κB inhibitors; Bay 11-7082 (clear circle) and PDTC 
(triangle), before being exposed to 10µg/ml LPS. Cells were harvested at 0, 6 and 12 
hours post-LPS exposure. Fold changes in EFLS ADAMTS5 gene expression were 
compared to the gene expression of EFLS cells in co-culture at 0h. EFLS without 
NF-κB inhibitor treatment are represented by the black circles. Error bars represent 
SEM.  
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4.4  Discussion 
 
The synovial membrane is an important source of pro-inflammatory and 
catabolic mediators that contribute to the pathophysiology of osteoarthritis. 
Aggrecanases, such as ADAMTS4 and -5, are produced by synoviocytes 
and chondrocytes. We were particularly interested to observe an increase in 
the secretion of ADAMTS5 protein by FLS on exposure to LPS. Upon 
secretion from the cell, the ADAMTS5 zymogen (101.7kDa) is cleaved at 
furin cleavage sites, becoming activated (Fosang, Rogerson et al. 2008). The 
active form of ADAMTS5 (73kDa) is further cleaved into smaller breakdown 
products (40-50kDa) (Vankemmelbeke, Holen et al. 2001). Using western 
blotting, three variants of the ADAMTS5 protein were identified within the 
FLS cell layer; a major band (75kDa) consistent with the active form of the 
aggrecanase protein, and minor bands (55-60kDa and 100kDa) consistent 
with ADAMTS5 breakdown products and the ADAMTS5 zymogen 
respectively. The density of the major band (75kDa) increased in proportion 
to culture time, which reflects a higher degree of FLS activation with 
increasing time of exposure to LPS. Western blot analysis of cell media 
revealed extracellular ADAMTS5 protein (55kDa) present; levels increased 
with the addition of LPS and with increasing time of exposure to LPS. The 
LPS-induced increase in concentration of small ADAMTS5 fragments within 
the cell media may be caused by a combination of the following factors; the 
stimulation of EFLS ADAMTS5 secretion, the suppression of LRP-mediated 
endocytic clearance of ADAMTS5 from the media, or an increase in furin 
cleavage of ADAMTS5. The presence of LPS-induced extracellular 
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ADAMTS5 consistent with the active form, suggests that FLS may respond 
to inflammatory conditions by secreting active ADAMTS5. 
Our co-culture model design was based on the inflammatory response 
observed in the synovial membrane. Normal synovium contains negligible 
numbers of lymphocytes. A moderate (grade 3 out of 4) synovitis has been 
classified, through microscopic histological examination, as having an 
infiltration of mononuclear cells in greater than 25 - 50% of the synovial 
membrane (McIlwraith, Frisbie et al. 2010). Macrophages are abundant 
within this cellular infiltration (Haseeb and Haqqi 2013) and are significant 
producers of IL-1β and TNF-α (Haywood, McWilliams et al. 2003, Bondeson, 
Wainwright et al. 2006) which drive the inflammatory pathway. Factors 
including TGF-β, platelet derived growth factor (PDGF) and macrophage 
chemoattractant protein-1 (MCP-1) are responsible for the chemotaxis of 
macrophages into the synovium. MCP-1 is produced by inflamed 
synoviocytes and this can be induced by IL-1β, TNF-α and LPS (Villiger, 
Terkeltaub et al. 1992). Cultures of synoviocytes isolated from digested 
synovium contain FLS and synovial macrophages. However, by passage 3, 
these cultures contain >95% FLS (Rosengren, Boyle et al. 2007). In this 
study we developed a co-culture model incorporating FLS from the horse, 
alongside canine macrophages, to create a model that closely resembled the 
cellular populations present in the inflammed synovium. This allows us to 
improve our understanding of intercellular signaling within the synovium 
during synovitis.  
During initial experiments, EFLS isolated from one horse were used at 
passage 9. However, mRNA levels produced by this sample were vastly 
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different to those generated by EFLS at passage 3-4. It is thought that cell 
senescence occurs by passage 9 (Rosengren, Boyle et al. 2007), and that 
this may have caused the difference in results. This indicates that, when 
approaching senescence, FLS differ considerably in their responses to 
inflammatory stimulation. When comparing EFLS isolated from different 
horses, those used prior to passage 4 experienced similar changes in mRNA 
expression upon LPS-stimulation, therefore all EFLS used in this experiment 
are < passage 4.  
To identify both EFLS and DH82 cells within co-cultures, we labeled both 
populations with fluorophores which emitted light at wavelengths which did 
not overlap. The concentration of efluor cell proliferation dye capable of 
labelling and subsequently producing good FI (>105) from the highest of 
proportion of EFLS cultured for 24 hours, was 8µM. Average FI detected by 
the 675/25nm interference filter, emitted by EFLS after 24 and 48 hours in 
culture was 1 x 106.1 and 1 x 105.1 respectively. This is consistent with a 
halving of FI between 24 and 48 hours in culture, which occurs when primary 
cells divide to produce two daughter cells. When EFLS were cultured with 
DH82 cells, this halving of FI occurred earlier, within the first 24 hours of 
culture. Interestingly, this indicates that EFLS mitosis was stimulated by the 
co-culture of DH82 cells, and the rate of EFLS mitosis was proportional to 
the percentage of DH82 cells present in the co-culture. Synovial hyperplasia 
is an important gross pathological change that occurs during osteoarthritis. 
Macrophage migration inhibitory factor (MIF) has been shown to significantly 
stimulate the proliferation of rheumatoid arthritis FLS, with indirect IL-1β and 
TNF-α involvement (Lacey, Sampey et al. 2003). IL-1 is also known to 
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increase FLS proliferation (Alvaro-Gracia, Zvaifler et al. 1990). As 
macrophages are majors producers of both IL-1 and MIF, these factors may 
explain the increase in rates of EFLS proliferation when in co-culture with 
DH82 cells.   
As previously stated, the co-culture model was designed to culture 
macrophages and FLS, in proportions comparable to those in the synovial 
membrane when experiencing a moderate synovitis. Based upon initial 
experiments, we had hypothesised that EFLS would proliferate faster than 
DH82 cells. When analysing rates of proliferation over a 24 hour time course, 
EFLS proliferated slightly faster than DH82 cells. Equal numbers of EFLS 
and DH82 cells were therefore used to generate a 60% EFLS and 40% 
DH82 co-culture model after 24 hours, ready to undergo experimentation 
Successful equine GAPDH, IL-1β, IL-6, ADAMTS4 and -5, and canine IL-1β 
and IL-6 species-specific primer designs were supported by their associated 
dissociation curves; comparable single peaks were produced by double 
stranded (ds)DNA of the same species and from the co-culture. A single 
peak at the same temperature may reflect production of the same amplicon 
product from both samples of dsDNA, consistent with robust species-
specificity of the primer. This was further supported by the generation of Ct 
values reflecting low gene expression when primers designed for one 
species, were mixed with cDNA from the second species, supporting low or 
absent cross-species primer annealing. Areas of dissimilarity between 
equine and canine genes, to enable species-specific primer design, were not 
found for equine TNF-α, or canine ADAMTS4 and -5 genes. The canine 
GAPDH primer was not considered fully species-specific, producing a small 
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degree of equine GAPDH dsDNA. As the genes of interest are normalised to 
GAPDH in this study, changes in canine mRNA expression may be 
underestimated using this canine GAPDH primer. However, canine IL-1β and 
IL-6 gene expression are both normalised to canine GAPDH and are 
therefore comparable.  
All equine primers, and canine IL-1β and IL-6 primers, proved to have 
excellent amplification efficiency, and efficiency of determination (R) values 
when used on cDNA of the same species. Ideally, the amount of cDNA of the 
gene of interest, within the sample, should equal the amount of dsDNA 
produced by the PCR. This would reflect 100% amplification efficiency 
achieved by the primer. When analysing gene expression using the 2-ΔCt 
method, primer efficiency is not taken into account, which may lead to small 
errors in gene expression quantification. In this study error was minimised by 
using primers with similar efficiencies. R values indicate the accuracy of the 
standard curve and associated linear equation to calculate for example, the y 
value using a known x value. Ideally the R value should be 1, which reflects 
100% accuracy, however, 0.99 is also accepted. Dissociation curves 
produced by equine dsDNA at all serial dilutions, produced highly 
comparable single peaked curves, consistent with robust primer design. The 
dissociation curves produced by canine dsDNA at serial dilutions were highly 
variable; each primer produced several peaks at different dilutions, reflecting 
sub-optimal primer design. However, the amplification efficiency and R 
values produced by canine IL-1β and IL-6 are excellent. As was their 
species-specificity when used with co-culture cDNA. Canine GAPDH has 
sub-optimal amplification efficiency.  
! 208 
EFLS ADAMTS5 gene expression was significantly attenuated when cells 
were co-cultured with DH82 macrophages (p<0.05). Macrophage expression 
of IL-1β tended to be higher when they were co-cultured with EFLS. 
However, siRNA-mediated knockdown of the elevated DH82 cell IL-1β 
expression did not effect the attenuation of EFLS ADAMTS5 expression that 
we observed in co-culture. This finding is consistent with previous reports of 
equine synoviocyte ADAMTS5 gene expression being unresponsive to IL-1β 
(Ross, Kisiday et al. 2012). EFLS ADAMTS5 gene expression was also 
suppressed when cells were exposed to macrophage-conditioned medium, 
and even more strongly when EFLS cells were cultured with macrophages 
indirectly using well inserts. This suppressive effect of DH82 conditioned 
medium was also evident when it had been heat denatured. A soluble factor 
released by macrophages is likely to be responsible for these findings, and it 
is either thermally stable or able to denature reversibly upon heating. A 
reduced expression of equine synoviocyte ADAMTS5 mRNA was found 
when normal synoviocytes were cultured with injured cartilage, compared to 
normal cartilage (Lee, Kisiday et al. 2013). This was proposed to be a 
protective synoviocyte mechanism to protect injured cartilage. The role of 
macrophages within the inflammatory response to joint injury has been 
investigated using murine macrophage depleted experimental OA models. A 
reduction in osteophyte formation, fibrosis, synovial activation, synovial lining 
growth factor production, MMP-induced neoepitope formation, and synovial 
MMP3 and -9 mRNA expression, were observed in macrophage-depleted 
subjects, suggesting that synovial macrophages are principal moderators of 
OA joint pathology (Blom, van Lent et al. 2004). However, macrophage-
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depletion in OA models, have also been linked to increased acute joint 
inflammation involving significantly higher synovitis scores, increased cellular 
density, and a reduction in bone mineral density (Bailey 2014, Bailey 2015). 
Macrophages are obviously pivotal in the synovial response to joint injury, 
and provide essential moderation of joint inflammation.  
It is interesting that we have observed regulation of FLS ADAMTS5 mRNA 
levels. Earlier work demonstrated that OA equine chondrocyte ADAMTS5 
mRNA levels were similar to normal chondrocyte levels (Fushimi, Troeberg 
et al. 2008). Yet normal chondrocyte ADAMTS5 mRNA levels were mildly 
up-regulated by LPS and IL-1β (Busschers, Holt et al. 2010, Ross, Kisiday et 
al. 2012). Gene expression levels do not always correlate with protein levels. 
Chondrocyte ADAMST5 protein production can also be influenced by factors 
such as endocytic clearance mediated by chondrocyte LRP-1 receptors 
(Yamamoto, Troeberg et al. 2013). This may represent a means for 
increased levels of ADAMTS5 activity in the joint without any change in 
mRNA levels. FLS regulation of ADAMTS5 mRNA may indicate an additional 
source of this matrix-degrading factor.  
Given the key role that the NF-κB pathway has been shown to have in the 
regulation of ADAMTS5 transcription, we were interested to examine how the 
inhibition of this pathway would affect ADAMTS5 expression in our co-culture 
system. When treating EFLS with Bay 11-7086, ADAMTS5 gene expression 
was similar to that of untreated EFLS in co-culture with macrophages. 
However, co-cultured EFLS ADAMTS5 gene expression was further 
attenuated when using a broad NF-κB inhibitor (PDTC). The proximal aspect 
of the 5’-end-flanking region, containing the ADAMTS5 promoter is highly 
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conserved between species (Kobayashi, Hirata et al. 2013) and RelA/p65, an 
NF-κB family member, is a strong transcriptional activator of ADAMTS5 in 
chondrocytes (Kobayashi, Hirata et al. 2013). PDTC is a broad potent 
inhibitor of NF-κB activity; inhibiting NF-κB-DNA-binding activity, IκB 
phosphorylation, and expression of nuclear p65 protein (Zhang, Xu et al. 
2011), can specifically block LPS-induced NF-κB mobilisation (Ziegler-
Heitbrock, Sternsdorf et al. 1993), and can attenuate acute and chronic 
arthritis inflammation (Cuzzocrea, Chatterjee et al. 2002). Bay 11-7086 
inhibits phosphorylation of IκB-α, leading to sequestration of free NF-κB 
within the cytoplasm, unable to translocate to the nucleus. The attenuation of 
EFLS ADAMTS5 mRNA using PDTC further supports the theory that NF-κB 
is a transcriptional activator of EFLS ADAMTS5. 
 
4.4.1  Conclusion 
To summarise, we have developed a novel, multi-species co-culture model 
of synovial cell interaction to enable cell-specific responses to be examined 
in response to inflammatory stimulation. We have found that macrophages 
stimulate FLS mitosis, and modulate its ADAMTS5 mRNA expression in an 
inflammatory environment. Future work will be required to identify the 
mechanism by which this attenuation occurs, as this may present a means of 
modulating the expression of this enzyme to prevent the progression of joint 
diseases in clinical and veterinary medicine. 
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Chapter 5.  
The Effect of Anti-Equine IL-1β siRNA Loaded PLGA-Microspheres on 
an Equine Co-Culture Model Incorporating Synoviocytes and Cartilage 
 
5.1  Introduction  
 
5.1.1  Intra-Articular Drug Delivery Systems  
Intra-articular (IA) disease modifying osteoarthritis drugs (DMOADs) to 
counteract pain and joint degradation driven by OA are of major interest. 
These therapies decrease the risk of adverse systemic effects, and optimise 
bioavailability and therapeutic efficacy directly for the target cells. However 
factors within the IA environment can impede the efficacy of such 
therapeutics. For example synovial fluid serum nucleases can hydrolyse 
certain therapeutic molecules, rendering them useless (Mountziaris, Sing et 
al. 2011, Jensen, Griger et al. 2012, Présumey, Salzano et al. 2012), whilst 
rapid drug clearance is facilitated by the dense vascular and highly active 
lymphatic systems within the synovial membrane (Allen, Adams et al. 2010, 
Edwards 2011). Delivery systems to facilitate sufficient targeted sustained 
release of a drug at the target cell, are being designed to overcome these 
issues (Patil, Panyam et al. 2009, Janssen, Mihov et al. 2014). A number of 
drug delivery system are used in both clinical and laboratory settings 
(Janssen, Mihov et al. 2014, Bodick, Lufkin et al. 2015), however this study 
concentrates on biodegradable polymer microspheres which contain a 
homogenous mixture of the polymer and encapsulated drug (Janssen, Mihov 
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et al. 2014). When designing a DDS a number of technical and practical 
issues have to be considered. These include: 
! Size of the vehicle (Caldorera-Moore, Guimard et al. 2010, Mitragotri, 
Burke et al. 2014). 
! Resistance of the microsphere to IA degradation (Présumey, Salzano 
et al. 2012). 
! Ability to retain the drug during delivery (Présumey, Salzano et al. 
2012). 
! Sustained release of the drug at a therapeutic dose within the target 
cell (Présumey, Salzano et al. 2012, Zhang and Huang 2012). 
! Biocompatibility within the intra-articular environment (no toxicity) 
(Zhang and Huang 2012). 
 
Targeted intra-articular DMOADs have been historically hindered by the lack 
of an effective drug delivery system. Research into the use of PLGA 
microspheres as a drug delivery agent started in the 1980s (Janssen, Mihov 
et al. 2014) and specific investigation into its use in targetting IA disease 
processes has been on-going since 1985 (Tice, Lewis et al. 1985, Tice, 
Lewis et al. 1985). PLGA-microspheres phagocytosed by synovial 
macrophages offer a system which not only delivers the drug directly to the 
target inflammatory cell, but also provides sustained controlled release 
(Edwards 2011). Phagocytosis of these particles appears to be size 
dependent, and particles 1-10µm in diameter were found to be optimal for 
synoviocyte phagocytosis (Butoescu, Seemayer et al. 2009). PLGA 
microspheres have excellent biocompatibility within IA environments 
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(Mitragotri, Burke et al. 2014), especially when used in horses (Bragdon, 
Bertone et al. 2001), and do not stimulate an immune response (Janssen, 
Mihov et al. 2014). They are degraded within the cell by both surface and 
bulk erosion (Bragdon, Bertone et al. 2001, Larsen, Ostergaard et al. 2008), 
into the fully resorbable natural metabolites lactic and glycolic acid 
(Kavanaugh, Werfel et al. 2015). PLGA microspheres experience an initial 
burst release which may cause local toxic effects (Janssen, Mihov et al. 
2014) as high levels of lactic acid can be toxic (Kavanaugh, Werfel et al. 
2015). Efforts are being made to reduce this initial burst release with 
additives such as polyethylene glycol (PEG), however these can also 
antagonise macrophage phagocytosis, therefore it would depend on the 
intended application of the microspheres (Kavanaugh, Werfel et al. 2015).  
PLGA microspheres are approved by the Food and Drug Administration 
(FDA) (Janssen, Mihov et al. 2014, Kavanaugh, Werfel et al. 2015) and their 
use in OA-targeted treatment is currently in phase 3 development, testing the 
provision of IA sustained steroid release to treat patients with moderate to 
severe OA pain (Kumar, Bendele et al. 2012, Bodick, Lufkin et al. 2015). 
Flexion therapeutics (Massachusetts, USA) also have two other PLGA 
encapsulated products in development; a TrkA receptor antagonist intended 
for post-operative pain, and a p38 MAP kinase inhibitor intended for end-
stage OA patients (Kumar, Boehm et al. 2003, Kavanaugh, Werfel et al. 
2015).   
Natural polymers, such as chitosan and gelatin, have been used as drug 
delivery systems in OA models, incorporating non-steroidal anti-inflammatory 
drugs (NSAIDs) and anti-TNF proteins (Janssen, Mihov et al. 2014, 
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Kavanaugh, Werfel et al. 2015). However, these natural formulations are 
more immunogenic which is an undesirable characteristic when treating OA.  
Synthetic polymer microspheres have been extensively modified to enable 
sustained drug release, specific targeting properties and improved cellular 
uptake. For example, a polypropylene sulphide (PPS) particle preparation 
can become hydrophilic in response to reactive oxygen species, triggering 
the release of hydrophobic encapsulated drugs, providing an ‘on demand’ 
release when needed (Poole, Nelson et al. 2015). Other particles incorporate 
a tethering moiety to attach the therapeutic protein, in this case IL-1RA, to 
the particle, decreasing rate of release and therefore extending the retention 
of IL-1RA within the joint (Whitmire, Wilson et al. 2012). Nanoparticles are 
also capable of targeting specific molecular structures, such as collagen I, 
using a surface peptide as a ligand. This has allowed nanoparticles to 
infiltrate cartilage in vivo, targetting chondrocytes, and maintaining their 
presence within the ECM for extended periods (Rothenfluh, Bermudez et al. 
2008).  
 
5.1.2  Gene Therapy  
Gene therapy either facilitates an increase or decrease in gene expression, 
depending on the desired outcome. Viral vectors enable plasmid cDNA 
comprising the required gene, to either be incorporated into the target cell 
chromosomal cDNA, or remain in the cytoplasm, and subsequently be 
translated into a protein (Casal and Haskins 2006). Viral vectors can be used 
in vivo or ex vivo. Retroviral-based vectors that integrate into host DNA and 
stably modify target cells are often used for ex vivo modification (Robbins, 
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Evans et al. 2003). This process modifies tissues in vitro before injecting the 
cells back into the target area in vivo. Studies using autologous synoviocytes 
modified by a retroviral vector to constitutively express IL-1RA have been 
shown to be safe and effective (Robbins, Evans et al. 2003). In vivo gene 
therapy involves IA injection of the vector, directly at the site where 
expression is required, such as the synovium during OA. For this purpose 
vectors must have high transduction efficiency and sustained gene 
expression, and cause minimal immunogenic stimulation. ScAAV IL-1RA 
equine gene serotype 2, has good transduction efficiency in both equine 
synoviocytes and chondrocytes (Goodrich, Choi et al. 2009, Ishihara, Bartlett 
et al. 2012, Watson, Broome et al. 2013) in an inflammatory environment 
(Kay, Gouze et al. 2009), and are safe for IA use (Ishihara, Bartlett et al. 
2012). IA therapeutic levels of IL-1RA have been attained over substantial 
periods (Goodrich, Phillips et al. 2013).  During a ‘proof of concept’ study, 
this increased expression of IL-1RA provided marked protection from the 
progression of joint pathologies developed in an equine osteochondral 
fragment model (Watson, Broome et al. 2014).  
 
Post-transcriptional gene silencing (PTGS) reduces translation of a target 
gene by decreasing mRNA levels through RNA interference (RNAi). Using 
synthetic siRNA loaded biodegradable polymer particles as non-viral vectors, 
safe, non-toxic, non-immunogenic gene silencing has been carried out in 
vitro and in vivo (Murata, Takashima et al. 2008, Lee, Yang et al. 2009, Patil, 
Panyam et al. 2009). This method has suppressed tumour growth in mice 
using anti-VEGF siRNA (Murata, Takashima et al. 2008), induced potent 
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silencing of anti-TNF-α secretion in murine peritoneal-residing macrophages 
(Brunner, Cohen et al. 2010) and PLGA microspheres encapsulating anti-
TNF-α siRNA inhibited IA TNF-α expression by 40-50% over 11 days and 
reduced synovial inflammation in a murine model (Présumey, Salzano et al. 
2012).  
 
We have previously described the successful reduction of EFLS IL-1β gene 
expression using RNA interference, and demonstrated the ability of equine 
peripheral blood mononuclear cells (EPBMCs) to phagocytose PLGA 
microspheres. This study incorporates EFLS and EPBMCs which, when 
cultured together, will be referred to by the umbrella term “synoviocytes”. 
Synoviocytes will be cultured with cartilage explants to investigate the 
success of PLGA microspheres in the capacity of therapy delivery vehicles 
loaded with anti-IL-1β siRNA. The influence of synoviocytes with and without 
anti-IL-1β siRNA loaded PLGA-microsphere treatment, on cartilage health, 
will be investigated. 
 
5.1.3 Aims 
! To determine the influence of synovitis on cartilage health.  
! To investigate whether anti-IL-1β siRNA loaded PLGA-microspheres 
can effect synoviocyte gene expression.  
! To investigate whether anti-IL-1β siRNA loaded PLGA-microsphere 
treatment alters the effect of synovitis on cartilage health.  
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5.2  Study Design  
 
An overview of the experimental design can be found in Schema 5.1. 
 
5.2.1   Co-Culture Model Design 
 
5.2.1.1  Metacarpophalangeal Joint Scoring 
Equine distal limbs from 12 horses, disarticulated at the carpus, were 
collected from an abattoir. Limbs were prepared and MCPJ exposed under 
sterile conditions, using techniques described in Chapter 2. Materials and 
Methods, section 2.1. Cartilage of the distal condyles of the third metacarpal 
bone, and proximal aspect of the first phalanx (P1), were grossly scored 
using a macroscopic cartilage scoring system encompassing pathology such 
as cartilage wear lines, cartilage erosion and palmar arthroses (McIlwraith, 
Frisbie et al. 2010). Other abnormalities, such as remodelling of the 
dorsoproximal aspect of the P1 were noted, and the condition of the synovial 
membrane and synovial fluid were also taken into consideration when 
grading the joint (Table 5.1). Nine joints with an overall score of <1 were 
used in the study, others with additional pathology such as remodelling of the 
dorsoproximal aspect of the P1 were disregarded (Figure 5.1). 
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EPBMCs cultured in 
24-well plates for 8 
days 
Control microspheres 
added to EPBMCs for 
48 hours 
EFLS (n=2) were 
mixed and added to 
wells for 24h 
Day 0 = Cartilage 
explants in well inserts 
added to wells and 
10µg/ml LPS added to 
wells 
Media replenished at 
day 4, 8, 12, 17, 20 
and 24  
Synoviocytes, media 
and cartilage explants 
harvested at days 1, 8, 
and 28. 
Media: protein 
extracted for Western 
blot analysis 
Cartilage explants: wet 
weight recorded 
Snap frozen in liquid 
nitrogen  or 4% PFA 
for histology 
Synoviocytes 
harvested for PCR and 
western blot analysis 
Anti-IL-1β siRNA 
loaded microspheres 
added to EPBMCs for 
48 hours 
EFLS (n=2) were 
mixed and added to 
wells for 24h 
Day 0 = Cartilage 
explants in well inserts 
added to wells and 
10µg/ml LPS added to 
wells 
Cartilage explants 
harvested and cultured 
for 48h to allow 
cartilage swelling 
pressure to decrease 
Cartilage explants 
cultured independently 
to act as controls 
10µg/ml LPS added to 
n=2, no LPS added to 
n=2  
Schmema 5.1 Experimental strategy for work within Chapter 5. 
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Table 5.1 Cartilage, synovial membrane and synovial fluid macroscopic grading scores.  
 
 
Horse 
 
 
Limb 
Macroscopic cartilage score Synovial  
 
Synovial Fluid 
 
 
Other 
 
 
Used in study 
 
 
Total score 
Wear lines Erosion Palmar Arthroses membrane 
Grade Position Grade Position Grade Position Inflammation 
             
1 Right 0 - 1 Medial 0 - 0 0 No Yes 1 
2 Left 0 - 0 - 1 Medial 0 0 Yes* No 1 
3 Right 0 - 1 
1 
Medial 
Lateral 
0 - 0 0 No Yes 1 
4 Left 1 Medial 0 - 0 - 0 0 No Yes 1 
 Right 1 Medial 0 - 0 - Moderate Haemorrhagic No No 1 
5 Left 0 - 1 Medial 0 - 0 0 Yes** No 1 
 Right 0 - 0 - 0 - 0 0 Yes** Yes 0 
6 Left 0 - 1 Lateral 0 - 0 0 No Yes 1 
7 Left 0 - 0 - 0 - 0 0 No Yes 0 
8 Left 0 - 0 - 0 - 0 0 No Yes 0 
9 Right 0 - 0 - 0 - Mild 0 No No 0 
10 Left 0 - 1 Lateral 0 - Mild 0 No No 1 
11 Left 0 - 0 - 0 - 0 0 No Yes 0 
12 Right 0 - 0 - 0 - 0 0 No Yes 0 
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Figure 5.1 Distal condyles of the third metacarpal bone. A. Normal (horse 11). B. Grade 1 Erosion (Arrowhead, 
horse 6, left forelimb). C. Grade 1 Palmar arthroses (Arrow, horse 2, left forelimb). D. Hard white deposits within the 
HAC (Small arrowheads, horse 5, right forelimb).!
A. B. 
C. D. 
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5.2.1.2  Tissue Harvesting 
Cartilage explants, approximately 5mm2 and <1mm thick, were harvested 
from nine MCPJs, as described in Chapter 2 Materials and Methods, section 
2.1, and pooled in PBS. Three cartilage explants were chosen at random and 
inserted in each cell culture well-insert (0.45µm, Merck Millipore, 
Hertfordshire UK). Explants were immersed in 1ml Dulbecco’s Modified 
Eagle Medium (DMEM, Life Technologies, Maryland, USA) with 10% foetal 
bovine serum (FBS, Gibco, Paisley, UK), 100U/ml penicillin/streptomycin 
(Penstrep, Life Technologies, Paisley, UK), 500ng/ml amphotericin B (Life 
Technologies, Paisley, UK), this will be referred to as ‘standard culture 
media’ when associated with cartilage explants and EFLS. Explants were 
incubated for 48 hours at 37°C in 5% CO2, to allow the cartilage swelling 
pressure to decrease.  
 
Synovium was harvested from two MCPJs and digested using a 
trypsin/EDTA and type 2 collagenase (Worthington, UK) protocol as 
described in Chapter 2 Materials and Methods, section 2.1. Isolated EFLS 
were cultured in normal media and cultures were expanded. All EFLS used 
within this study had undergone less than 4 passages.  
 
Osteochondral wedge biopsies incorporating cartilage and subchondral 
bone, and synovial explants were taken from joints which had scored 0 when 
using the macroscopic cartilage scoring system. Osteochondral wedge 
biopsies (5mm thick) were extracted using a bone saw. The osteochondral 
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wedge biopsies and synovial explants were immediately placed in 4% PFA 
and were processed for histopathology sections.  
 
5.2.1.3  EPBMC Isolation and Culture 
EPBMCs (n=1, passage 1) were isolated as described in Chapter 2. 
Materials and Methods, section 2.1, and cultured in 24 well plates at a 
seeding density of 1 x 105 cells per well in 1ml RPMI-1640 medium with L-
alanyl-L-glutamine (RPMI 1640 Medium, GlutaMAX™ Supplement, Life 
Technologies, UK). This was supplemented with 10% horse serum (New 
Zealand origin, Life Technologies, UK), 100U/ml penicillin/streptomycin 
(Penstrep, Life Technologies, Paisley, UK), 500ng/ml amphotericin B (Life 
Technologies, Paisley, UK) and 50ng/ml recombinant human granulocyte-
macrophage colony stimulating factor (rhGMCSF 300-03, Peprotech, NJ, 
USA). This will be referred to as ‘standard EPBMC culture media’. Half the 
media was replenished every 3 days for 8 days.  
 
5.2.1.4  Anti-IL-1β Microspheres Cultured with EPBMCs 
PLGA microspheres, 2-6µm in diameter, were loaded with anti-IL-1β siRNA 
at 0.2nM/mg, and suspended in PBS at 50mg/ml. Five pM siRNA (0.125mg 
microspheres) were added to half of the wells containing EPBMCs. 
Fluorescein isothiocyanate-dextran (FD4, FD10s) microspheres, acting as 
control microspheres, were suspended in PBS at 16.7mg/ml; 0.125mg 
control microspheres were added to the remainder of the wells. Cells were 
incubated with the microspheres for 48 hours.  
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5.2.1.5  Synoviocyte Co-Culture 
Once the EPBMCs had been cultured with the microspheres for 48 hours, 
EFLS were seeded in the same wells as the EPBMCs, at a seeding density 
of 1 x 105 cells per well. Cells were immersed in 1ml of media consisting of 
500µl standard culture media, and 500µl standard EPBMC culture media. 
Cells were incubated at 37°C in 5% CO2 for 24 hours. 
 
5.2.1.6  Cartilage and synoviocyte Co-Culture 
Synoviocyte (EFLS and EPBMC) media was discarded and replenished with 
700µl fresh culture media at the same ratio (50% standard culture media and 
50% standard EPBMC culture media) containing 10µg/ml LPS. Cartilage 
explant media was removed and the well-inserts (containing cartilage 
explants) were placed into the wells containing the synoviocyte cultures. 
Cartilage explants were then immersed in 200µl standard culture media. Co-
culture of synoviocytes, cartilage explants and LPS within the same well, was 
considered the start of the experiment (day 0) (Figure 5.2). 
 
5.2.1.7  Control Cartilage Explants 
Three cartilage explants per well were cultured in a 24-well plate, that did not 
contain synoviocyte cultures. These explants were cultured in 1ml standard 
culture media, with (n=2) and without (n=2) 10 µg/ml LPS. Media, with and 
without LPS, was replenished at the same time points as described below, 
and stored at -20°C. 
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5.2.1.8  Media Changes Across the Course of the Experiment 
Synoviocyte culture media was replenished with 700µl fresh media at the 
same ratio of standard culture:standard EPBMC culture media containing 
10µg/ml LPS approximately every four days (day 4, 8, 12, 17, 20 and 24). 
The cartilage explants also received 200µl fresh standard culture media 
placed within the well-insert, at these time points. Synoviocyte and cartilage 
media samples were combined and stored at -20°C.  
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Cartilage 
Explant 
Standard 
Culture Media 
Standard 
EPBMC Culture 
Media 
EFLS 
Microsphere 
EPBMCs 
Well-insert 
Figure 5.2 Synoviocyte and cartilage co-culture. EPBMCs were cultured with either control or anti-IL-1β 
siRNA loaded microspheres, and EFLS. Cartilage explants in a well-insert were placed into the main well. 
Cells were cultured in media containing 10µg/ml LPS. 
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5.2.1.9  Cell and Tissue Harvesting 
Synoviocytes, media and cartilage explants were harvested at days 1, 8 and 
28 of the experiment. Media was removed and cell layers were harvested 
either in 0.5ml tri-reagent (Sigma-Aldrich, Missouri, USA) and stored at -
80°C, or were first washed with 1ml 1x PBS before being macerated using a 
cell scraper, in 45µl (1X) Novex tris-glycine SDS sample buffer 2X (Life 
Technologies, California, USA) and stored at -20°C. Media from the main 
well and well-insert were combined, and frozen at -20°C. Excess media was 
gently blotted from cartilage explants, which were then weighed. Cartilage 
wet weights were recorded before explants were either snap frozen in liquid 
nitrogen, or fixed in 4% PFA, and stored at -80°C.  
 
5.2.2  Synoviocyte Gene Expression Analysis 
As described in Chapter 2 Materials and Methods, section 2.7, synoviocyte 
samples harvested in tri-reagent underwent RNA extraction using the 
guanidinium-thiocyanate-phenol-chloroform technique with ethanol. Reverse 
transcription was carried out using 1µg RNA, random hexonucleotides and 
M-MLV reverse transcriptase (Promega, Wisconsin, USA). Quantitative RT-
PCR was carried out using validated equine primers specific for GAPDH, IL-
1β, IL-6, ADAMTS4, ADAMTS5, MMP3 and MMP13 (primers are listed in 
Chapter 2. Materials and Methods, section 2.7). The relative quantification of 
each gene normalised to the GAPDH reference gene, was calculated using 
the 2-ΔCt method (Livak, Schmittgen et al. 2001). !
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5.2.3  Sulphated Glycosaminoglycan Assay 
All media samples, including those stored when media was changed on days 4, 
12, 17, 20 and 24, and those harvested at days 1, 8 and 28, were subjected to a 
sGAG assay, as described in Chapter 2 Materials and Methods, section 2.5. This 
1-9 dimethylmethylene blue (DMMB) assay measures the concentration of sGAG 
within the cell media (Farndale, Buttle et al. 1986). This will reflect the quantity of 
sGAG released from cartilage explants, and to a lesser extent, secreted from 
EPBMCs and EFLS. A standard curve was created using known chondroitin 
sulphate (shark cartilage, C-4384, Sigma-Aldrich, Missouri, USA) concentrations 
ranging from 0 - 70µg/ml. Unknown sample sGAG concentrations were 
determined using the standard curve and linear equation. Absorbance was 
measured spectrophotometrically at a wavelength of 570nm. As the majority of 
sGAG will have originated from the cartilage explants, sGAG concentrations were 
normalized to total cartilage wet weight of the corresponding cartilage explants. 
 
5.2.4  Analysis of Protein Within Culture Media  
Western blot analysis was conducted using protein extracted from both cell 
media and cell lysate samples. 
 
5.2.4.1  PierceTm 660 Protein Assay  
The protein concentrations of all samples were quantified using the PierceTm 660 
protein assay (Thermo-Fisher Scientific, Massachusetts, USA). A standard curve 
of absorbance, using a series of known bovine serum albumin (BSA) dilutions (0 - 
2000µg/ml), was used to determine unknown protein concentrations. Absorbance 
was measured by a plate reader at a wavelength of 660nm.!!
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5.2.4.2  Proteinase and Chondroitinase Treatment 
Culture media samples harvested on day 1, 8 and 28 were treated with 
chondroitinase (0.001U/10µg sGAG) and proteinase inhibitors at 1 tablet/10ml 
media (Complete ULTRA tablets (EDTA-free), Roche, Basel, Switzerland) and 
incubated overnight. 
 
5.2.4.3  Protein Extraction From Culture Media  
Once protein concentrations of culture media samples were determined using the 
PierceTm 660 protein assay, 10µl StrataCleanTm Resin (Agilent, California, USA) 
was added to a known volume of culture media containing 80µg protein. Samples 
were processed as described in Chapter 2 Materials and Methods, section 2.6. 
Once the suspension had been thoroughly vortexed, the protein-bound resin was 
washed with DDH2O and re-suspended in 15µl 1 x SDS-loading buffer to result in 
a total volume of 40µl containing 80µg protein per sample.  
 
5.2.4.4  Western Blot Analysis  
Sample were supplemented with 1µl mercaptoethanol (for reducing conditions) 
and incubated at 100°C for 5 minutes. Protein-bound resin samples were 
thoroughly mixed to re-suspend the resin in SDS-loading buffer. Samples of 
equal protein content (40µg) were loaded into a 4-12% Bis-Tris gel cassette. 
Proteins were separated by electrophoresis and transferred to a nitrocellulose 
membrane. The membrane was incubated in 1% non-fat milk blocking buffer to 
prevent non-specific antibody binding, before being exposed to the aggrecan 
interglobular doman (IGD) aggrecanase site-specific neoepitope monoclonal 
antibody (mAb) BC-3 1:200 (a kind gift from Professor Bruce Caterson, Cardiff 
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University). An anti-mouse IgG-peroxidase monoclonal antibody raised in the 
goat (Sigma-Aldrich, Missouri, USA) was used as a secondary antibody at 
1:2000. 
 
5.2.5  Cartilage Histology and Scoring 
 
5.2.5.1  Sample Preparation 
Each well-insert contained three cartilage explants; two explants were fixed in 4% 
neutral buffered PFA for 48 hours, before being immersed in 70% ethanol. 
Explants were embedded in paraffin wax, cut into 10µm sections and mounted 
onto glass slides. Control synovial membrane explants were processed using the 
same method.  
 
Osteochondral wedge biopsies were fixed in 4% neutral buffered PFA for at least 
24 hours. Samples were then de-calcified in 7.4% EDTA for one month. Water 
within the sample was first replaced with alcohol by dehydrating the samples; the 
tissue was passed through increasing concentrations of ethyl alcohol (0 to 
100%). The alcohol was then replaced by xylene, which is miscible with paraffin 
wax, in the clearing step. Finally, the tissue was impregnated with, and 
embedded in, paraffin wax. Explants were cut into 10µm sections using a 
microtome, and mounted onto glass slides.  
 
5.2.5.2  Histology Staining and Scoring 
All histological cartilage, synovial membrane and osteochondral sections were 
stained with either H&E, or celestine blue, 0.5% fast green and 1% Safranin-O 
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stains. Sections were visualised using a Nikon Eclipse 80i microscope, and 
images were acquired using a Nikon DS-L2 standalone control unit. Cartilage 
explant sections were scored using a modified version of the cartilage 
histopathologic scoring system (McIlwraith, Frisbie et al. 2010). Osteochondral 
sections and synovial sections were scored using unmodified scoring systems 
(McIlwraith, Frisbie et al. 2010). Sections were scored twice by two users blinded 
to section identity. Inter- and intra- variability was assessed using the Cohen’ 
kappa coefficient (Cohen 1960). Cartilage explant depth was measured at three 
different locations on each explant, using lines drawn perpendicular to the long 
axis of the explant.  
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5.3  Results 
 
5.3.1  Synoviocyte Gene Expression 
Synoviocyte gene expression levels of all cytokines, aggrecanases and MMPs on 
day 28 of the experiment, were dramatically lower than levels measured on day 1 
(Figure 5.3). Gene expression levels of ADAMTS4, ADAMTS5 and MMP13 on 
day 8 were comparable to those measured on day 1. When comparing 
synoviocytes cultured with control microspheres to those cultured with anti-IL-1β 
siRNA loaded microspheres, gene expression levels of all cytokines, 
aggrecanases and MMPs were comparable between the two conditions at day 1, 
8 and 28. However, synoviocytes cultured with anti-IL-1β siRNA loaded 
microspheres expressed a significantly higher amount of MMP3 mRNA on day 8 
than synoviocytes cultured with control microspheres (p<0.05). The order of 
relative amount of synoviocyte gene expression from the most expressed to least 
expressed, was IL-6, ADAMTS5, MMP3, IL-1β, ADAMTS4 then MMP13, across 
the 28-day period.     
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Figure 5.3 Synoviocyte gene expression when in co-culture. Synoviocyte 
(n=3) gene expression at day 1, 8 and 28 was analysed by qRT-PCR and 
normalised to GAPDH. Synoviocytes (EFLS and EPBMCs) were cultured with 
control microspheres (black bars) or anti-IL-1β siRNA loaded microspheres (grey 
bars). Genes investigated included (A) IL-1β, (B) IL-6, (C) ADAMTS4, (D) 
ADAMTS5, (E) MMP3, (F) MMP13. Standard error bars are shown. * = p < 0.05. 
* 
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5.3.2  Sulphated Glycosaminoglycan Content 
Sulphated glycosaminoglycan (sGAG) content within culture media was 
measured at day 1, 4, 8, 12, 17, 20, 24, and 28 of the experiment, and levels 
were normalised to cartilage wet weight. sGAG in culture media was evident 
within the first 24 hours of the experiment (Figure 5.4A). On day 1 of the 
experiment, media culturing control cartilage explants contained relatively more 
sGAG than media co-culturing synoviocytes and cartilage explants; this varied at 
each media change but the trend occurred again on days 12, 17, and 24 (Figure 
5.4A). Individual assays of sGAG content measured at intervals, displayed a 
cyclic-like trend (Figure 5.4A). Sulphated GAG measurements at each media 
change were highly variable, however, sGAG content did decrease between day 
1 and 28 in cartilage media but not in co-culture media (Figure 5.4A).  
 
When analysing the cumulative sum of sGAG content within the media of each 
well over 28 days, significant increases were observed over the course of the 
experiment (Figure 5.4B). No significant difference in sGAG content of media 
containing synoviocytes treated with control microspheres compared to those 
treated with anti-IL-1β siRNA loaded microspheres was observed. When 
comparing media sGAG content of cartilage cultured with and without LPS, no 
significant difference was detected. However media co-culturing synoviocytes 
and cartilage, contained a significantly lower amount of sGAG, compared to 
media culturing solely cartilage (p = 0.001) (Figure 5.4C). 
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Figure 5.4 Culture media sulfated glycosaminoglycan (sGAG) 
content. (A) Individual daily and (B) cumulative sum of sGAG 
content within culture media of co-cultures (n=3) containing control 
microspheres (circle) or anti-IL-1β siRNA loaded microspheres 
(filled circle), or individual (n=2) cartilage explant culture without 
(triangle) or with (filled triangle) 10µg/ml LPS, collected at each 
media change. No significant differences were detected between 
conditions. (C) Cumulative sum of mean sGAG within culture media 
of cartilage co-cultured with synoviocytes (filled circle) compared to 
cartilage cultured without synoviocytes (circle), a significant 
difference was observed (p = 0.001). sGAG mass (µg) was 
normalised to cartilage wet weight (mg). Error bars represent SEM. 
A. B. 
C. 
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5.3.3  Western Blot Analysis 
Proteins extracted from co-culture media of synoviocytes treated with control 
microspheres and anti-IL-1β siRNA loaded microspheres on days 1, 8, and 
28 underwent western blotting. Proteins of 175kDa, 100kDa, 62-70kDa, 
45kDa and 35kDa were detected using an aggrecan IGD aggrecanase site-
specific neoepitope monoclonal antibody (mAb) BC-3 (Figure 5.5). The band 
at 62-70kDa is consistent with C-terminally truncated, ADAMTS-cleaved 
aggrecan (Busschers, Holt et al. 2010). Smaller fragments are consistent 
with smaller aggrecan breakdown products.  
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Figure 5.5 Detection of aggrecan breakdown products within the 
culture media of synoviocyte and cartilage co-cultures. Proteins 
within co-culture media of synoviocytes (n=3) treated with control 
microspheres and anti-IL-1β siRNA loaded microspheres on days 1, 
8, and 28 were detected using an aggrecan interglobular doman 
(IGD) aggrecanase site-specific neoepitope monoclonal antibody 
(mAb) BC-3. Proteins of 175kDa, 100kDa, 62-70kDa, 45kDa, and 
35kDa were detected.  
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5.3.4  Cartilage, Osteochondral and Synovial Histology Scores 
Sections of the osteochondral wedge biopsies (Figure 5.6) and synovial 
explants, taken from joints which had scored 0 using the macroscopic 
cartilage scoring system, scored 0-2.67 out of 20 when using the cartilage 
and synovium histopathologic scoring systems. This supported the use of the 
macroscopic scoring system to detect joints free from orthopaedic disease. 
Inter- and intra-observer variability was moderate; 0.44 (95% CI: 0.2-0.67) 
and 0.6 (95% CI: 0.34-0.86) respectively.  
 
 When comparing histopathological scores of cartilage explants (Figure 5.7 & 
5.8) co-cultured with synoviocytes that had either been treated with control 
microspheres (mean score: 4.75 out of 12, minimum-maximum score: 1 – 7, 
95% CI: 0.57-8.94), or anti-IL-1β siRNA loaded microspheres (mean score: 
3.8 out of 12, minimum – maximum score: 2 – 6, 95% CI: 2.29 – 5.38), 
scores were comparable. However, the scores of cartilage explants 
independently cultured (mean score: 1.19 out of 12, minimum – maximum 
score: 0.88-1.5, 95% CI: -2.78 – 5.38) were significantly lower than those co-
cultured with synoviocytes (p<0.05).  
 
Five of fourteen cartilage explants contained the most superficial aspect of 
the calcified cartilage layer. None of the explants contained subchondral 
bone. Cartilage explants that contained solely hyaline articular cartilage, or 
hyaline articular cartilage and the superficial aspect of the calcified cartilage 
layer, were approximately 0.04 - 0.41mm thick (mean: 0.2mm) and 0.09 - 
0.24mm thick (mean: 0.16mm) respectively. Cartilage explants <0.1mm were 
! 238 
more difficult to correctly orientate for histopathological scoring than those 
that had a greater depth. 
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Figure 5.6 Healthy osteochondral wedge biopsy sections with no pathology. Osteochondral sections were scored using a 
histopathological cartilage scoring system, assessing focal cell loss, chondrocyte necrosis, fibrillation of the articular surface, and 
chondrocyte cluster (more than one chondrocyte within the same lacunae in the superficial zone). A. x4, scale bar = 1000µm. B. x10, 
C. x20, D. x40. B-D Scale bars = 100µm. 
 
  
C. D. 
! 240 
!
Figure 5.7 Cartilage explant sections graded. Sections were scored for focal cell loss (arrows), chondrocyte cluster formation (more 
than one chondrocyte within the same lacunae in the superficial zone of the explant) (arrowhead) and fibrillation of the articular surface 
(arrowhead outline). A. x4, B & C. x20, D & E. x40. All scale bars = 100µm. Sample A-E was graded 1.5, sample F-H was graded 6.5. 
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Figure 5.8 Cartilage explant (A & B) and osteochondral 
wedge biopsy (C) sections stained with Safranin-O to 
visualise the cartilage explant proteoglycan content. 
Sections were stained with celestine blue, 0.5% fast green 
then 1% safranin-O. Sections were scored for degree of 
normal staining; a loss of normal staining reflects a 
decrease in glycosaminoglycan content. (A) (same sample 
as Figure 5.7A-E) and (C) scored <1, and (B) (same sample 
as Figure 5.7F-H) scored 4 which indicates normal staining 
and >75% loss of staining characteristics, respectively. 
Scale bars = 100µm. 
A. 
C. 
B. 
C. 
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5.4  Discussion  
 
5.4.1 Synoviocytes Reduce sGAG Loss from Cartilage Explants 
The co-culture model designed in this study is based on an inflamed intra-
articular environment. Direct co-culture of EFLS and EPBMCs reflect the 
close proximity of FLS and mononuclear cells within the synovium during 
synovitis. Indirect co-culture of synoviocytes and cartilage explants in a 
common culture media which provides a transport medium between the cells 
is synonymous to synovial fluid facilitating cellular signalling between intra-
articular synovial membrane and cartilage.  
Inflammation is one of the first events to occur in the pathogenesis of OA 
(Heinegård and Saxne 2011); severe synovitis has been detected early in 
the disease process and can aid in predicting cartilage breakdown (Sellam 
and Berenbaum 2010). Cytokine and aggrecanase release are both up-
regulated during equine synovitis (Kamm, Nixon et al. 2010), therefore a true 
synovitis model should emulate these responses. An inflammatory response 
in this model, was induced by exposing synoviocytes and cartilage to LPS. 
Synoviocyte gene expression levels of all cytokines, aggrecanases and 
MMPs analysed were detectable from day 1, apart from TNF-α. The relative 
abundance of IL-6, ADAMTS5 and MMP3 mRNA transcripts were higher 
than IL-1β, ADAMTS4 and MMP13. Abundant IL-6 mRNA indicates a 
synovitis-like response. Synovial fluid (SF) IL-6 levels have been associated 
with the OA biomarker C-reactive protein, thought to be indicative of an 
increasing inflammatory cellular infiltrate in the synovial tissue (Pearle, 
Scanzello et al. 2007). The synoviocyte gene expression profiles produced in 
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this study reliably demonstrate a synovitis-like response within the co-culture 
model. A similar equine co-culture model failed to detect IL-1β and TNF-α 
mRNA expression, and found IL-6 expression unaffected in co-culture (Lee, 
Kisiday et al. 2013), however this model used a predominantly FLS culture. 
Co-culture models using bovine synovial explants, which may have retained 
a heterogeneous synoviocyte cell population more closely resembling that 
found during joint inflammation, observed an increase in IL-1β mRNA 
expression during co-culture but no detectable change in TNF-α mRNA 
expression (Lee, Fitzgerald et al. 2009).  
Minor fibrillation of the cartilage surface and substantial release of aggrecan 
fragments from the cartilage define early OA pathology (Heinegård and 
Saxne 2011). This increase in aggrecan turnover has also been observed in 
early equine OA through the use of CA856 mAb and GAG assays, facilitating 
the measurement of aggrecan fragments within SF (Frisbie, Al-Sobayil et al. 
2008, de Grauw, Van de Lest et al. 2009). Aggrecanases, which cleave the 
aggrecan core protein at four separate cleavage sites, have been inextricably 
linked to this early joint pathology  (Glasson, Askew et al. 2004, Stanton, 
Rogerson et al. 2005). When analysing the amount of sGAG in this model, 
significantly lower total sGAG within the culture media of cartilage co-
cultured with synoviocytes, compared to that of cartilage cultured 
independently (p < 0.01) was observed. This finding was also observed by 
Gregg et al. (2006) (Gregg, Fortier et al. 2006) who demonstrated a 
reduction in IL-1β-stimulated cartilage GAG loss when co-cultured with 
synoviocytes. However, this study also observed a reduction in IL-1β-
induced suppression of chondrocyte aggrecan gene expression when in co-
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culture with synoviocytes. Chondrocytes should increase the synthesis of 
these molecules to counteract the loss of aggrecan (Heinegård and Saxne 
2011); whereas Lee et al. (2013) (Lee, Kisiday et al. 2013) observed less 
chondrocyte aggrecan gene expression when in co-culture with 
synovicoytes. It is therefore unknown whether this reduction of GAG loss is 
due to a protective synoviocyte mechanism encouraging anabolic 
metabolism, the inhibition of chondrocyte aggrecan synthesis, or suppression 
of aggrecanase production. The equal increase in sGAG content in culture 
media between conditions, throughout the first 8 days, may reflect early loss 
of aggrecan from cartilage ECM commonly observed in early stage OA. 
However after 8 days, sGAG content in co-culture media, is significantly 
lower than that of cartilage cultured independently.  
Whether synoviocytes were treated with control or anti-IL-1β siRNA loaded 
microspheres made no difference to the amount of sGAG detected in culture 
media at day 1, 8 or 28. These results were consistent when using the 
DMMB assay, and through western blot analysis using the BC-3 mAb. The 
BC-3 antibody detects fragments of aggrecan that have been released after 
cleavage of aggrecan within the interglobular domain aggrecanase site (Ala-
Glu) and therefore contain a new N-terminus (Busschers, Holt et al. 2010). 
The western blot analysis of culture media displayed a major band at 62-
70kDa which is consistent with C-terminally truncated, ADAMTS-cleaved 
aggrecan. This indicates that GAG release in this system is driven, at least in 
part, by aggrecanase cleavage of the aggrecan core protein in the cartilage 
explants. 
! 245 
 In vivo equine synoviocyte ADAMTS4 mRNA expression increases on 
exposure to LPS and recombinant human IL-1β (Ross, Kisiday et al. 2012). 
Synoviocyte aggrecanase mRNA expression was evident in this study, with 
relative abundance of ADATMS5 mRNA transcripts being approximately 10 x 
more than those of ADAMTS4 on day 1. However, it has also been shown 
that EFLS ADAMTS5 gene expression is moderated in response to external 
stimuli. In Chapter 4, it was established that EFLS ADAMTS5 gene 
expression is attenuated by macrophages, in an inflammatory environment. 
Other co-culture models have reported a decrease in synoviocyte 
aggrecanase gene expression in the presence of injured cartilage (Lee, 
Kisiday et al. 2013), however the model in this study did not incorporate 
macrophages. A similar negative feedback mechanism may be generated by 
macrophages and injured cartilage to suppress synoviocyte aggrecanase 
production, favouring an anabolic environment.   
Cartilage explants cultured with synoviocytes had a significantly higher 
cartilage histopathological score than those cultured without synoviocytes (p 
<0.05). Cartilage explant histopathological scores were based upon the 
degree of articular surface cartilage fibrillation, superficial zone chondrocyte 
cluster (chondrone formation) and safranin-O stain uptake observed. 
However, changes based upon these criteria may not be very sensitive for in 
vitro measurements of cartilage pathology. For example, fibrillation is 
dependent on mechanical wear, however the degree of fibrillation may 
change with loss of sGAG from the ECM. Chondrocyte necrosis and focal 
cell loss were removed from the modified scoring system as it was 
hypothesised that these changes are more likely to occur during in vivo 
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cartilage degradation. This significant difference in cartilage degradation 
when explants were cultured with and without synoviocytes, could be due to 
the abundant production of cytokines, aggrecanases and MMPs produced by 
the inflamed synoviocytes.  
The method used in this study to dissect cartilage explants from the distal 
aspect of the condyles of the third metacarpal bone reliably ensured that 
subchondral bone was not incorporated in the sample. The inclusion of the 
tidemark and superficial aspect of the calcified cartilage layer, in samples up 
to 0.41mm thick, helped orientate the sample, allowing reliable deduction of 
articular surface location. This greatly aided the process of grading. Very thin 
explants (<0.1mm) were difficult to correctly orientate within paraffin wax, 
resulting in sections lacking an articular surface. This posed a problem with 
the histopathological grading system used in this study, as the scoring 
system demanded the inclusion of the superficial zone adjacent to the 
articular surface.  
 
5.4.2 SiRNA-Loaded Microspheres Do Not Effect the Co-Culture 
Treatment of synoviocytes with anti-IL-1β siRNA loaded microspheres 
compared to control microspheres, caused no significant differences in 
synoviocyte gene expression profiles, sGAG measurements within culture 
media, or cartilage histopathological scores. Previous work in Chapter 3, has 
verified post-transcriptional synoviocyte RNA interference through the use of 
equine anti-IL-1β siRNA, and successful EPBMC phagocytosis of small (2-
6µm) PLGA-microspheres. However, in this co-culture model we were 
unable to reproduce these results when using the PLGA microspheres as 
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siRNA delivery vehicles. Many factors regarding the delivery of siRNA to 
target mRNA within the cell, need further investigation. These include the 
rate of EPBMC phagosome microsphere degradation and the subsequent 
rate of siRNA release, the route of siRNA translocation to the nucleus, and 
the dose of siRNA required to produce a therapeutic response at the 
determined rate of siRNA release.    
EPBMCs were cultured with the microspheres for 48 hours before EFLS 
were introduced, allowing sufficient time for EPBMC phagocytosis of the 
microspheres. However, the rate of microsphere degradation and 
subsequent release of siRNA within the EPBMC phagosome is unknown. 
Previous work investigating siRNA-loaded PLGA microsphere phagocytosis 
with canine macrophage cells (DH82 cell line) (by John Hunt and colleagues) 
observed a controlled release of siRNA over 6 weeks, resulting in 30-40% 
siRNA remaining in the microsphere at week 6.  
Subsequent to the release of siRNA from the PLGA microsphere, some 
reports suggest that it may become sequestered within the phagosome. To 
enable siRNA to move into the cell cytosol and target mRNA, a triggered 
colloid osmotic disruption of the phagosome may be required (Lee, Yang et 
al. 2009). As reported by Lee et al. (2009) (Lee, Yang et al. 2009) this was 
caused by hydrolysis of an acid-sensitive microparticle, and subsequent 
osmotic disruption of the phagosome. The exact mechanism of siRNA 
translocation out of the phagosome and into the cytosol requires further 
investigation. This could be achieved using fluorescent siRNA-loaded 
microspheres in culture with EPBMCs.  
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Synoviocyte mRNA was analysed via qRT-PCR on days 1, 8 and 28 of the 
experiment. IL-1β mRNA has a half life of 4-5 hours in monocytes and 
macrophages (Herzyk, Allen et al. 1992). siRNA release at the correct dose 
and cleavage of target mRNA would need to be simultaneous to detect an 
efficient reduction of IL-1β mRNA via qRT-PCR. The dose of siRNA used in 
this study was extrapolated from those used in the siRNA-lipofectamine 
transfection protocol in Chapter 3. However, in this study siRNA is 
encapsulated within microspheres, and only one microsphere can interact 
with one EPBMC. Therefore, the siRNA dose required to cause an overall 
therapeutic effect on synoviocyte gene expression, detectable via qRT-PCR, 
may have been underestimated. Secreted IL-1β protein measurement via an 
equine IL-1β ELISA kit is the preferred method to investigate RNA 
interference. However previous work demonstrated low concentrations of 
EPBMC secreted IL-1β protein that were undetectable by the ELISA assays 
used.  
 
5.4.3 Conclusion 
This study suggests that synoviocytes help moderate the inflammatory 
response during OA. They exert a protective mechanism over cartilage 
sGAG release during synovitis. However, they also drive the inflammatory 
response through production of pro-inflammatory cytokines, aggrecanases 
and MMPs. siRNA-loaded microspheres did not elicit an anti-inflammatory 
response from the synoviocytes, nor did they exert a positive effect on 
cartilage health. However, further investigation is warranted, to examine 
secreted IL-1β protein levels, and different siRNA doses.  
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Chapter 6. General Discussion 
 
6.1  General Discussion 
The inflamed synovial membrane is a significant source of pro-inflammatory 
cytokines and cartilage extracellular matrix degrading enzymes, which drive 
catabolic processes and contribute to the cartilage degradation observed 
during OA (Sellam and Berenbaum 2010). As synovitis has been directly 
linked to both bone (Blom, van Lent et al. 2004) and cartilage (Blom, van 
Lent et al. 2007) structural changes occurring in the joint during OA, the 
synovial membrane represents an important potential disease-modifying 
target. The experimental aims within this thesis were to design and test an 
anti-cytokine therapy using siRNA to decrease target catabolic cytokines 
produced by synoviocytes. An siRNA vehicle in the form of biodegradable 
polymer microspheres, designed to deliver siRNA to target cells, was also 
tested. In vitro co-culture systems were created to facilitate assessments of 
the therapy and therapy-delivery system on synoviocyte and cartilage health, 
and to examine interactions between the two predominant cell populations 
present during synovitis; synovial macrophages and FLS.  
 
In Chapter 3, the gene expression profiles of both EFLS and EPBMCs were 
investigated in response to a range of LPS concentrations. It was decided 
that exposure to 10µg/ml LPS induced sufficient changes in cytokine gene 
expression and protein levels, to facilitate the testing of anti-cytokine siRNAs. 
A successful siRNA-mediated reduction of 65.7% of IL-1β transcripts was 
achieved when treating EFLS with a specific anti-IL-1β siRNA sequence. 
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EPBMCs also showed a moderate reduction in secreted IL-1β protein when 
transfected with the same anti-IL-1β siRNA sequence. Two factors appeared 
crucial in detecting siRNA-mediated changes in gene expression. (I) The 
length of LPS-exposure before analysing gene expression levels, as EFLS 
IL-1β mRNA levels peak 1-3 hours after inflammatory stimulation this is the 
most sensitive period in which to detect siRNA-mediated decreases in 
expression. (II) The relative siRNA and primer positions on the target mRNA 
sequence; 3’ mRNA fragments may fail to undergo effective intracellular 
degradation and can subsequently be detected and amplified by primers 
designed to complement cDNA within this region, resulting in a false 
negative siRNA-mediated decrease in gene expression. These factors must 
be taken into consideration when measuring mRNA transcripts with regards 
to siRNA-mediated treatment. However, to produce an effective therapy, the 
reduction in mRNA transcripts must be translated to a reduction in protein 
levels. Therefore, the gold standard techniques to measure siRNA-mediated 
reductions in target gene expression are western blot analysis using an 
appropriate antibody, or ELISA kits. These techniques were used within this 
thesis; cell culture media IL-1β concentrations were measured using an 
equine IL-1β ELISA kit, however concentrations measured were below the 
lower concentration threshold of this assay making this data inconclusive. 
Protein concentration from cell culture media using Strataclean resin was 
undertaken to concentrate cell culture media proteins in an attempt to allow 
reliable IL-1β  protein levels. However, the proteins extracted using protein-
resin binding represented a subset of the range of proteins expected to be 
found in cell culture media, and it was hypothesised that a far greater 
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dispersity in protein size would be found. Protein concentrations measured 
before and after protein-resin binding reflected successful protein extraction 
from the cell culture media, however this was not reflected in the proteins 
identified through ponseau staining of the nitrocellulose membrane once 
proteins had been transferred after being processed by polyacrylamide gel 
electrophoresis. Why this process has extracted and concentrated proteins 
of a specific size, and not the entire range of proteins normally found in cell 
culture media, need further investigation. A lack of equine specific reactive 
reagents further impedes successful and thorough investigation into gene 
translation.   
 
Having successfully designed and tested an equine anti-cytokine siRNA 
sequence, Chapter 3 also described evidence of highly efficient EPBMC 
phagocytosis of biodegradable polymer microspheres. A z-stack series of 
multichannel scanning confocal laser microscopy images allowed the entire 
volume of the cell to be visualised. Through these images, the phagocytosis 
of fluorescent microspheres was evident; multiple intracellular fluorescent 
phagosomes were present consistent with the phagocytic digestion. The 
phagocytic capabilities of synovial macrophages within synovial explants 
were also tested through co-culture with fluorescent microspheres. 
Fluorescent microspheres were clearly associated with the explants and had 
been degraded into smaller fluorescent particles. Although these particles 
appeared to be cell associated, it was not possible to definitively prove 
whether these particles were intracellular. Visualisation of synovial explant 
sections using confocal laser microscopy was inadequate to determine 
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whether microspheres had been internalised and phagocytosed, further work 
is required to achieve this.  
 
In order to determine both the beneficial and disadvantageous effects of 
reducing target cytokine gene expression, we first needed to elucidate the 
cell-specific responses to inflammatory stimulation, of the two predominant 
cell populations present within the synovial membrane during synovitis; the 
FLS and synovial macrophages. This was achieved through the creation of a 
multi-species co-culture model, using equine FLS and a canine macrophage 
cell line (DH82), and through the design of species-specific primers for 
mRNA transcript quantification. It was interesting to note an increase in 
EFLS active ADAMTS5 protein secretion and mRNA expression upon 
exposure to LPS whereas mRNA expression was attenuated when EFLS 
were in co-culture with DH82 cells. This attenuation appeared to be caused 
by a thermally stable soluble factor produced by DH82 cells, which acted in 
an IL-1β independent manner. This moderation of the inflammatory response 
caused by macrophages, which are chiefly recognised as drivers of 
inflammation (Bondeson, Wainwright et al. 2006), has also been noted in 
other studies (Bailey 2014, Bailey 2015). Presence of macrophages in co-
culture with EFLS also stimulated FLS mitosis, which may explain the 
synovial hyperplasia which occurs during synovitis and is recognised as a 
gross pathological change during OA.    
 
Chapter 5 went on to further investigate the interactions between EFLS and 
EPBMC co-cultures, cultured with cartilage explants, to examine the effects 
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of synovitis on cartilage health, and to assess whether the anti-cytokine 
siRNA-mediated therapy delivered to cells via biodegradable polymer 
microspheres could help counteract the injurious effects of synovitis on 
cartilage.  One of the most noteworthy results found in this chapter, was the 
significantly lower total sGAG measured within the culture media of cartilage 
co-cultured with synoviocytes, compared to that of cartilage cultured 
independently (p < 0.01). This finding indicates that synoviocytes reduce the 
GAG loss from cartilage, which has previously been reported (Gregg, Fortier 
et al. 2006) however, whether this is a protective synoviocyte mechanism 
encouraging anabolic metabolism, the inhibition of chondrocyte aggrecan 
synthesis, or suppression of aggrecanase production is unknown. In contrast 
to this finding, synoviocyte gene expression levels of pro-inflammatory 
cytokines and cartilage ECM degrading enzymes were abundant. No anti-
inflammatory effects of siRNA loaded microspheres were observed on either 
synoviocyte gene expression levels or cartilage health. 
 
To conclude, this thesis has successfully completed the initial design and 
testing of an anti-cytokine siRNA therapy, and delivery vehicle. It has also 
identified interesting and important interactions synovial like fibroblasts and 
inflammatory cells which may be involved in regulating pro-inflammatory and 
cartilage ECM degrading processes during synovitis. To successfully target 
the synovial membrane and produce a disease-modifying therapy, 
knowledge of these cellular responses, and how they are affected by the 
therapy, is critical when trying to re-create the intra-articular homeostatic 
balance that conserves cartilage health.  
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6.2  Further Work 
There are several avenues of further investigation that could proceed from 
this thesis. 
 
6.2.1  EFLS and EPBMC Co-Culture Experimental Work 
Further investigation to determine how to extract and separate the full range 
of proteins present within EFLS and EPBMC cell culture media would allow 
analysis of changes in protein secretion.  
To test the anti-equine IL-1β monoclonal antibody used in this thesis, for 
adequate cross-matching with recombinant equine IL-1β protein in western 
blot analysis.  
Further investigate the influence macrophages have on joint cells by using 
single-species co-culture models. Canine models would include the canine 
macrophage cell line (DH82) with either primary canine fibroblast-like 
synoviocytes (CFLS) or primary canine chondrocytes. To produce the equine 
co-culture models, equine peripheral blood mononuclear cells (EPBMCs) 
isolated from equine blood using density cell separation would be co-cultured 
with EFLS or with primary equine chondrocytes. Differential fluorescent 
labeling of cell dyes within the co-cultures with cell tracker dyes could 
facilitate cell separation through FACS enabling the quantification of 
individual cell population gene expression of cytokines (IL-1β and IL-6), 
aggrecanases (ADAMTS4 and -5) and MMP-3 and -13. Flow cytometry 
analysis would also provide information about the proliferation of FLS whilst 
in co-culture with monocytes/macrophages of the same species.! 
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6.2.2  Anti-cytokine siRNA-loaded Microsphere Experimental Work  
To ensure siRNA-loaded onto microspheres can effectively translocate from 
the phagosome to the cell nucleus, fluorescent-siRNA-loaded microspheres 
should be cultured with synoviocytes. Through the use of fluorescently 
labelled dyes, the location of fluorescent-siRNA could be identified using 
multichannel laser scanning confocal microscopy.  
When anti-IL-1β siRNA-loaded microspheres were cultured with 
synoviocytes in Chapter 5, a comparable reduction in synoviocyte IL-1β 
mRNA expression to that produced when transfecting EFLS with siRNA in 
Chapter 3, was not reproduced. As mentioned previously, this may have 
been due to the timing of synoviocyte mRNA analysis. A range of different 
time periods to include time of synoviocyte and siRNA-loaded microsphere 
culture, and time of exposure to LPS before cell harvesting, need to be 
trialled to ensure siRNA-mediated decrease in IL-1β mRNA is detected.  
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